Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Antibody, immunoglobulin, or fragment thereof fused via peptide linkage to nonimmunoglobulin protein, polypeptide, or fragment thereof (i.e., antibody or immunoglobulin fusion protein or polypeptide)

Subclass of:

424 - Drug, bio-affecting and body treating compositions

424130100 - IMMUNOGLOBULIN, ANTISERUM, ANTIBODY, OR ANTIBODY FRAGMENT, EXCEPT CONJUGATE OR COMPLEX OF THE SAME WITH NONIMMUNOGLOBULIN MATERIAL

424133100 - Structurally-modified antibody, immunoglobulin, or fragment thereof (e.g., chimeric, humanized, CDR-grafted, mutated, etc.)

Patent class list (only not empty are listed)

Deeper subclasses:

Entries
DocumentTitleDate
20110206668METHODS AND COMPOSITIONS FOR MODULATING IMMUNITY - Methods and compositions for inducing immune suppression are disclosed. The methods involve administering an effective amount of a CD200 protein or a nucleic acid encoding a CD200 protein. The methods are useful in preventing graft rejection, fetal loss, autoimmune disease, and allergies. Methods and compositions for preventing immune suppression are also disclosed. The methods involve administering an effective amount of an agent that inhibits CD200. Such methods are useful in treating cancer.08-25-2011
20090123468TRANSDUCIBLE POLYPEPTIDES FOR MODIFYING METABOLISM - Methods and compositions for modifying the metabolism of a subject are provided. One embodiment provides a recombinant polypeptide having a polynucleotide-binding domain, a protein transduction domain, and a targeting domain. In a preferred embodiment, the polynucleotide-binding domain includes one or more HMG box domains.05-14-2009
20090123467Polypeptide-Nucleic Acid Conjugate for Immunoprophylaxis or Immunotherapy for Neoplastic or Infectious Disorders - The present invention discloses compositions which induce cross-activation of immune mediated and direct death signaling in targeted cells by exploiting the properties of a antibody/peptide-nucleic acid conjugate. The conjugate is able to simultaneously activate multiple death signaling mechanisms. Methods of using the conjugate of the present invention as an immunotherapeutic modality for the treatment or prevention of infectious disease, neoplastic diseases or other disorders.05-14-2009
20100015144Methods for dosing an activin-actriia antagonist and monitoring of treated patients - In certain aspects, the present invention provides methods for dosing a patient with an activin-ActRIIa antagonist and methods for managing patients treated with an activin-ActRIIa anatagonist. In certain aspects, the methods involve measuring one or more hematologic parameters in a patient.01-21-2010
20080260737COMBINATION OF BLyS AND/OR APRIL INHIBITION AND IMMUNNOSUPPRESSANTS FOR TREATMENT OF AUTOIMMUNE DISEASE - The invention relates to novel combination therapies involving BLyS or BLyS/APRIL inhibition and immunosuppressants for the treatment of autoimmune diseases. One preferred method is where the BLyS and/or APRIL antagonist is a Fc-fusion protein which can be a TACI-Fc-fusion protein comprising the extracellular domain of TACI or a functional fragment thereof, a BAFF-R-Fc-fusion protein comprising the extracellular domain of BAFF-R or a functional fragment thereof, or a BCMA-Fc-fusion protein comprising the extracellular domain of BCMA or a functional fragment thereof. In the methods of the present invention some of the immunosuppressive drugs contemplated include cyclophosphamide (CYC), azathioprine (AZA), cyclosporine A (CSA), or mycophenolate mofetil (MMF), although any drug that suppresses the immune system may be suitable. The methods of the present invention reduce the levels of various immunoglobulins in patients in need of such reduction, such as those suffering from autoimmune diseases.10-23-2008
20100008919COMPOSITIONS AND METHODS TO CONTROL ANGIOGENESIS WITH CUPREDOXINS - The present invention relates to compositions comprising cupredoxins, and their use to inhibit angiogenesis in mammalian cells, tissues, and animals, and particularly the angiogenesis that accompanies tumor development and particularly in humans. Specifically, the present invention relates to compositions comprising the cupredoxin(s), and or peptides that are variants, derivatives or structural equivalents of cupredoxins, which retain the ability to inhibit angiogenesis in mammalian cells, tissues or animals. These compositions may be peptides or pharmaceutical compositions, among others. The compositions of the invention may be used to treat any pathological condition that has as a symptom or cause, inappropriate angiogenesis, and particularly inappropriate angiogenesis related to tumor development.01-14-2010
20090191199GLYCOENGINEERED, RECOMBINANT ANTIBODY - The present invention relates to a cell for the production of an antibody molecule such as an antibody useful for various diseases having high antibody-dependent cell-mediated cytotoxic activity, a fragment of the antibody and a fusion protein having the Fc region of the antibody or the like, a method for producing an antibody composition using the cell, the antibody composition and use thereof.07-30-2009
20090053223EXPRESSION-ENHANCED POLYPEPTIDES - A composite polypeptide, said composite polypeptide comprising a desired polypeptide and an expression enhancing domain (“EED”), said EED comprising first and second cysteine amino acid residues Cys1 and Cys2, respectively, Cys1 being located closer to the N-terminus of the composite polypeptide molecule than Cys2, wherein Cys1 and Cys2 are separated by a polypeptide linker, said linker—being free of cysteine and proline;—defining a length sufficient to allow Cys1 and Cys2 to engage in an intramolecular disulfide bond with one another; and—having a flexible polypeptide conformation essentially free of secondary polypeptide structure in aqueous solution, wherein at least one of Cys1 and Cys2 is derivatized with a derivatization moiety.02-26-2009
20120244157USE OF TNF-ALPHA INHIBITORS FOR TREATING A NERVE DISORDER MEDIATED BY NUCLEUS PULPOSUS - The present invention relates to a method and a pharmaceutical composition for treatment of nerve disorders comprising administration of a therapeutically effective dosage of at least two substances selected from the group consisting of TNF inhibitors, IL-1 inhibitors, IL-6 inhibitors, IL-8 inhibitors, FAS inhibitors, FAS ligand inhibitors, and IFN-gamma inhibitors. Preferably, at least one of the substances is a TNF inhibitor.09-27-2012
20120244156LEPTIN AS AN ANTI- AMYLOIDOGENIC BIOLOGIC AND METHODS FOR DELAYING THE ONSET AND REDUCING ALZHEIMER'S DISEASE-LIKE PATHOLOGY - The present invention relates to methods for treating, preventing, or diagnosing the pathology of progressive cognitive disorders resulting from accumulation of an amyloid peptide, in particular, Alzheimer's disease, Down's syndrome and cerebral amyloid angiopathy, in mammalian subjects using a composition comprising therapeutically effective amount of a leptin, leptin mimic, leptin derivative, leptin agonist, or AMP-dependent protein kinase activator, alone, or in combination with, one or more lipolytic/antilipogenic compounds. It further relates to methods for improving cognitive function using a composition comprising a therapeutically effective amount of leptin, a leptin mimic, a leptin derivative, an AMP-dependent protein kinase activator, a leptin agonist, a leptin blocker, a mimic of a leptin blocker, a leptin antagonist, an AMP-dependent protein kinase inhibitor; or a pharmaceutically acceptable salt thereof.09-27-2012
20120244155Dendritic Cells (DCs) Targeting for Tuberculosis (TB) Vaccine - Compositions and methods comprising high affinity monoclonal antibody conjugates against several DC receptors are described herein. The inventors prepared fusion proteins with antigens for DC-targeting vaccine generation by conjugating several 09-27-2012
20120244154Activatable Binding Polypeptides and Methods of Identification and Use Thereof - Activatable binding polypeptides (ABPs), which contain a target binding moiety (TBM), a masking moiety (MM), and a cleavable moiety (CM) are provided. Activatable antibody compositions, which contain a TBM containing an antigen binding domain (ABD), a MM and a CM are provided. Furthermore, ABPs which contain a first TBM, a second TBM and a CM are provided. The ABPs exhibit an “activatable” conformation such that at least one of the TBMs is less accessible to target when uncleaved than after cleavage of the CM in the presence of a cleaving agent capable of cleaving the CM. Further provided are libraries of candidate ABPs, methods of screening to identify such ABPs, and methods of use. Further provided are ABPs having TBMs that bind VEGF, CTLA-4, or VCAM, ABPs having a first TBM that binds VEGF and a second TBM that binds FGF, as well as compositions and methods of use.09-27-2012
20130078243CONJUGATE MOLECULE - This invention relates to a therapeutic molecule capable of suppressing an immune response against an organ or tissue transplantation in a patient. In particular, the invention relates to a conjugate comprising a first portion connected to a second portion, wherein the first portion binds to an MHC Class I molecule and the second portion has HLA-G activity. This conjugate may be used as a medicament to modulate immune responses and induce immunological tolerance specific to allogenic MHC complexes.03-28-2013
20120183546TREATMENT OF OVARIAN CANCER USING A SPECIFIC BINDING AGENT OF HUMAN ANGIOPOIETIN-2 IN COMBINATION WITH A TAXANE - Methods and compositions for treating ovarian cancer in a patient comprising administering a therapeutically effective amount of an Angiopoictin-2 inhibitor in combination with a taxane.07-19-2012
20120183545CD20-Binding Polypeptide Compositions and Methods - A method of treating an autoimmune disease comprising administering to a patient a therapeutically effective amount of a CD20-binding polypeptide composition comprising a combination of a modified heavy chain variable region polypeptide and a modified light chain variable region polypeptide. The combination can be (a) a modified 2B8 antibody heavy chain variable region polypeptide of SEQ ID NO: 48; and a modified 2B8 antibody light chain variable region polypeptide of SEQ ID NO: 49; or (b) a modified Leu16 antibody heavy chain variable region polypeptide of SEQ ID NO: 50; and a modified Leu16 antibody light chain variable region polypeptide of SEQ ID NO: 51.07-19-2012
20120183544DIAGNOSIS AND TREATMENT OF NEUROECTODERMAL TUMORS - The present invention provides fusion proteins for the detection and treatment of neuroectodermal tumors. Previous work demonstrated that chlorotoxin is specific for glial-derived or meningioma-derived tumor cells. The current invention has extended the use of chlorotoxin-cytotoxin fusion proteins to treat the whole class neuroectodermal tumors such as gliomas, meningiomas, ependymonas, medulloblastomas, neuroblastomas, gangliomas, pheochromocytomas, melanomas, PPNET's, small cell carcinoma of the lung, Ewing's sarcoma, and metastatic tumors in the brain. Also, diagnostic methods are provided for screening neoplastic neuroectodermal tumors.07-19-2012
20120183543DIAGNOSTIC BIOMARKERS FOR FIBROTIC DISORDERS - The present invention provides novel methods of inhibiting fibrosis, as well as methods of treating or inhibiting fibrotic disorders, using BMP9 and/or BMP10 antagonists. The present invention also provides methods of assessing whether a subject has or is at risk of developing a fibrotic disorder by detecting levels of BMP9 and/or BMP10. Further provided are methods of assessing the efficacy of a treatment regimen for treating a fibrotic disorder by detecting and comparing pre-treatment levels of BMP9 and BMP10 with post-treatment levels of BMP9 and BMP10.07-19-2012
20120183542TREATING NEUROLOGICAL DISORDERS - Methods of treating neuronal disorders, such as mechanical neuronal traumas and neurodegenerative disorders, with TWEAK or a TWEAK receptor blocking agents are presented.07-19-2012
20130078244METHODS FOR DETECTING AND REGULATING ALOPECIA AREATA AND GENE COHORTS THEREOF - The invention provides for methods for controlling hair growth by administering a HLDGC modulating compound to a subject. The invention further provides for a method for screening compounds that bind to and modulate polypeptides encoded by HLDGC genes. The invention also provides methods of detecting the presence of or a predisposition to a hair-loss disorder in a human subject as well as methods of treating such disorders.03-28-2013
20130078245ANTIBODIES TO THE C3d FRAGMENT OF COMPLEMENT COMPONENT 3 - The present invention relates to methods and materials for modulating the complement alternative pathway (CAP), the complement classical pathway (CCP), the complement lectin/mannose pathway (CMP), or combinations thereof, as well as methods and materials for targeting prophylactic or therapeutic agents to localized areas of tissue within the body where they may more directly exert their effects upon the intended target cells or tissue, with reduced, associated systemic effects compared with administration of the same or similar agents in an untargeted, systemic manner. The methods and materials of the present invention may therefore allow for increased efficacy, lower threshold effective dosages and/or lower effective maintenance doses, and/or reduced associated undesired or adverse effects in terms of frequency or severity of occurrence, or both. The present invention also relates to methods and materials for modulating a host humoral immune response, especially reducing, inhibiting, or preventing a host humoral immune response.03-28-2013
20100150926FUSION PROTEIN CAPABLE OF BINDING VEGF-A AND TNF-ALPHA - The present application describes an isolated nucleic acid molecule encoding a polypeptide capable of synchronously binding VEGF polypeptide and TNF polypeptide comprising: (a) a nucleotide sequence encoding a TNFR2 component and VEGFR1 component operatively linked to (b) a nucleotide sequence encoding a multimerizing component, wherein the TNFR2 component consists essentially of a nucleotide sequence encoding the amino acid sequences of cystein rich domain 1, cystein rich domain 2, cystein rich domain 3, and cystein rich domain 4 of the extracellular domain of TNFR2, and wherein the VEGFR1 component consists essentially of a nucleotide sequence encoding the amino acid sequences of Ig-like domain 2 of the extracellular domain of VEGFR1.06-17-2010
20100150925TREATMENT OF B-CELL CANCERS WITH ANTI-CD70 ANTIBODY-DRUG CONJUGATES - Disclosed are anti-CD70 antibodies and derivatives thereof conjugated to cytotoxic therapeutic agents, as well as pharmaceutical compositions and kits comprising the antibody- and antibody derivative-drug conjugates. Also disclosed are methods, for the treatment of a CD70-expressing cancer, comprising administering to a subject the disclosed pharmaceutical compositions.06-17-2010
20100034819HUMAN EPO MIMETIC HINGE CORE MIMETIBODIES, COMPOSITIONS, METHODS AND USES FOR PREVENTING OR TREATING GLUCOSE INTOLERANCE RELATED CONDITIONS ON RENAL DISEASE ASSOCIATED ANEMIA - The present invention relates to at least one novel human EPO mimetic hinge core mimetibody or specified portion or variant, including isolated nucleic acids that encode at least one EPO mimetic hinge core mimetibody or specified portion or variant, EPO mimetic hinge core mimetibody or specified portion or variants, vectors, host cells, and methods of making and using thereof, for preventing or treating glucose intolerance and/or renal disease associated anemia, including therapeutic compositions, methods and devices.02-11-2010
20130084292Antagonists for the Prevention of Treatment of Inflammatory Bowel Disease, and More Particularly of Crohn's Disease - An antagonist of the interaction between the Gp96 receptor and 04-04-2013
20130084291COMPOSITIONS AND METHODS FOR INCREASING SERUM HALF-LIFE - Provided herein are glycovariant Fc fusion proteins having increased serum half lives. Also provided are methods for increasing the serum half life of an Fc fusion protein by introducing one or more non-endogenous glycosylation sites.04-04-2013
20130034553Fusion Polypeptides Capable of Activating Receptors - A fusion polypeptide comprising (A)02-07-2013
20090186025Fusion Protein Comprising an Fc Receptor Binding Polypeptide and an Antigenic Polypeptide for Mediating an Immune Response - The present invention provides a fusion protein comprising an Fc receptor binding polypeptide and an antigenic polypeptide. The fusion peptide may further comprise a linker sequence or hinge portion which joins the Fc receptor biding polypeptide and the antigenic polypeptide. The Fc receptor binding polypeptide typically comprises the CH2 constant domain of a human IgG immunoglobulin. The antigenic polypeptide can be any polypeptide which induces an immune response. Administration of the fusion protein to a subject results in a cytotoxic T lymphocyte response being induced against the antigenic polypeptide provided within the fusion protein. The invention further extends to methods for the treatment of a disease condition in a subject using the fusion proteins of the invention.07-23-2009
20130039912ROBO1-FC FUSION PROTEIN AND USE THEREOF FOR TREATING TUMOURS - The present invention relates to a Robo1-Fc recombinant protein and to the use thereof for treating diseases in which a Slit protein is overexpressed, in particular cancer. The invention also relates to a composition including such a recombinant Another aspect of the invention involves using a Robo1-Fc molecule as a diagnostic tool for detecting the overexpression of a molecule belonging to the Slit family in a patient.02-14-2013
20130039911Compositions and Methods for Targeted Immunomodulatory Antibodies and Fusion Proteins - The present invention is based on the seminal discovery that targeted immunomodulatory antobodies and fusion proteins can counter act or reverse immune tolerance of cancer cells. Cancer cells are able to escape elimination by chemotherapeutic agents or tumor-targeted antobodies via specific immunosuppressive mechanisms in the tumor microenvironment and such ability of cancer cells is recognized as immune tolerance. Such immuno-suppressive mechanisms include immunosuppressive cytokines (for example, Transforming growth factor beta (TGF-β)) and regulatory T cells and/or immunosuppressive myeloid dendritic cells (DCs). By conteracting tumor-induced immune tolerance, the present invention provides effective compositions and methods for cancer treatment, optional in combination with another existing cancer treatment. The present invention provides strategies to counteract tumor-induced immune tolerance and enhance the antitumor efficacy of chemotherapy by activating and leveraging T cell-mediated adaptive antitumor immunity against resistant or disseminated cancer cells.02-14-2013
20130039910METHODS AND COMPOSITIONS FOR MODULATING ANGIOGENESIS AND PERICYTE COMPOSITION - In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. Additionally, the disclosure demonstrates that inhibitors of ALK1 may be used to increase pericyte coverage in vascularized tissues, including tumors and the retina. The disclosure also identifies ligands for ALK1 and demonstrates that such ligands have pro-angiogenic activity, and describes antibodies that inhibit receptor-ligand interaction.02-14-2013
20100111952TREATMENT OF AUTOIMMUNE DISORDERS - Methods of treating disease with soluble inhibitors of the lymphotoxin pathway having improved properties. Improved LTBR-Ig fusion proteins, and pharmaceutical compositions thereof, are also described.05-06-2010
20120263719COMPOSITIONS AND METHODS FOR TREATING ASPERGILLOSIS - The present invention provides monoclonal antibodies specific for members of the 10-18-2012
20100322931ANTI-VEGF ANTIBODIES AND THEIR USES - The present disclosure relates to antibodies directed to vascular endothelial growth factor (“VEGF”) and uses of such antibodies, for example to treat diseases associated with the activity and/or overproduction of VEGF.12-23-2010
20100322928METHODS OF DIAGNOSING, MONITORING TREATMENT AND TREATING SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) - A method of treating systemic lupus erythematosus (SLE) in a subject are provided. The method comprise altering in cells of the subject activity and/or expression of at least one gene selected from the group consisting of Mpo, Ltf, Lcn, Camp, Ngp, Slfn, Ctsg, Thbs1, S100a8, 1190003K14Rik, Prtn3, S100a9, Tfpi, Fzd6, Nid1, 5830484A20Rik, 5830484A20 LOC 545340, Tnfsf4, IPstpip2, Pigr, 270022B06Rik, L5R-alpha, A130040M12Rik, Gpr132, Cd8b1, Dhx9, Cyp11a1, Lmo7, Rnf184, Pstpip2, Hdgfrp3, Ass1 and Zbtb20, thereby treating SLE. Also provided are methods of diagnosing SLE and monitoring treatment of SLE.12-23-2010
20130136739METHODS OF USE OF SOLUBLE CD24 FOR THERAPY OF RHEUMATOID ARTHRITIS - Provided herein is a method of treating rheumatoid arthritis using a CD24 protein. The CD24 protein may include mature human or mouse CD24, as well as a N- or C-terminally fused portion of a mammalian immunoglobulin.05-30-2013
20090155270CASPASE INHIBITORS, ESPECIALLY CASPASE 3 INHIBITORS, FOR THE TREATMENT OF INFLUENZA - The invention relates to the use of at least one caspase inhibitor, in particular a caspase-3 inhibitor, for preparing a pharmaceutical composition for the prophylaxis or therapy of a viral infection, in particular an infection with an RNA negative-strand virus, preferably an influenza infection, and to a test system for identifying suitable active substances.06-18-2009
20090155266Methods and Compositions Relating to Vascular Endothelial Growth Factor and TH2 Mediated Inflammatory Diseases - The present invention includes compositions and methods for the treatment of a Th2 mediated inflammatory disease, relating to inhibiting a VEGF. The invention further includes methods to identify new compounds for the treatment of a Th2 mediated inflammatory disease, including, but not limited to, asthma and the like. This is because the present invention demonstrates, for the first time, that expression of VEGF induces asthma-like phenotype and that inhibiting VEGF reverses the phenotype. Thus, the invention relates to the novel discovery that inhibiting VEGF treats and prevents an Th2 mediated inflammatory disease.06-18-2009
20130045205Methods and Compositions Related to Glycoprotein-Immunoglobulin Fusions - Disclosed herein are compositions and methods for eliciting immune responses against HCV antigens. In particular embodiments, the compounds and methods elicit immune responses against all or a segment of HCV glycoprotein E1 and/or HCV glycoprotein E2.02-21-2013
20130034552TEMPERATURE SENSITIVE CONJUGATE COMPOSITIONS, AND USES RELATED THERETO - This disclosure relates to temperature sensitive conjugates, compositions, and uses related thereto. In certain embodiments, the disclosure relates to conjugate polymers comprising a) a temperature sensitive polymer and b) an antibody. Typically the antibody has an epitope to a platelet receptor. The antibody may be a single-chain antibody wherein the platelet receptor is GPIIb/IIIa, such as an anti-GPIIb/IIIa antibody. In certain embodiments, the antibody binds specifically to the activated conformation of GPIIb/IIIa, i.e., an activation-specific GPIIb/IIIa antibody.02-07-2013
20130034551Wnt Antagonists and Methods of Treatment and Screening - The present invention relates to compositions comprising Wnt antagonists and methods of treating Wnt-associated diseases and disorders, such as cancer, inducing differentiation, and reducing the frequency of cancer stem cells, as well as novel methods of screening for such Wnt antagonists. In particular, the invention discloses soluble FZD, SFRP and Ror receptors and their use.02-07-2013
20130028894METHODS OF TREATING IL-TIF ASSOCIATED INFLAMMATORY OR IMMUNE DISEASES USING ANTIBODIES AGAINST SOLUBLE ZCYTOR 11 CYTOKINE RECEPTORS - Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for soluble zcytor11 receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides and antibodies can also be used to block TIF activity in vitro and in vivo, and may be used in conjunction with TIF and other cytokines to selectively stimulate the immune system. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.01-31-2013
20130028893Therapeutic antibodies with reduced side effect - A therapeutic protein, such as a therapeutic antibody, that is modified with a compound that inhibits binding of the protein to its therapeutic target, thereby reducing side effects caused by the protein.01-31-2013
20130089547Hybrid Constant Regions - The invention provides hybrid constant regions and antibodies or fusion proteins incorporating the same. The hybrid constant regions include at least CH2 and CH3 regions of an IgG or IgA constant region and Cμ3 and Cμ4 regions of a Cμ constant region. The hybrids retain properties of both component constant regions. The hybrids retain the ability of a Cμ constant region to form multivalent complexes, e.g., pentameric or hexameric structures. IgG hybrids also retain IgG properties including pH-dependent FcRn binding, which is associated with a relatively long in vivo half-life, and specific binding to protein G, which facilitates purification. Depending on the isotype and subtype, the nature of the antigen and presence of additional IgG CH1 and hinge domains, IgG hybrids may also retain properties of specific binding to protein A, and effector functions ADCC, CDC and opsonization. IgA hybrids retain the property of IgA of binding to an Fc-alpha receptor CD89.04-11-2013
20130089546THERAPEUTIC NUCLEASE COMPOSITIONS AND METHODS - Hybrid nuclease molecules and methods for treating an immune-related disease or disorder in a mammal, and a pharmaceutical composition for treating an immune-related disease in a mammal.04-11-2013
20130089549B CELL ACTIVATING FACTOR ANTAGONIST AND PREPARATION METHOD AND USE THEREOF - The present invention relates to the field of genetic engineering drugs, particularly to a novel B cell activating factor (BAFF) antagonist and use thereof. The technical problem to be solved by the invention is to find a new and effective selection for the prevention and treatment of autoimmune diseases. The B cell activating factor receptor antagonist is mainly obtained by the fusion of the domain 2 binding BAFF in TACI receptor and the domain binding BAFF in Br3 receptor, and it also can be fused with a Fc segment of IgG1 to obtain a new fusion protein molecule. Experiments indicate that said new fusion protein molecule has the function of BAFF antagonist, which can treat the autoimmune diseases, and supply a new and effective selection for the prevention and treatment of the autoimmune diseases.04-11-2013
20130089550NOVEL CTLA4-IG IMMUNOADHESINS - The present application relates to CTLA4-Ig immunoadhesins that target CD80 and CD86, and their use, particularly for therapeutic purposes.04-11-2013
20130089548METHOD AND COMPOSITIONS TO INDUCE APOPTOSIS OF TUMORAL CELLS EXPRESSING SHH - A method for inducing apoptosis of tumoral cells in a patient having cancer cells bearing Cell-adhesion molecule-related/Downregulated by Oncogenes (CDO) receptors and expressing Sonic Hedgehog (SHH), including administering to the patient an effective amount of an agonist of CDO's apoptotic function, wherein the agonist is selected from the group consisting of a CDO fragment, a fusion protein comprising a CDO fragment, an antibody against SHH, and an siRNA which is capable of inhibiting SHH expression, and related CDO fragments, fusion proteins comprising a CDO fragment, antibodies against SHH, and siRNAs which are capable of inhibiting SHH expression.04-11-2013
20130089545NOVEL COMPOUNDS AND THEIR EFFECTS ON FEEDING BEHAVIOUR - The invention provides a peptide comprising the amino acid sequence given below, together with uses of the peptide and methods associated therewith. The peptide finds particular use as an appetite suppressant and in the treatment of obesity.04-11-2013
20130052192Activatable Constructs - The current invention relates to a construct, a polynucleotide that encodes said construct and a cell that expresses said construct. Furthermore, the current invention relates to the use of said construct for the treatment of bleedings and their associated co-morbidities and to a method of treatment of bleedings, inflammation and metastasis of cancer cells.02-28-2013
20100136007CSF1R EXTRACELLULAR DOMAIN FUSION MOLECULES AND TREATMENTS USING SAME - The present invention relates to specific CSF1R ECD fusion molecules that exhibit improved therapeutic properties. The invention also relates to polypeptide and polynucleotide sequences, vectors, host cells, and compositions comprising or encoding such molecules. The invention also relates to methods of making and using the CSF1R ECD fusion molecules. The invention further relates to methods of treatment using the CSF1R ECD fusion molecules. For example, certain CSF1R ECDs of the invention may be used to treat rheumatoid arthritis (RA) or multiple sclerosis (MS).06-03-2010
20090304694Ang2 and Vegf Inhibitor Combinations - The invention provides methods for using Ang2 inhibitors in combination with VEGF inhibitors to treat disease. The invention also provides compositions, kits, formulations, and specific disease treatments relating thereto.12-10-2009
20110008342COMPOSITIONS OF HUMANIZED NOTCH FUSION PROTEINS AND METHODS OF TREATMENT - This invention provides a fusion protein comprising a single peptide, an extracellular domain of human Notch receptor protein and an Fc portion of an antibody bound thereto. This invention also provides a method for treating a subject having a tumor, a method for inhibiting angiogenesis in a subject, a method for treating a subject having ovarian cancer, and a method for treating a subject having a metabolic disorder, comprising administering to the subject an amount of the above fusion protein effective to treat the subject. This invention further provides uses of the above fusion protein for the preparation of a pharmaceutical composition for the treatment of a subject having a tumor, for inhibiting angiogenesis in a subject, for treating a subject having ovarian cancer, and for treating a subject having a metabolic disorder.01-13-2011
20130071394Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and methods of use - Provided are compositions and combinations containing an organophosphorus bioscavenger and a hyaluronan-degrading enzyme. The provided compositions and combinations can be used to treat or prevent organophosphorus poisoning, including nerve agent poisoning and pesticide poisoning.03-21-2013
20130071393METHODS FOR INCREASING RED BLOOD CELL LEVELS AND TREATING ANEMIA USING A COMBINATION OF GDF TRAPS AND ERYTHROPOIETIN RECEPTOR ACTIVATORS - In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.03-21-2013
20130071392Small Heat Shock Proteins and Active Fragments Thereof as a Therapy for Inflammation and Ischemia - The invention provides methods for treating inflammatory diseases by administering to the subject an effective amount of an agent that provides small heat shock protein activity, where the dose is effective to suppress or prevent initiation, progression, or relapses of disease, including the progression of established disease.03-21-2013
20130071395COMPOSITIONS AND METHODS FOR TREATING PATHOLOGIES - A composition for treating a neoplastic disorder includes an activatable cell penetrating peptide coupled to antibody and/or fragment thereof to an essential gene product of a neoplastic cell.03-21-2013
20130071391Methods of Treating Glucose Metabolism Disorders - Methods of treating individuals with a glucose metabolism disorder, and compositions thereof, are provided.03-21-2013
20090092606Antibacterial treatments - The present invention provides a method of providing a bacterium binding component suitable for use in the preparation of a product for use in combating a target bacterium (including the inactivation of said bacterium and/or the treatment or diagnosis of an infection by said bacterium). The method comprises the steps of: contacting bacterium binding components of an eukaryotic micro-organism with the target bacterium for binding of the target bacterium with a bacterium binding component, and lysing the eukaryotic micro-organism; separating out the bacterium; treating the separated out bacterium so as to release the bacterium binding component from said bacterium; and recovering the bacterium binding components.04-09-2009
20130058931METHODS OF PREDICTING AND DECREASING THE RISK OF PREGNANCY LOSS - Described are methods for diagnosing and predicting the risk of pregnancy loss in a subject based on the presence of an aberrant humoral response to three proteins, Apolipoprotein B-100, alpha2macrogloblin (alpha2M), and fibronectin. The presence or a detectable level of maternal IgG antibodies to trophoblast-derived fibronectin and/or ApoB-100, and/or the absence or a non-detectable level of antibodies specifically binding to alpha2M is associated with a history of RPL and an increased risk of pregnancy loss. Also described are methods for identifying subjects at risk of pregnancy loss, selecting subjects for participation in a clinical study, and methods of decreasing the risk of pregnancy loss in a subject which include detecting the presence or absence of antibodies to one or more of trophoblast-derived ApoB-100, alpha2M, and fibronectin. Also provided are kits that contain ApoB-100, alpha2M, and fibronectin.03-07-2013
20130058929FUSION PROTEINS FOR INHIBITION AND DISSOLUTION OF COAGULATION OF THROMBI - Fusion proteins containing a ligand which specifically binds to a selected vascular bed linked to an anti-thrombotic molecule are provided. Also provided are methods for use of these fusion proteins to prevent coagulation, to dissolve blood clots and to protect against the risk of iatrogenic side effects including those arising from cancer therapy and specific vascular occluding agents.03-07-2013
20130058932USE OF PKC-IOTA INHIBITORS FOR THE TREATMENT OF GLIOMA - The present invention pertains to use of PKC-iota inhibitors for treatment of glioma. In a specific embodiment, the treatment method comprises administering ICA-1 or a salt thereof to a subject with glioma. In another embodiment, the treatment method comprises contacting glioma cells with an effective amount of ICA-1 or a salt thereof.03-07-2013
20130058930SUBCUTANEOUS NEEDLE ASSISTED JET INJECTION ADMINISTRATION OF METHOTREXATE - The present application is directed, at least in part, to a method of treating an autoimmune disorder in a subject in need of treatment. In one exemplary embodiment, the method comprises introducing into the subcutaneous tissue of the subject, from a needle assisted jet injection device, a composition comprising methotrexate in a dose ranging from about 5 mg to about 50 mg, wherein the pharmacokinetic profile of said methotrexate, obtained following administration of the methotrexate by the needle assisted jet injection device, is substantially the same as the pharmacokinetic profile of the same dose of methotrexate when administered by an intramuscular injection or a subcutaneous injection. The present invention provides benefits and improvements, including an improved clinical utility, improved therapeutic efficacy, over conventional methods of administering methotrexate.03-07-2013
20130058928HAIR GROWTH METHODS USING FGFR3 EXTRACELLULAR DOMINS - The present invention relates to a method of promoting hair growth comprising administering a fibroblast growth factor receptor 3 (FGFR3) extracellular domain (ECD), including native FGFR3 ECDs, variants, fragments, and fusion molecules, to a subject in an amount sufficient to promote hair growth.03-07-2013
20110014196Drug Transfer into Living Cells - The invention relates to compounds comprising a plurality of enzyme substrates suitably linked and further carrying one or more cargo entities. In particular such compounds have the structure (substrate)01-20-2011
20120225067Composition and Method for Mediating an Immune Response - The present invention provides a fusion protein comprising an Fc receptor binding polypeptide and an antigenic polypeptide. The fusion protein may further comprise a linker sequence or hinge portion which joins the Fc receptor binding polypeptide and the antigenic polypeptide. The Fc receptor binding polypeptide typically comprises the CH2 constant domain of a human IgG immunoglobulin. The antigenic polypeptide can be any polypeptide which induces an immune response. Administration of the fusion protein to a subject results in a cytotoxic T lymphocyte response being induced against the antigenic polypeptide provided within the fusion protein. The invention further extends to methods for the treatment of a disease condition in a subject using the fusion proteins of the invention.09-06-2012
20120225066THERAPEUTIC NUCLEASE COMPOSITIONS AND METHODS - Hybrid nuclease molecules and methods for treating an immune-related disease or disorder in a mammal, and a pharmaceutical composition for treating an immune-related disease in a mammal.09-06-2012
20130064819Biomarkers - The use of HLA-DQA1 as a biomarker for predicting or determining the therapeutic efficacy of anti-TNF therapy.03-14-2013
20130064818USE OF IMMUNESUPPRESSANT RECEPTOR - The present invention relates to use of an antagonist of BIR1 (B cell immunoglobulin receptor 1) related to the present invention, a method for screening the antagonist, in addition to subtype polypeptides of BIR1, the polynucleotide encoding them and antibodies for the polypeptides.03-14-2013
20090232810IMMUNOCONJUGATES TARGETING CD138 AND USES THEREOF - Disclosed are immunoconjugates having in particular specificity for CD138 expressed on target cells and which display homogenous targeting. The immunoconjugates may be sterially hindered and/or contain a cleavable linker.09-17-2009
20090232809Type 2 cytokine receptor and nucleic acids encoding same - The present invention provides novel isolated CRF2-13 polynucleotides and polypeptides encoded by the CRF2-13 polynucleotides. Also provided are the antibodies that immunospecifically bind to a CRF2-13 polypeptide or any derivative (including fusion derivative), variant, mutant or fragment of the CRF2-13 polypeptide, polynucleotide or antibody. The invention additionally provides methods in which the CRF2-13 polypeptide, polynucleotide and antibody are utilized in the detection and treatment of a broad range of pathological states, as well as to other uses.09-17-2009
20090232808MOLECULES AND CHIMERIC MOLECULES THEREOF - The present invention relates generally to the fields of proteins, diagnostics, therapeutics and nutrition. More particularly, the present invention provides an isolated protein molecule in or related to the tumour necrosis factor (TNF) superfamily such as TNF-a, Lymphotoxin-a (LT-a), TNFRI, TNFRII, OX40, BAFF, NGFR, Fas Ligand or chimeric molecules thereof comprising at least a portion of the protein molecule, such as TNF-a-Fc, LT-a-Fc, TNFRI-Fc, TNFRII-Fc, OX40-Fc, BAFF-Fc, NGFR-Fc, Fas Ligand-Fc; wherein the protein or chimeric molecule thereof has a profile of measurable physiochemical parameters, wherein the profile is indicative of, associated with or forms the basis of one or more pharmacological traits. The present invention further contemplates the use of the isolated protein or chimeric molecule thereof in a range of diagnostic, prophylactic, therapeutic, nutritional and/or research applications.09-17-2009
20090232807GLP-1 ANALOG FUSION PROTEIN FORMULATIONS - The invention provides a stable solution formulation comprising a GLP-1-Fc fusion at a pH between about pH 6 and about pH 8.5. analogs fused to specific IgG4-Fc derivatives. These formulations provide unexpected and considerably greater chemical stability than when compared to GLP-1 -Fc fusions at a pH outside the described ranges. The formulations comprising a GLP-09-17-2009
20120114647 ANTI-SERUM ALBUM SINGLE VARIABLE DOMAINS - The invention relates to improved anti-serum albumin immunoglobulin single variable domains, as well as ligands and drug conjugates comprising such variable domains, compositions, nucleic acids, vectors and hosts.05-10-2012
20120114646LYOPHILIZED FORMULATIONS FOR SMALL MODULAR IMMUNOPHARMACEUTICALS - The present invention provides, among other things, stable formulations for small modular immunopharmaceutical (SMIP™) proteins. In some embodiments, the present invention provides a formulation containing a lyophilized mixture of a small modular immunopharmaceutical protein, wherein less than 7% of the lyophilized small modular immunopharmaceutical protein exists in aggregated form. Formulations according to the invention may contain buffering agents, stabilizers, bulking agents, surfactants and/or other excipients. The present invention also provides formulations for lyophilization, reconstitution and methods of use thereof.05-10-2012
20120114645USE OF IL-1 ANTAGONISTS TO TREAT PSEUDOGOUT - Methods of treating, inhibiting, or ameliorating gout, including chronic active (refractory) gout, pseudogout, or drug-induced gout, in a human subject, are provided. The methods comprise administering to a subject in need thereof a therapeutic amount of an interleukin 1 (IL-1) antagonist, such as IL-1 trap rilonacept.05-10-2012
20090010933METHODS FOR USING CHIMERIC VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR PROTEINS - The present invention is directed to novel chimeric VEGF receptor proteins comprising amino acid sequences derived from the vascular endothelial growth factor (VEGF) receptors flt-1 and KDR, including the murine homologue to the human KDR receptor FLK-1, wherein said chimeric VEGF receptor proteins bind to VEGF and antagonize the endothelial cell proliferative and anglogenic activity thereof. The present invention is also directed to nucleic acids and expression vectors encoding these chimeric VEGF receptor proteins, host cells harboring such expression vectors, pharmaceutically acceptable compositions comprising such proteins, methods of preparing such proteins and to methods utilizing such proteins for the treatment of conditions associated with undesired vascularization.01-08-2009
20130164286Fc FUSION PROTEINS - The embodiments of the invention relate to compositions, methods, and kits comprising a fusion protein. The fusion proteins of the embodiments include monomer polypeptides which in one embodiment have at least a binding domain, an optional hinge region, a collagen-like domain and the Fc domain of a human IgG.06-27-2013
20130183307ABERRANT CELL-RESTRICTED IMMUNOGLOBULINS PROVIDED WITH A TOXIC MOIETY - Described are immunoglobulins provided with a toxic moiety, comprising at least an immunoglobulin variable region that specifically binds to an MHC-peptide complex preferentially associated with aberrant cells. These immunoglobulins provided with a toxic moiety are preferably used in selectively modulating biological processes. The provided immunoglobulins provided with a toxic moiety are of particular use in pharmaceutical compositions for the treatment of diseases related to cellular aberrancies, such as cancers and autoimmune diseases.07-18-2013
20130183308THERAPEUTIC NUCLEASE COMPOSITIONS AND METHODS - Hybrid nuclease molecules and methods for treating an immune-related disease or disorder in a mammal, and a pharmaceutical composition for treating an immune-related disease in a mammal.07-18-2013
20120237513Vaccines Based on Targeting Antigen to DCIR Expressed on Antigen-Presenting Cells - The present invention includes compositions and methods for increasing the effectiveness of antigen presentation using a DCIR-specific antibody or fragment thereof to which an antigen is attached that forms an antibody-antigen complex, wherein the antigen is processed and presented by a dendritic cell that has been contacted with the antibody-antigen complex.09-20-2012
20120237512Activatable Binding Polypeptides and Methods of Identification and Use Thereof - Activatable binding polypeptides (ABPs), which contain a target binding moiety (TBM), a masking moiety (MM), and a cleavable moiety (CM) are provided. Activatable antibody compositions, which contain a TBM containing an antigen binding domain (ABD), a MM and a CM are provided. Furthermore, ABPs which contain a first TBM, a second TBM and a CM are provided. The ABPs exhibit an “activatable” conformation such that at least one of the TBMs is less accessible to target when uncleaved than after cleavage of the CM in the presence of a cleaving agent capable of cleaving the CM. Further provided are libraries of candidate ABPs, methods of screening to identify such ABPs, and methods of use. Further provided are ABPs having TBMs that bind VEGF, CTLA-4, or VCAM, ABPs having a first TBM that binds VEGF and a second TBM that binds FGF, as well as compositions and methods of use.09-20-2012
20120237511FGFR1 EXTRACELLULAR DOMAIN COMBINATION THERAPIES - Methods of treating cancer comprising administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule in combination with at least one additional therapeutic agent selected from docetaxel, paclitaxel, vincristine, carboplatin, cisplatin, oxaliplatin, doxorubicin, 5-fluorouracil (5-FU), leucovorin, pemetrexed, and bevacizumab are provided. Dosage packs comprising an FGFR1 ECD and/or an FGFR1 ECD fusion molecule and/or at least one additional therapeutic agent selected from docetaxel, paclitaxel, vincristine, carboplatin, cisplatin, oxaliplatin, doxorubicin, 5-fluorouracil (5-FU), leucovorin, pemetrexed, and bevacizumab are also provided. In some embodiments, a dosage pack comprises instructions for administering FGFR1 ECD and/or FGFR1 ECD fusion molecule with at least one additional therapeutic agent.09-20-2012
20130164287SOLUBLE TUMOR NECROSIS FACTOR RECEPTOR TREATMENT OF MEDICAL DISORDERS - The invention pertains to methods and compositions for treating medical disorders characterized by elevated levels or abnormal expression of TNFα by administering a TNFα antagonist, such as recombinant TNFR:Fc.06-27-2013
20130164288READTHROUGH ACETYLCHOLINESTERASE (ACHE-R) FOR TREATING OR PREVENTING PARKINSON'S DISEASE - A method of treating or preventing Parkinson's disease in a subject in need thereof is disclosed. The method comprises administering to the subject a therapeutically effective amount of AChE-R, wherein the AChE-R is devoid of an N-terminal extension. An additional method of treating or preventing Parkinson's disease in a subject is disclosed. The method comprises administering to the subject a therapeutically effective amount of AChE-R, wherein the AChE-R comprises a modification for increasing bioavailability.06-27-2013
20130164289HUMAN CYTOMEGALOVIRUS VACCINE - Combination peptides, polypeptides and proteins that elicit high titer neutralizing antibodies against cytomegalovirus (CMV) are provided. The combination peptides, polypeptides and proteins encompass epitopes located within the UL130 and UL131 components of the gH/gL/UL128-131 protein complex, in particular, epitopes located within amino acid residues 27-46 of UL130 and amino acid residues 90-106 of UL131. The combination peptides, polypeptides and proteins, and the nucleic acids encoding them, may be used in vaccines, and as diagnostic and research tools.06-27-2013
20090142342B7-H4 RECEPTOR AGONIST COMPOSITIONS AND METHODS FOR TREATING INFLAMMATION AND AUTO-IMMUNE DISEASES - Compositions containing B7-H4 receptor agonists in an amount effective to reduce, inhibit, or mitigate an inflammatory response in an individual and methods for the treatment or prophylaxis of inflammatory disorders and autoimmune diseases or disorders have been developed. It has been discovered that B7-H4 receptor agonists, for example B7-H4 fusion proteins function as an agonist of the B7-H4 receptor on T cells to suppress both humoral and cellular autoimmunity activity. In one embodiment, B7-H4 fusion proteins compete with sH4 for a common receptor on T cells.06-04-2009
20120189626TREATMENT OF COMPLEMENT-ASSOCIATED DISORDERS - The present invention concerns a recently discovered macrophage specific receptor, CRIg, and its use in the treatment of complement-associated disorders.07-26-2012
20110280877Inhibition of B7-H1/CD80 interaction and uses thereof - The present invention provides a composition comprising an agent which specifically blocks interaction between B7-H1 and CD80 but not interaction between B7-H1 and PD-1 and a vaccine, optionally in a pharmaceutically acceptable carrier. Further provided is a method of treating or inhibiting abnormal cell proliferation or a viral infection in a host comprising the step of administering an agent which specifically blocks interaction between B7-H1 and CD80 but does not block interaction between B7-H1 and PD-1 in combination with a vaccine against the cancer to a host in need thereof.11-17-2011
20110142834TREATMENT OF HEARING AND BALANCE IMPAIRMENTS USING COMPOUNDS HAVING ERYTHROPOIETIN ACTIVITY - Compositions and methods are provided for prophylactic or therapeutic treatment of a mammal for hearing or balance impairments involving neuronal damage, loss, or degeneration, preferably of spiral ganglion neurons, by administration of a therapeutically effective amount of one or more molecules having erythropoietin activity selected from EPO, or a biosimilar, a variant, or a mutant thereof; a protein or peptide mimetic of EPO; a small molecule mimetic of EPO and an erythropoiesis stimulating agent. Also provided are improved compositions and methods for treatments of ototoxicity requiring administration of a pharmaceutical having an ototoxic side-effect in combination with a therapeutically effective amount of a molecule having erythropoietin activity.06-16-2011
20110081343VACCINES DIRECTED TO LANGERHANS CELLS - The present invention includes isolated anti-Langerin vaccines, methods for making and using an isolated anti-Langerin antibody or binding fragment thereof and one or more antigenic peptides at the carboxy-terminus of the isolated anti-Langerin antibody, wherein when two or more antigenic peptides are present, the peptides are separated by the one or more linker peptides that comprise at least one glycosylation site. The present invention also includes isolated vectors for the expression of the anti-Langerin antigen delivery vectors and their manufactures and use.04-07-2011
20110142836B-cell depleting agents for the treatment of chronic fatigue syndrome - The present invention relates in a first aspect to a B-cell depleting anti-CD20 antibody or a CD20-binding antibody fragment thereof for the treatment of chronic fatigue syndrome and myalgic encephalomyelitis. In particular, the present invention relates to the use of anti-CD20 monoclonal antibodies or fragments thereof which are preferably humanized for the treatment of chronic fatigue syndrome/myalgic encephalomyelitis in a subject afflicted with said disease.06-16-2011
20110002925Use of Anti-IL-20 Antibody for Treating Rheumatoid Arthritis and Osteoporosis - Treatment of rheumatoid arthritis and osteoporosis using an anti-IL-20 antibody 7E, and optionally, in combination with an etanercept polypeptide.01-06-2011
20100055102COMPOSITIONS OF PD-1 ANTAGONISTS AND METHODS OF USE - Methods of treating cancer and infectious diseases utilizing a treatment regimen comprising administering a compound that reduces inhibitory signal transduction in T cells, in combination with a potentiating agent, such as cyclophosphamide, to produce potent T cell mediated responses, are described. Compositions comprising the PD-1 antagonists and potentiating agents useful in the methods of the invention are also disclosed.03-04-2010
20100266593WNT ANTAGONISTS AND THEIR USE IN THE DIAGNOSIS AND TREATMENT OF WNT-MEDIATED DISORDERS - The present invention provides for chimeric Wnt antagonists comprising a Frz domain component derived from a Frizzled protein, a secreted Frizzled related protein or Ror protein and an Fc immunoglobulin component, and their use in the treatment and diagnostic detection of cellular Wnt signaling and Wnt-mediated disorders, including cancer.10-21-2010
20100266590COMBINATION THERAPY - Disclosed are methods for treating various cancers. Methods encompass the administration of a first drug such as AP23573, temsirolimus or everolimus in combination with a second drug selected from Remicade, Humira, Enbrel, Raptiva, Abatacept, Actermra, Cimzia or anakinra.10-21-2010
20100196370FUSION PROTEIN OF IMMUNOGLOBULIN FC AND HUMAN APOLIPOPROTEIN(A) KRINGLE FRAGMENT - The present invention relates to an LK8-Fc fusion protein, which has increased angiogenesis inhibitory activity and in vivo stability. More specifically, relates to an LK8-Fc fusion protein in which an LK8 protein having angiogenesis inhibitory activity is fused with the Fc region of human immunoglobulin IgG1, as well as a composition for treating cancer, which contains the fusion protein. The LK8-Fc fusion protein has not only angiogenesis inhibitory activity leading to anticancer and metastasis inhibitory activities, but also a very long in vivo half-life, and thus can be used as a more efficient and economic cancer therapeutic agent or cancer inhibitor.08-05-2010
20110300142USE OF ZEBURALINE FOR THE TREATMENT OF AUTOIMMUNE DISEASES OR IMMUNE REJECTION OF TRANSPLANTS - The invention relates to the use of 1-(β-D-Ribofuranosyl)-1,2-dihydropyrimidin-2-one derivative or mimetic or an analogue, derivatives, metabolites, variants or salts thereof for the manufacturing of a medicament to increase the amount of Indoleamine 2,3-dioxygenase (IDO) production in order to induce immunological tolerance as well as a method of treating a mammal in need thereof.12-08-2011
20110123530COMPOSITIONS AND METHODS FOR TREATING AND DIAGNOSING ASTHMA - Compositions, kits and methods for treating and diagnosing subtypes of asthma patients are provided. Also provided are methods for identifying effective asthma therapeutic agents and predicting responsiveness to asthma therapeutic agents.05-26-2011
20110293612Method for the Treatment of Neurodegenerative Diseases - Disclosed are methods for treating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis, Alzheimer's Disease, Parkinson's Disease, Myasthenia Gravis, Multifocal Motor Neuropathy, Primary Lateral Sclerosis, Spinal Muscular Atrophy, Kennedy's Disease, and Spinocerebellar Ataxia, by administration of a compound that blocks the interaction of CD40 and CD40L.12-01-2011
20110293611Prevention of immunological rejection of transplanted stem cells by leukocyte costimulatory molecule blockade - Compositions and methods are provided for transplantation of pluripotent stem cells and differentiated cells derived therefrom.12-01-2011
20100015143Compositions and Methods Relating to Modulation of Immune System Components - A composition comprising a molecular blockade agent to a costimulatory molecule which costimulatory molecule satisfies the following criteria: a. absent in naÊve or resting T-lymphocytes; b. inducible; c. expressed; and d. prominent at the height of an immunopathological response, such as a disease/condition response. Preferably, the costimulatory molecule is OX40 and the molecular blockade agent is an antibody or antibody fragment having antibody activity to OX40. Further, the system may involve modulation of the molecular signal pathway of the aforesaid costimulatory molecule.01-21-2010
20100239579CD47 Related Compositions and Methods for Treating Immunological Diseases and Disorders - Provide herein are fusion polypeptides that comprise a CD47 extracellular domain or a variant thereof that is fused to a Fc polypeptide. The fusion polypeptides are useful for treating an immunological disease or disorder in a subject according to the methods described herein. The fusion polypeptides are capable of suppressing immunoresponsiveness of an immune cell, inhibiting production of proinflammatory cytokines, including inhibiting immune complex-induced production of cytokines.09-23-2010
20100129367HUMAN BETA-GLUCURONIDASE MUTANTS WITH ELEVATED ENZYMATIC ACTIVITY UNDER PHYSIOLOGICAL CONDITIONS AND METHOD FOR IDENTIFYING SUCH - A number of human beta-glucuronidase variants having higher enzymatic activity at physiological pH as compared with wild-type beta-glucuronidase and uses thereof in prodrug therapy. Also disclosed herein is a method for identifying enzyme variants having elevated enzymatic activity using a mammalian surface display system.05-27-2010
20110300144METHODS AND COMPOSITIONS FOR DIAGNOSIS AND TREATMENT OF CANCER - The present invention relates to the identification of nucleic acid and amino acid sequences that are characteristic of tumor tissues such as ovarian tumor and lung tumor tissues and which represent targets for therapy or diagnosis of tumor diseases in a subject.12-08-2011
20110300143PRENATAL ENZYME REPLACEMENT THERAPY - The invention contemplates transplacental enzyme replacement therapy (ERT) for deficiency of a polypeptide such as a tissue-nonspecific alkaline phosphatase (TNSALP) by administering a before-described pharmaceutical composition to a pregnant animal whose fetus or embryo is in need of such therapy. The fusion protein of such a composition comprises a water-soluble TNSALP portion, e.g., C-terminus-truncated TNSALP peptide-bonded to an IgG1 antibody Fc portion.12-08-2011
20110300141Novel Alphabeta-Binding protein and its peptide derivatives and uses thereof - A protein kinase C inhibitor that binds B-amyloid and its peptide derivatives with the same function are disclosed. These may be useful in the treatment of Alzheimer's disease, for example as pseudo vaccines comprising antibodies, or as part of fusion proteins which are able to pass through cell membranes or through the blood-brain barrier. Methods of using the PKC inhibitor and its peptide derivatives for treating Alzheimer's disease are also disclosed.12-08-2011
20090214534Bispecific Domain Antibodies Targeting Serum Albumin And GLP-1 Or PYY - Drug fusions and conjugates that contain an incretin therapeutic or diagnostic agent that is fused or conjugated to an antigen-binding fragment of an antibody that binds serum albumin. The conjugates and fusion have a longer in vivo half life in comparison with the unconjugated or unfused therapeutic or diagnostic agent.08-27-2009
20110217302TCR Complex Immunotherapeutics - Single chain fusion proteins that specifically bind to a TCR complex or a component thereof, such as TCRα, TCRβ, or CD3ε, along with compositions and methods of use thereof are provided.09-08-2011
20100028345IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS - The present invention relates to IL-17 Receptor A (IL-17RA or IL-17R) antigen binding proteins, such as antibodies, polynucleotide sequences encoding said antigen binding proteins, and compositions and methods for diagnosing and treating diseases mediated by IL-17 Receptor A activation by one or more IL-17 ligands. The present invention relates to the identification of neutralizing determinants on IL-17 Receptor A (IL-17RA or IL-17R) and antibodies that bind thereto. Aspects of the invention also include antibodies that compete for binding with the IL-17RA neutralizing antibodies described herein.02-04-2010
20090098121Immunoglobulin Directed Biocides - The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzymes) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing). The present invention also relates to methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in various diagnostic applications in number of diverse fields such as agriculture, medicine, and national defense.04-16-2009
20100111953ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO B LYMPHOCYTE STIMULATOR - The present invention relates to antibodies and related molecules that immunospecifically bind to B Lymphocyte Stimulator. The present invention also relates to methods and compositions for detecting or diagnosing a disease or disorder associated with aberrant B Lymphocyte Stimulator expression or inappropriate function of B Lymphocyte Stimulator comprising antibodies or fragments or variants thereof or related molecules that immunospecifically bind to B Lymphocyte Stimulator. The present invention further relates to methods and compositions for preventing, treating or ameliorating a disease or disorder associated with aberrant B Lymphocyte Stimulator expression or inappropriate B Lymphocyte Stimulator function comprising administering to an animal an effective amount of one or more antibodies or fragments or variants thereof or related molecules that immunospecifically bind to B Lymphocyte Stimulator.05-06-2010
20110268736METHOD FOR TREATING CONGENITAL MYOPATHY - The invention relates to methods and compositions for therapy for congenital myopathies.11-03-2011
20090081218FUSION PROTEINS - A fusion protein having a non-immunoglobulin polypeptide having a cysteine residue proximal to the C terminal thereof, and an immunoglobulin component with a mutated hinge region is provided. The mutation comprises a point mutated site corresponding in position to the position in a native hinge region of the cysteine residue located nearest the cysteine residue of the non-Ig component. The distance from the cysteine residue of the non-immunoglobulin polypeptide and any remaining cysteine residues of the mutated hinge region is sufficient to prevent the formation of a disulphide bond therebetween.03-26-2009
20090148447Binding Peptides Having a C-terminally Disposed Specific Binding Domain - Specific binding peptides having a general schematized structure of an optional N-terminal hinge region joined to an immunoglobulin-derived constant sub-region comprising a C06-11-2009
20100266591METHOD OF TREATING ERYTHROPOIETIN HYPORESPONSIVE ANEMIAS - The invention relates to methods of using compositions comprising EPO-mimetic peptides to treat anemia. The invention relates to methods of treating disorders characterized by the insufficient amounts of erythrocytes and hemoglobulin in the blood due to myelodysplastic syndrome (MDS) or by hemoglobinopathies, such as alpha- or beta-thalessemia or sickle cell disease.10-21-2010
20110091461BINDING DOMAIN-IMMUNOGLOBULIN FUSION PROTEINS - The invention relates to novel binding domain-immunoglobulin fusion proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, a hinge region polypeptide having either zero or one cysteine residue, and immunoglobulin CH2 and CH3 domains, and that are capable of ADCC and/or CDC while occurring predominantly as monomeric polypeptides. The fusion proteins can be recombinantly produced at high expression levels. Also provided are related compositions and methods, including immunotherapeutic applications.04-21-2011
20090041770Fc VARIANTS WITH ALTERED BINDING TO FcRn - The present application relates to optimized IgG immunoglobulin variants, engineering methods for their generation, and their application, particularly for therapeutic purposes.02-12-2009
20120141480METHODS OF TREATING WITH ANTI-FACTOR D ANTIBODIES - The invention relates to factor D inhibitors, which bind to factor D and block the functional activity of factor D in complement activation. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab′)06-07-2012
20120189625Compositions and Methods for Treating Hematological Cancers Targeting the SIRPA CD47 Interaction - The invention relates to modulating the SIRPα-CD47 interaction in order to treat hematological cancer and compounds therefor. In some embodiments, there is provided methods and uses of SIRPα polypeptides, fragments and fusion proteins for treating hematological cancer, preferably human acute myeloid leukemia.07-26-2012
20120189627Semi-Synthetic GLP-1 Peptide-FC Fusion Constructs, Methods and Uses - The invention relates to semi-synthetic biologic molecules which are conjugates of GLP-1 peptides and human multimeric proteins or protein fragments, such as an antibody Fc joined by a non-peptidyl bond. The constructs demonstrate biological activity and are useful making therapeutic compositions and therapeutic formulations for use in treating diseases characterized by lack of glycemic control.07-26-2012
20090269341LYTIC DOMAIN FUSION CONSTRUCTS AND METHODS OF MAKING AND USING SAME - The invention relates to fusion constructs, methods of using fusion constructs and methods of treating undesirable or aberrant cell proliferation or hyperproliferative disorders, such as tumors, cancers, neoplasia and malignancies.10-29-2009
20100119511LIGHT TARGETING MOLECULES AND USES THEREOF - LIGHT-targeting molecules (e.g., LIGHT fusion molecules), anti-HER2 antibody molecules, compositions, e.g., pharmaceutical compositions thereof, are disclosed. Methods of using these molecules to treat, prevent and/or diagnose hyperproliferative, e.g., neoplastic, diseases or conditions, including, but not limited to, cancer and metastasis are also provided.05-13-2010
20090087433ActRIIB Fusion Polypeptides and Uses Therefor - Methods and compositions for inhibiting growth and differentiation factor-8 (GDF-8) activity in vitro and in vivo are provided. The methods and composition can be used for diagnosing, preventing, or treating degenerative disorders of muscle, bone, or glucose homeostasis.04-02-2009
20120294855GLP-1 RECEPTOR AGONIST COMPOUNDS FOR OBSTRUCTIVE SLEEP APNEA - The disclosure provides, among other things, the use of GLP-1 receptor agonist compounds to treat obstructive sleep apnea. The GLP-1 receptor agonist compounds may be exendins, exendin analogs, GLP-1(7-37), GLP-1 (7-37) analogs (e.g., GLP-1 (7-36)-NH2) and th like. The GLP-1 receptor agonist compound may be exenatide.11-22-2012
20120107315Predicting progression to advanced age-related macular degeneration using a polygenic score - The present invention relates to methods for identifying individuals with intermediate age-related macular degeneration (AMD) who possess a greater risk of progression to advanced AMD, using a polygenic score calculated based on the results of genome-wide gene association studies, using thousands of single-nucleotide polymorphisms (SNPs).05-03-2012
20120107314CAB MOLECULES - The present invention relates to CAB molecules, ADEPT constructs directed against CEA, and their use in therapy.05-03-2012
20090047281Activin-ActRII antagonists and uses for increasing red blood cell levels - In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.02-19-2009
20090202542Rage protein derivatives - The present invention is drawn to fusion proteins comprising a Receptor for Advanced Glycation Endproducts (RAGE) and an immunoglobulin element. The invention also encompasses methods of treating a condition characterized by activation of an inflammatory cytokine cascade comprising administering such fusion proteins. The invention is also drawn to nucleic acids encoding the fusion proteins, as well as vectors and cells comprising such nucleic acids.08-13-2009
20110200600DIAGNOSIS AND PROGNOSIS OF IMMUNE DISORDERS USING STAT4 EXPRESSION - Methods and compositions that determine the expression levels of Stat4α and Stat4β isoforms for therapeutic efficacy of anti-inflammatory treatments, assessing an individual's risk for developing inflammatory diseases including Crohn's disease, ulcerative colitis, rheumatoid arthritis, and multiple sclerosis are disclosed.08-18-2011
20110171218COMPOSITIONS AND METHODS FOR INCREASING SERUM HALF-LIFE - Provided herein are glycovariant Fc fusion proteins having increased serum half lives. Also provided are methods for increasing the serum half life of an Fc fusion protein by introducing one or more non-endogenous glycosylation sites.07-14-2011
20110171219TREATING CANCER STEM CELLS USING TARGETED CARGO PROTEINS - The disclosure provides targeted cargo proteins that are useful for targeting cancer stem cells, and methods of their use in treating cancer.07-14-2011
20090285815IMMUNOCONJUGATES COMPRISING CD4 AND IMMUNOGLOBIN MOLECULES FOR THE TREATMENT OF HIV INFECTION - Nucleic acids encoding recombinant CD4-fusion proteins are disclosed herein that include a CD4 polypeptide ligated at its C-terminus with a portion of an immunoglobulin comprising a hinge region and a constant domain of a mammalian immunoglobulin heavy chain. The portion of the IgG is fused at its C-terminus with a polypeptide comprising a tailpiece from the C terminus of the heavy chain of an IgA antibody or a tailpiece from a C terminus of the heavy chain of an IgM antibody. Also disclosed herein are methods for using these CD4-fusion proteins.11-19-2009
20120121592Targeting Antigens to Human Dendritic Cells Via DC-Asialoglycoprotein Receptor to Produce IL-10 Regulatory T-Cells - Compositions and methods for targeting protein antigens to human DCs via DC-asialoglycoprotein receptor (DC-ASGPR) are disclosed herein. The DC-ASGPR carries an intracellular tyrosine-based and dileucine motif, resulting in the generation of such IL-10 Tregs both in vitro and in vivo. The methods of the present invention can be used for designing vaccines against autoimmune diseases where autoantigens are defined, such as type 1 diabetes and multiple sclerosis.05-17-2012
20080206246POLYPEPTIDES WITH ENHANCED ANTI-INFLAMMATORY AND DECREASED CYTOTOXIC PROPERTIES AND RELATING METHODS - The invention provides a polypeptide containing at least one IgG Fc region, wherein said at least one IgG Fc region is glycosylated with at least one galactose moiety connected to a respective terminal sialic acid moiety by a α2,6 linkage, and wherein said polypeptide having a higher anti-inflammatory activity as compared to an unpurified antibody.08-28-2008
20120121591SELECTIVE AND POTENT PEPTIDE INHIBITORS OF Kv1.3 - Disclosed are compositions of matter having an amino acid sequence of SEQ ID NO:4, or a pharmaceutically acceptable salt thereof, including embodiments comprising a toxin peptide analog related to ShK, HmK, and AETX-K and pharmaceutical compositions or medicaments containing them along with a pharmaceutically acceptable carrier. Some embodiments include a half-life extending moiety. Also disclosed are a method of preventing or mitigating a relapse of a symptom of multiple sclerosis and a method of treating an autoimmune disorder using the compositions.05-17-2012
20120294857Monomeric Bi-Specific Fusion Protein - The present invention embraces a bi-specific fusion protein composed of an effector cell-specific antibody-variable region fragment operably linked to at least a portion of a natural killer cell receptor. Methods for using the fusion protein in the treatment of cancer and pathogenic infections are also provided.11-22-2012
20100278826Designer Ubiquitin Ligases For Regulation Of Intracellular Pathogenic Proteins - The present invention relates to a designer or recombinant ubiquitin ligase molecule that includes an antibody fragment that is specific for a toxin active fragment, wherein the toxin active fragment is an enzymatically active fragment of one or more toxins or toxin serotypes; and an E3-ligase domain that comprises an E3-ligase or polypeptide that facilitates E2-mediated ubiquitination of the toxin active fragment. In an embodiment, the composition further includes a delivery system that allow the designer ubiquitin ligase to enter the cell. The present invention further includes methods for treating an individual intoxicated with a toxin by administering the designer ubiquitin ligase of the present invention.11-04-2010
20100136006TREATMENT OF OSTEOLYTIC DISORDERS AND CANCER USING CSF1R EXTRACELLULAR DOMAIN FUSION MOLECULES - Methods of using colony stimulating factor receptor (CSF1R) extracellular domain (ECD) fusion molecules to treat treating osteolytic bone loss, cancer metastasis, cancer metastasis-induced osteolytic bone loss, and tumor growth are provided. CSF1R ECD fusion molecules, polynucleotides encoding CSF1R ECD fusion molecules, and methods of making CSF1R ECD fusion molecules are also provided.06-03-2010
20120294856COMPOUNDS INHIBITING CD95 SIGNALING FOR THE TREATMENT OF PANCREATIC CANCER - The present invention is concerned with compounds inhibiting CD95 signaling in pancreatic cancer cells. Furthermore, contemplated by the current invention are medicaments comprising such a compound for the prevention and/or treatment of pancreatic cancer as well as the use of such a compound for the manufacture of a medicament for the prevention and/or treatment of pancreatic cancer, the prevention of migration of cancer cells, and/or the prevention and/or treatment of an inflammatory reaction. The present invention also refers to a method for the identification of a compound inhibiting CD95 signaling, as we to a method for the manufacture of a medicament comprising the steps of the method for the identification of a compound inhibiting CD95 signaling and the further step of formulating the inhibiting compound as a medicament.11-22-2012
20120294858USE OF LONG-ACTING RECOMBINANT HUMAN SOLUBLE TUMOR NECROSIS FACTOR ALPHA RECEPTOR IN MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT AND/OR PROPHYLAXIS OF HEPATIC FAILURE - The present invention belongs to the field of the application of genetic engineering and gene function, and it is directed to a new medical use of the gene encoding the recombinant soluble tumor necrosis factor α receptor (HusTNFR). The present invention made intervention to fulminant hepatic failure in mice by use of the long-acting recombinant human soluble tumor necrosis factor α receptor and the classic animal models of acute and sub-acute hepatic failure. The results showed that the long-acting soluble tumor necrosis factor α receptor of the present invention has a half-life extended more than 10 times, and it significantly decreased the mortality of model animals and has superior therapeutic effect for the treatment and/or prophylaxis of acute and sub-acute hepatic failure in model animals. These receptors have a noticeable therapeutic effect for the treatment and/or prophylaxis of acute and sub-acute hepatic failure in comparison with the non-long-acting HusTNFR.11-22-2012
20110142835METHOD OF PREVENTING THE DEVELOPMENT OF RHEUMATOID ARTHRITIS IN SUBJECTS WITH UNDIFFERENTIATED ARTHRITIS - The invention relates to methods and compositions for treating undifferentiated arthritis (UA) and/or preventing the development of rheumatoid arthritis (RA) in subjects with UA by administering to a subject in need thereof an effective amount of soluble CTLA4 molecule.06-16-2011
20110008341Polypeptides and methods for making the same - An isolated protein having at least 90% homology with the dimeric protein having the following amino acid sequence01-13-2011
20080206244COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF BREAST CANCER - Compositions and methods for the therapy and diagnosis of cancer, particularly breast cancer, are disclosed. Illustrative compositions comprise one or more breast tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly breast cancer.08-28-2008
20080206247Glycoprotein VI fusion proteins - The present invention relates to Glycoprotein VI (GPVI) fusion proteins (GPVI-fusion proteins) comprising a tag like myc, GST, HA, FLAG, STREP but preferably a Immunoglobulin molecule (Ig), more preferably a Fc portion of said Ig and a protein or oligopeptide having the biological activity of GPVI (GPVI-like protein) which is binding to collagen and their use in methods and kits for the screening of potential agonists or antagonists for GPVI-collagen and/or platelet-collagen interaction is disclosed.08-28-2008
20110268737HLA-G PROTEINS AND PHARMACEUTICAL USES THEREOF - The present invention relates to novel proteins and pharmaceutical uses thereof. The invention more specifically relates to novel fusion proteins comprising a domain of an HLA-G antigen fused to an Fc domain of an immunoglobulin. The invention also relates to methods of producing such polypeptides, pharmaceutical compositions comprising the same, as well as their uses for treating various diseases including organ/tissue rejection.11-03-2011
20110206669MCP1 FUSIONS - The present invention provides polypeptides including MCP1 fused, optionally, by a linker, to an immunoglobulin. Methods for using the polypeptides to treat medical disorders are also covered.08-25-2011
20090155269Mesothelin antibody protein fusions and methods of use - The invention relates to fusion proteins comprising a stress protein fused with an engineered antibody or fragment that binds to mesothelin, or a stress protein fused with a biotin-binding protein in combination with a biotinylated engineered antibody or fragment that binds to mesothelin. The invention also relates to fusion proteins comprising a stress protein fused with an antibody binding protein in combination with an engineered antibody or fragment that binds to mesothelin. The invention also relates to fusion proteins comprising an engineered antibody or fragment that binds specifically to mesothelin fused in frame with a biotin binding protein. The invention also provides fusion proteins comprising an engineered antibody or fragment, that binds to mesothelin, fused with an antibody binding protein. The invention also relates to methods of using fusion proteins of the invention to induce an immune response to mesothelin and to treat disease.06-18-2009
20090155271IL-17A AND IL-17F ANTAGONISTS AND METHODS OF USING THE SAME - The present invention relates antagonists of IL-17A and IL-17F. The antagonists of the invention are based on IL-17RC alone or on both IL-17RC and IL-17RA (“IL-17RC/IL-17RA”). Such antagonists serve to block, inhibit, reduce, antagonize or neutralize the activity of IL-17F, IL-17A, or both IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. IL-17RA is a receptor for IL-17A and IL-17RC is a common receptor for both IL-17A and IL-17F. The present invention includes soluble IL-17A and IL-17F anatagonists, as well as methods for using the same.06-18-2009
20090155268Growth Factor Binding Constructs Materials and Methods - The present invention provides materials and methods for antagonizing the function of vascular endothelial growth factor receptors, platelet derived growth factor receptors and other receptors. Soluble binding constructs able to bind vascular endothelial growth factors, platelet derived growth factors, and other ligands are provided.06-18-2009
20100272720Antibody Fusion Proteins with a Modified FcRn Binding Site - Disclosed are antibody fusion proteins with a modified FcRn binding site and nucleic acid molecules encoding them. The antibody fusion protein include two polypeptide chains, wherein the first polypeptide chain includes a biologically active molecule linked to at least a portion of an immunoglobulin constant region. The second polypeptide chain includes at least a portion of an immunoglobulin constant region. One of the polypeptide chains includes a mutation in the FcRn binding site that reduces binding to FcRn. Also disclosed are methods of producing the fusion proteins and methods of using the fusion proteins for treating diseases and conditions alleviated by the administration of the fusion proteins.10-28-2010
20090186026EPHRIN AND EPH RECEPTOR AGONISTS FOR MODULATION OF BONE FORMATION AND RESORPTION - Compositions that stimulate bone formation and inhibit bone resorption through activation of both arms of EphrinB2-EphB4 signaling are provided. The composition comprises a bi-functional molecule having at least one EphB4 ligand-binding domain conjugated to an anti-EphB4 antibody.07-23-2009
20120070436ANTIGEN-BINDING PROTEINS - The present invention relates to antigen binding proteins comprising a receptor-Fc fusion which is linked to one or more epitope-binding domains, methods for making such proteins, and uses thereof.03-22-2012
20120070434ANTIBODIES CONTAINING THERAPEUTIC TPO/EPO MIMETIC PEPTIDES - The present disclosure features therapeutic antibodies (e.g., TPO mimetic antibodies) and therapeutically-active fragments thereof as well as methods for preparing and using the antibodies and fragments. For example, the therapeutic antibodies and their fragments are useful in a variety of diagnostic and/or therapeutic applications such as methods for increasing platelet levels in a subject.03-22-2012
20090186024Gene Expression Signatures for Oncogenic Pathway Deregulation - The disclosure relates to identifying deregulated pathways in cancer. In certain embodiments, the methods of the disclosure can be used to evaluate therapeutic agents for the treatment of cancer.07-23-2009
20080317750ANTIBODY ANTAGONISTS OF VE-CADHERIN WITHOUT ADVERSE EFFECTS ON VASCULAR PERMEABILITY - The murine epitope sequence recognized by antibody E4B9 shares 100% homology with human VE-cadherin, so this antibody was examined to determine if it cross-reacts with human VE-cadherin. Western-blot analysis of several VE-cadherin expressing human and murine cells indicated that E4B9 indeed cross-reacts with human VE-cadherin (FIG. 12-25-2008
20130216537Methods of Treating Glucose Metabolism Disorders and Promoting Weight Loss - Compositions and methods for treating individuals with a glucose metabolism disorder and methods for promoting weight loss in an individual are provided.08-22-2013
20130122003METHODS OF INHIBITING TUMOR GROWTH BY ANTAGONIZING IL-6 RECEPTOR - The present invention provides methods for inhibiting or attenuating tumor growth in a subject by administering an IL-6 antagonist to the subject. In certain embodiments, the methods of the invention are used to inhibit the growth of an anti-VEGF-resistant tumor in a subject. The IL-6 antagonist may be, e.g., an antibody that specifically binds IL-6R. The IL-6 antagonist may be administered in combination with a VEGF antagonist, and/or an EGFR antagonist.05-16-2013
20090208502APOPTOSIS-INDUCING PROTEIN COMPLEXES AND THERAPEUTIC USE THEREOF - The invention relates to the fields of immunology and molecular medicine. In particular, it relates to protein complexes that can be applied as therapeutic agent to induce apoptotic cell death in a target cell population, for example tumour cells or virally infected cells. Provided is a multivalent monospecific protein complex comprising at least six polypeptides capable of recognizing and binding to a specific Major Histocompatibility Complex (MHC)-peptide complex, which complex induces apoptosis through the recognition of and binding to MHC-peptide molecules of a target cell. Also provided is the therapeutic use of a protein complex, for example for the manufacture of a medicament for the treatment of cancer, a viral or a microbial infection.08-20-2009
20090208500Method of producing antibodies with improved function - The invention provides methods for controlling fucosylation levels and improving ADCC activity in antibodies.08-20-2009
20090081217Modified Chimeric Polypeptides with Improved Pharmacokinetic Properties - Modified chimeric polypeptides with improved pharmacokinetics are disclosed. Specifically, modified chimeric Flt1 receptor polypeptides that have been modified in such a way as to improve their pharmacokinetic profile are disclosed. Also disclosed are methods of making and using the modified polypeptides including but not limited to using the modified polypeptides to decrease or inhibit plasma leakage and/or vascular permeability in a mammal.03-26-2009
20110229473METHODS FOR USING TACI-IMMUNOGLOBULIN FUSION PROTEINS - Molecules that interfere with the binding of a tumor necrosis factor receptor with its ligand, such as a soluble receptor, have proven usefulness in both basic research and as therapeutics. The present invention provides improved soluble transmembrane activator and calcium modulator and cyclophilin ligand-interactor (TACI) receptors.09-22-2011
20110229472Peptides and Related Compounds Having Thrombopoietic Activity - The present invention relates generally to novel peptides and related compounds that have thrombopoietic activity. The compounds of the invention may be used to increase production of platelets or platelet precursors (e.g. megakaryocytes) in a mammal.09-22-2011
20100158911Compositions and Methods of Treating Disease with FGFR Fusion Proteins - The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.06-24-2010
20090004190Rage Fusion Proteins And Methods Of Use - Disclosed are RAGE fusion proteins comprising RAGE polypeptide sequences linked to a second, non-RAGE polypeptide. The RAGE fusion protein may utilize a RAGE polypeptide domain comprising a RAGE ligand binding site and an interdomain linker directly linked to an immunoglobulin C01-01-2009
20090208501Anti-Pathogen Immunoadhesins - Chimeric molecules that include a pathogen recognition module derived from a pathogen binding domain of a pathogen recognition protein, e.g., a toll-like receptor (TLR), CD14, BPI, MD-2, scavenger receptors (SRs), surfactant proteins (SP), C-reactive protein (CRP), Mannan-binding lectin (MBL), or complement Clq globular binding domain, an optional linker, and an Fc portion of an antibody are described and are useful for, e.g., drug discovery and treatment of conditions related to TLR signaling.08-20-2009
20090110680Combination of an anti ED-B fibronectin domain antibody and gemcitabine - Disclosed is a combination of an anti edb fibronectin domain antibody and gemcitabine.04-30-2009
20090220506HUMAN EPO MIMETIC HINGE CORE MIMETIBODIES, COMPOSITIONS, METHODS AND USES - The present invention relates to at least one novel human EPO mimetic hinge core mimetibody or specified portion or variant, including isolated nucleic acids that encode at least one EPO mimetic hinge core mimetibody or specified portion or variant, EPO mimetic hinge core mimetibody or specified portion or variants, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.09-03-2009
20080260738SINGLE CHAIN FC, METHODS OF MAKING AND METHODS OF TREATMENT - The present invention relates generally to scFc molecules. The scFc molecules comprise at least two Fc regions and at least one linker, and can be produced in a variety of single chain configurations. The scFc molecules can further comprise at least one binding entity and/or at least one functional molecule. Binding entities can be fused to the scFc molecule in a variety of configurations. The present invention also relates generally to methods for making such molecules and methods for their use. The scFc molecules provided herein can be recombinantly produced. Also provided are monovalent forms of the scFc molecules that have an equivalent or superior ADCC and/or CDC response than do bivalent molecules targeting the same antigens. Provided herein are improved antigen binding compositions. Methods for using the scFc molecules of the present inventions are provided10-23-2008
20080260736Methods and Compositions to Regulate Iron Metabolism - The present invention provides new systems and strategies for the regulation of iron metabolism in mammals. In particular, methods of using agonists and antagonists of TGF-β superfamily members to modulate the expression or activity of hepcidin, a key regulator of iron metabolism, are described. The inventive methods find applications in the treatment of diseases associated with iron overload, such as juvenile hemochromatosis and adult hemochromatosis, and in the treatment of diseases associated with iron deficiency, such as anemia of chronic disease and EPO resistant anemia in end-stage of renal disease. The present invention also relates to screening tools and methods for the development of novel drugs and therapies for treating iron metabolism disorders.10-23-2008
20120141482MOLECULAR COMPLEXES WHICH MODIFY IMMUNE RESPONSES - Extracellular domains of transmembrane heterodimeric proteins, particularly T cell receptor and major histocompatibility complex proteins, can be covalently linked to the heavy and light chains of immunoglobulin molecules to provide soluble multivalent molecular complexes with high affinity for their cognate ligands. The molecular complexes can be used, inter alia, to detect and regulate antigen-specific T cells and as therapeutic agents for treating disorders involving immune system regulation, such as allergies, autoimmune diseases, tumors, infections, and transplant rejection.06-07-2012
20100150923FUSION PROTEINS OF RECOMBINANT SARS CORONAVIRUS STRUCTURAL PROTEINS, THEIR PRODUCTION AND USES - Fusion proteins of recombinant SARS coronavirus structural proteins, their production and uses are provided. An optimized SARS coronavirus S protein gene which can be highly expressed in the mammalian cell strains and SARS coronavirus S protein variants comprising deletion, modification or mutation amino acids 318-510 corresponding to SARS coronavirus S protein are also provided.06-17-2010
20090258018Methods for treating juvenile idiopathic arthritis - The invention provides methods and compositions for the treatment of juvenile idiopathic arthritis (JIA) where a TNFα inhibitor, such as a human TNFα antibody, or antigen-binding portion thereof, is used to treat JIA. In particular, the invention is directed to methods and compositions relating to a fixed dosing regimen for treating JIA with a TNFα inhibitor.10-15-2009
20090297521CD33-SPECIFIC SINGLE-CHAIN IMMUNOTOXIN AND METHODS OF USE - A single-chain immunotoxin composition and method of treatment with the composition is disclosed. Preferably, the immunotoxin is comprised of a CD33-specific single chain Fv antibody fragment and a genetically engineered variant of 12-03-2009
20100183608DRG11-RESPONSIVE (DRAGON) GENE AND USES THEREOF - This invention features methods and compositions useful for treating and diseases caused by a dysregulation of the BMP/GDF branch of the TGF-β signaling pathway. Also disclosed are methods for identifying compounds useful for such therapy.07-22-2010
20100183611TARGETED CRYPTOSPORIDIUM BIOCIDES - The present invention relates to fusion proteins comprising a microorganism targeting molecule (e.g., immunoglobulin) and a biocide. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in diverse fields.07-22-2010
20100260758IN VIVO MODULATION OF NEURONAL TRANSPORT - The invention relates to means for in vivo delivery of a composition into the human or animal central nervous system or spinal cord, wherein the composition comprises a non-toxic, proteolytic fragment of tetanus toxoid in association with at least a molecule having a biological function, and said molecule is capable of in vivo retrograde axonal transport and transynaptic transport into the CNS or spinal cord of the human or animal. In a particular embodiment, the composition comprises a fragment C and a fragment B of tetanus toxoid or a fraction thereof of at least 11 amino acid residues. The composition can further comprise a fraction of fragment A of tetanus toxoid.10-14-2010
20100260759IMMUNOSUPPRESSIVE POLYPEPTIDES AND NUCLEIC ACIDS - The invention provides immunosuppressive polypeptides and nucleic acids encoding such polypeptides. In one aspect, the invention provides mutant CTLA-4 polypeptides and nucleic acids encoding mutant CTLA-4 polypeptides. Compositions and methods for utilizing such polypeptides and nucleic acids are also provided.10-14-2010
20100183609TACI-IMMUNOGLOBULIN FUSION PROTEINS - Molecules that interfere with the binding of a tumor necrosis factor receptor with its ligand, such as a soluble receptor, have proven usefulness in both basic research and as therapeutics. The present invention provides improved soluble transmembrane activator and calcium modulator and cyclophilin ligand-interactor (TACI) receptors.07-22-2010
20110129469METHODS FOR TREATING FATTY LIVER DISEASE - In certain aspects, the present invention provides compositions and methods for treating fatty liver disease by administering an antagonist of an ActRIIB signaling pathway. Examples of such antagonists include ActRIIB polypeptides, anti-ActRIIB antibodies, anti-myostatin antibodies, anti-GDF3 antibodies and anti-activin A or B antibodies. A variety of hepatic and metabolic disorders may be improved by treating fatty liver disease.06-02-2011
20100215656DELETIONS IN DOMAIN II OF PSEUDOMONAS EXOTOXIN A THAT REMOVE IMMUNOGENIC EPITOPES - The invention provides mutated, cytotoxic forms of 08-26-2010
20100221252MDL-1 USES - The invention provides methods for treating bone resorption disorders with antagonists of MDL-1.09-02-2010
20100150924REGULATION OF MYELINATION BY NECTIN-LIKE (NECL) MOLECULES - The invention provides polypeptides comprising isolated domains of Necl proteins, particularly of Necl4, that mediate axon-glia adhesion required for myelination. The invention further provides pharmaceutical compositions comprising as the active ingredient a polypeptide comprising an isolated Necl4 domain, or a polynucleotide encoding a polypeptide comprising an isolated Necl4 domain. Further provided are antibodies directed against isolated Necl domains, siRNA capable of down regulating Necl4 expression, and methods for treating neurological disorders which are associated with aberrant myelination.06-17-2010
20100254985Protein Formulations - The present invention provides formulations of proteins comprising a variant Fc region that improve the stability in part by reducing the propensisty of such molecules to rapidly aggregate. The invention provides both liquid and lyophilized formulations either of which can be utilized to generate a high protein concentration liquid suitable for administration to a subject. The invention further provides methods of utilizing the formulations of the present invention for therapeutic or prophylactic treatment of diseases and disorders or for diagnostic purposes.10-07-2010
20120195897HUMAN DOMAIN ANTIBODIES AGAINST COMPONENTS OF THE HUMAN INSULIN-LIKE GROWTH FACTOR (IGF) SYSTEM - The invention provides antibodies or antibody fragments that bind to insulin-like growth factor (IGF) 1 receptor (IGF-1R) or IGF-2, as well as method of using the antibodies for inhibiting the IGF-mediated signaling pathway, inhibiting IGF-1R signaling, and treating cancer. The invention also provides a method of detecting the presence of IGF-1R or IGF-2 in a sample using the inventive antibodies and antibody fragments.08-02-2012
20120195894REGULATORY T CELL MEDIATOR PROTEINS AND USES THEREOF - The present invention relates to novel regulatory T cell proteins. One protein, designated PD-L3, resembles members of the PD-L1 family, and co-stimulates αCD3 proliferation of T cells in vitro. A second, TNF-like, protein has also been identified as being upregulated upon αCD3/αGITR stimulation. This protein has been designated T08-02-2012
20110129468PURIFIED IMMUNOGLOBULIN FUSION PROTEINS AND METHODS OF THEIR PURIFICATION - The invention provides methods and compositions for separating impurities during the manufacture of immunoglobulin (Ig) fusion proteins. Examples of impurities which may be removed in accordance with the methods of the invention include inactive forms of the Ig fusion protein and/or aggregates.06-02-2011
20130216538Compositions and Methods for Treating Inflammatory Disorders - The invention relates to compositions and methods for treating inflammatory disorders. More specifically, the invention relates to antibody compositions and their use in the treatment of inflammatory disorders.08-22-2013
20130216539Methods of Generation and Treatment with Modified Derivatives of HSP 70 - The present invention includes methods of generating derivatives of a protein, as well as methods of treating a subject with the derivatized proteins. More particularly, the present invention includes methods of generating derivatives of HSP 70 proteins and methods of treating a subject with the derivatized HSP 70 proteins.08-22-2013
20130216540MODULATION OF THE INNATE IMMUNE SYSTEM THROUGH THE TREM-LIKE TRANSCRIPT 2 PROTEIN - TREM-like transcript 2 (TLT2), is expressed on neutrophils, macrophages, and B lymphocytes. Expression of TLT2 is up-regulated on neutrophils and macrophages in response to inflammatory stimuli in vivo and synergizes with agonists that bind to G-protein coupled receptors (GPCR) to potentiate the neutrophil antibacterial and chemotactic response. Administration of anti-TLT2 mAb enhances the acute inflammatory response in vivo that is associated with increased neutrophil recruitment to sites of inflammation. TLT2 ligation in vivo also potentiates chemokine and growth factor production indicating that TLT2 can exert both neutrophil intrinsic and extrinsic effects. The administration of anti-TLT2 mAb alone promotes neutrophil recruitment to the lung and peritoneum, as well as the rapid production of G-CSF, CXCL1 (KC) and CXCL2 (MIP-2). Additionally, the administration of an agent to the circulatory system of an animal can reduce the availability of a TLT2 endogenous ligand to reduce the extent of a neutrophil or macrophage-induced inflammatory response.08-22-2013
20130216541STABLE SUBCUTANEOUS PROTEIN FORMULATIONS AND USES THEREOF - The present invention relates generally to stable formulations comprising CTLA4Ig molecules, including lyophilized, and liquid formulations for administration via various routes including, for example, routes such as intravenous (IV) and subcutaneous (SC) for treating immune system diseases and tolerance induction.08-22-2013
20100239580TACI-IMMUNOGLOBULIN FUSION PROTEINS FOR TREATMENT OF OPTIC NEURITIS - The invention relates to TACI-Immunoglobulin fusion proteins for the treatment of optic neuritis.09-23-2010
20100226921Methods for treating obesity using Fibroblast Growth Factor-Like Polypeptides - The present invention provides novel Fibroblast Growth Factor-like (FGF-like) polypeptides and nucleic acid molecules encoding the same. The invention also provides vectors, host cells, antibodies and methods for producing FGF-like polypeptides. Also provided for are methods for the diagnosis and treatment of diseases associated with FGF-like polypeptides.09-09-2010
20100254984FUSION CONSTRUCTS CONTAINING ACTIVE SECTIONS OF TNF LIGANDS - Disclosed is a recombinant fusion protein containing an amino-acid sequence which comprises: (a) the Fc section or part of an Fc section of an immunoglobulin as component (A) or a functional variant of component (A); (b) the extracellular part of a TNF ligand or a partial sequence of the extracellular part of a TNF ligand as component (B) or a functional variant of component (B); and optionally (c) a transition area between component (A) and component (B), containing a linker.10-07-2010
20100254982CANCER SPECIFIC ANTIBODY AND CELL SURFACE PROTEINS - The present invention provides the amino acid and nucleic acid sequences of heavy chain and light chain complementarity determining regions of a cancer specific antibody. In addition, the invention provides cancer specific antibodies and immunoconjugates comprising the cancer specific antibody attached to a toxin or label, and methods and uses thereof. The invention also relates to diagnostic methods and kits using the cancer specific antibodies of the invention. Further, the invention provides a novel cancer-associated antigen and its uses thereof.10-07-2010
20120141481WNT ANTAGONISTS AND THEIR USE IN THE DIAGNOSIS AND TREATMENT OF WNT-MEDIATED DISORDERS - The present invention provides for chimeric Wnt antagonists comprising a Frz domain component derived from a Frizzled protein, a secreted Frizzled related protein or Ror protein and an Fc immunoglobulin component, and their use in the treatment and diagnostic detection of cellular Wnt signaling and Wnt-mediated disorders, including cancer.06-07-2012
20120141483METHODS OF TREATING OR PREVENTING PSORIASIS, AND/OR ALZHEIMER'S DISEASE USING INDANE ACETIC ACID DERIVATIVES - The present invention provides indane acetic acids and their derivatives and methods for the treatment and/or prevention of psoriasis and/or Alzheimer's diseases using the same.06-07-2012
20120141479Histone Deacetylase Inhibitors Sensitize Cancer Cells To Epidermal Growth Factor Inhibitors - Disclosed is the use of a combination of histone deacetylase inhibitors and kinase inhibitors with anti-EGFR activity.06-07-2012
20120141478COMPOSITIONS AND METHODS FOR DELIVERING ANTI-ACTIVATED RAS ANTIBODIES - The present invention concerns a chimeric polypeptide comprising: (i) a first domain comprising an amino-acid sequence facilitating active transport across a biological membrane by the binding to an glycosaminoglycan, which is selected from the group consisting of a) (XBBBXXBX)n; (XBBXBX)n; c) (BBXmBBXp)n; d) (XBEXXTBX)n; e) (BXmBB)n; f) (BmXX)n or g) an antibody fragment, wherein each B is independently a basic amino acid preferably lysine or arginine; each X is independently a non-basic amino acid preferably hydrophobic amino acid; each m is independently an integer from zero to five; each n is independently an integer between one and ten; and each p is independently an integer between zero to five; and (ii) a second domain comprises an anti-activated RAS neutralizing antibody, fragment or derivative thereof; a polynucleotide encoding said polypeptide; a pharmaceutical composition comprising said polynucleotide or said polypeptide; and the use of said polypeptide for the manufacture of a medicament for treating cancer.06-07-2012
20090041769Methods of treatment using CTLA4 mutant molecules - The present invention provides soluble CTLA4 mutant molecules which bind with greater avidity to the CD80 and/or CD86 antigen than wild type CTLA4 or non-mutated CTLA4Ig. The soluble CTLA4 molecules have a first amino acid sequence comprising the extracellular domain of CTLA4, where certain amino acid residues within the S25-R33 region and M97-G107 region are mutated. The mutant molecules of the invention may also include a second amino acid sequence which increases the solubility of the mutant molecule.02-12-2009
20120195896IGF-1 FUSION POLYPEPTIDES AND THERAPEUTIC USES THEREOF - A fusion protein comprising at least one IGF1 variant component and a fusion component (F), and, optionally, a signal sequence, exhibits improved stability relative to the native IGF1 or IGF2 polypeptide. The fusion component (F) may be a multimerizing component, such as an immunoglobulin domain, in particular, the Fc domain of IgG or a heavy chain of IgG. IGF1 variants were shown to have improved ability to increase muscle mass in a subject suffering from muscle atrophy caused by cachexia, immobilization, aging, chronic disease, cancer, hereditary condition, an atrophy-causing agent, and the like. IGF1 variants are also effective in decreasing blood glucose in a subject suffering from diabetes or hyperglycemia.08-02-2012
20120195895 Fusion Protein of an Anti-CD20 Antibody Fab Fragment and Lidamycin, a Method for Preparing the Same, and the Use Thereof - The present invention relates to an anticancer drug, an energized fusion protein Anti-CD20(Fab)-LDM of lidamycin, a gene encoding the same; and further relates to a method for construction of the energized fusion protein in a genetic engineering manner and the use of the energized fusion protein. The applicant provides an anti-tumor drug with a good targeting ability by providing the energized fusion protein.08-02-2012
20120195893TH1/TH2 polarizing vaccines - The present invention relates to recombinant chimeric molecules that are capable of providing T cell receptor (TCR) interaction and costimulation for activation and differentiation of pathogen-specific T cells toward effector T helper 1 (Th1) or T helper 2 (Th2) cells. The chimera may capable of elicit antibodies against pathogen-specific B cell epitope(s). The present invention also relates method of using these chimeric molecules in whole or as a component of a vaccine.08-02-2012
20090280119Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis - The invention relates to methods and compositions for treating undifferentiated arthritis (UA) and/or preventing the development of rheumatoid arthritis (RA) in subjects with UA by administering to a subject in need thereof an effective amount of soluble CTLA4 molecule.11-12-2009
20090074768Activin-actriia antagonists and uses for treating or preventing breast cancer - In certain aspects, the present invention provides compositions and methods for treating or preventing breast cancer in humans.03-19-2009
20090074767Isolated human phosphodiesterase proteins, nucleic acid molecules encoding human phosphodiesterase proteins, and uses thereof - The present invention provides amino acid sequences of peptides that are encoded by genes within the human genome, the phosphodiesterase peptides of the present invention. The present invention specifically provides isolated peptide and nucleic acid molecules, methods of identifying orthologs and paralogs of the phosphodiesterase peptides, and methods of identifying modulators of the phosphodiesterase peptides.03-19-2009
20120244153TREATMENT OF DEMYELINATING DISORDERS WITH SOLUBLE LYMPHOTOXIN-BETA-RECEPTOR - The invention relates to the treatment of demyelinating disorders, e.g. multiple sclerosis, using a soluble lymphotoxin beta receptor (LTβR) as an inhibitor of the lymphotoxin pathway.09-27-2012
20120189624TREATMENT AND PROPHYLAXIS OF AMYLOIDOSIS - Methods useful for effecting prophylaxis or treatment of amyloidosis, including AA Amyloidosis and AL amyloidosis, by administering peptides comprising neoepitopes, such as AA fragments from a C-terminal region of AA, and antibodies specific for neoepitopes of aggregated amyloid proteins, for example, antibodies specific for the C-terminal region of AA fibrils. Antibodies for inhibition of formation and/or increasing clearance of amyloid deposits in a patient thus effecting prophylaxis or treating amyloid disease.07-26-2012
20130129723Heterodimer Binding Proteins and Uses Thereof - The present disclosure provides polypeptide heterodimers formed between two different single chain fusion polypeptides via natural heterodimerization of an immunoglobulin CH1 region and an immunoglobulin light chain constant region (CL). The polypeptide heterodimer comprises two or more binding domains that specifically bind one or more targets (e.g., a receptor). In addition, both chains of the heterodimer further comprise an Fc region portion. The present disclosure also provides nucleic acids, vectors, host cells and methods for making polypeptide heterodimers as well as methods for using such polypeptide heterodimers, such as in directing T cell activation, inhibiting solid malignancy growth, and treating autoimmune or inflammatory conditions.05-23-2013
20130129724DUAL FUNCTION PROTEINS FOR TREATING METABOLIC DISORDERS - The present invention relates to the identification of new proteins comprising fibroblast growth factor 21 (FGF21) and other metabolic regulators, including variants thereof, known to improve metabolic profiles in subjects to whom they are administered. Also disclosed are methods for treating FGF21-associated disorders, GLP-1-associated disorders, and Exendin-4-associated disorders, including metabolic conditions.05-23-2013
20130129727METHODS AND SYSTEMS FOR INCREASING PROTEIN STABILITY - Methods and systems for increasing stability of a target polypeptide in a serum are described. The methods and systems utilize a fusion protein comprising a single-domain antibody against a serum albumin (SASA), the target polypeptide and optionally a linker. The fusion protein has a significantly prolonged serum half life in comparison with the target polypeptide alone. The SASA fusion tag also facilitates the expression and purification of the fusion protein. This allows direct in vivo screening or utilization of the target polypeptide for its biological activity or efficacy regardless of its intrinsic serum half life, which has significantly increased the number of candidates for the development of novel protein based diagnosis or treatment.05-23-2013
20110236385BLOCKING MESOTHELIN PEPTIDE FRAGMENTS - The present invention provides mesothelin peptide fragments corresponding to the CA125 binding site of mesothelin. The peptide fragments find use in disrupting the binding interaction between mesothelin and CA 125, for example, in the treatment and prevention of cancers that require the interaction of mesothelin and CA125 for growth, progression and/or metastasis.09-29-2011
20100297122FORMULATIONS FOR TACI-IMMUNOGLOBULIN FUSION PROTEINS - The invention relates to formulations of TACI-Immunoglobulin fusion proteins.11-25-2010
20100297123COMBINATION THERAPY TO INHIBIT T CELL EFFECTOR FUNCTION - Methods and compositions are provided for inhibiting the responsiveness of CD411-25-2010
20100297119BONE TARGETED ALKALINE PHOSPHATASE, KITS AND METHODS OF USE THEREOF - A bone targeted alkaline phosphatase comprising a polypeptide having the structure: Z-sALP-Y-spacer-X-W11-25-2010
20110117092COMPOSITIONS AND METHODS FOR INHIBITING G-CSFR - The present invention relates to therapeutic targets for multiple sclerosis and other inflammatory and neurological diseases. In particular, the present invention relates to altering G-CSF/G-CSFR signaling in the treatment of such disorders.05-19-2011
20100291082ANTIGEN PRESENTING CELL TARGETED ANTI-VIRAL VACCINES - The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.11-18-2010
20100291080COMPOSITIONS AND METHODS FOR TISSUE REPAIR - The present invention provides compositions and methods for targeting an extracellular matrix derived (EMD) peptide predominantly to an injured tissue, as opposed to an uninjured tissue in vivo. The targeted EMD peptide facilitates the repair and/or regeneration of the injured tissue by providing a surface for cells to attach and grow, thereby facilitating the repair and/or regeneration of the injured tissue.11-18-2010
20100310560Novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof - Novel activating receptors of the Ig super-family expressed on human myeloid cells, called TREM(s) (triggering receptor expressed on myeloid cells) are provided. Specifically, two (2) members of TREMs, TREM-1 and TREM-2 are disclosed. TREM-1 is a transmembrane glycoprotein expressed selectively on blood neutrophils and a subset of monocytes but not on lymphocytes and other cell types and is upregulated by bacterial and fungal products. Use of TREM-1 in treatment and diagnosis of various inflammatory diseases is also provided. TREM-2 is also a transmembrane glycoprotein expressed selectively on mast cells and peripheral dendritic cells (DCs) but not on granulocytes or monocytes. DC stimulation via TREM-2 leads to DC maturation and resistance to apoptosis, and induces strong upregulation of CCR12-09-2010
20100303814Antibodies Against a Cancer-Associated Epitope of Variant HNRNPG and Uses Thereof - The present application provides the amino acid and nucleic acid sequences of heavy and light chain complementarity determining regions of a cancer specific antibody directed to an epitope of variant Heterogeneous Ribonucleoprotein G (HnRNPG). In addition, the application provides cancer specific antibodies and immunoconjugates comprising the cancer specific antibody attached to a toxin or label, and methods of uses thereof. The application also relates to diagnostic methods and kits using the cancer specific antibodies disclosed herein. Further, the application provides novel cancer-associated epitopes and antigens of variant HnRNPG, and uses thereof.12-02-2010
20100303815METHOD OF TREATING ANEMIA BY ADMINISTERING IL 1ra - The invention relates to methods of treating a blood disorder in a mammal with an interleukin-1 (IL-1) inhibitor. The invention also relates to methods of treating a blood disorder in a mammal with an IL-1 inhibitor, a TNF inhibitor and an erythropoietin (EPO) receptor agonist. The invention also relates to compositions of an IL-1 inhibitor and compositions of an IL-1 inhibitor, a TNF inhibitor and an EPO receptor agonist.12-02-2010
20100303812NEUTRALIZING MONOCLONAL ANTIBODY AGAINST HUMAN DLL4 - The present invention provides a binding protein capable of binding to DLL4 as well as methods and uses thereof in therapy, diagnosis or imaging. Also provided are fusion proteins and protein conjugates, nucleic acid molecules encoding the binding proteins and methods of preparing binding proteins capable of binding to DLL4.12-02-2010
20130136738Methods of Treating Glucose Metabolism Disorders - Methods of treating individuals with a glucose metabolism disorder, and compositions thereof, are provided.05-30-2013
20130136740METHODS OF TREATING CANCER - Methods of treating cancers comprising FGFR1 gene amplification are provided. In some embodiments, the methods comprise administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule. In some embodiments, the methods comprise administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule in combination with at least one additional therapeutic agent.05-30-2013
20130136741Novel Enhanced Selectin Antagonists - Recombinant proteins comprised of multiple selectin binding domains derived from the glycopeptide PSGL-1, in a novel tandem configuration, are disclosed, including their fusions with immunoglobulins and/or other polypeptides. Polynucleotides encoding such proteins, compositions and kits containing such proteins, and methods of using such proteins are also disclosed.05-30-2013
20130136742PEPTIDE HAVING CELL MEMBRANE PENETRATING ACTIVITY - Provided are transmembrane complexes that contain a protein transduction domain (PTD) from the N-terminus of IgE-dependent histamine-releasing factor (HRF) and a target substance that is to be delivered into a cell. Also provided are nucleic acid molecules encoding the transmembrane complex, and methods of delivering the target substance into a cell interior by contacting the transmembrane complex with a cell. Also provided are transfection kits containing the PTD and the target substance.05-30-2013
20100310562SYSTEM FOR DELIVERY INTO XCR1 POSITIVE CELL AND USES THEREOF - The present invention relates to a delivery system suitable for delivering a substance into a XCR1 positive professional antigen-presenting cell, one or more nucleic acids coding for the same, a vector comprising the nucleic acid(s), a medicament comprising the delivery system or the one or more nucleic acid(s) and an adjuvant comprising XCL1 or a functionally active fragment thereof.12-09-2010
20100310563METHODS FOR TREATING INDUCED CELLULAR PROLIFERATIVE DISORDERS - Methods are provided for treating a subject with a cellular proliferative disorder that include administering to the subject a therapeutically effective amount of a JAK2 inhibitor and a therapeutically effective amount of a TNF-alpha inhibitor. In addition, methods are provided herein for determining if a subject with a cellular proliferative disorder would benefit from treatment with an agent that inhibits tumor necrosis factor (TNF)-alpha. Methods are also provided for identifying an agent of use in treating a subject with a cellular proliferative disorder or with a predisposition for cellular proliferative disorder. The methods include contacting an isolated cell expressing an activating mutation in the JAK2 protein with a test agent, and detecting the amount of tumor necrosis factor (TNF)-alpha produced by the cell.12-09-2010
20130142794Methods and Compositions for Increasing Arylsulfatase A Activity in the CNS - Provided herein are methods and compositions for treating a subject suffering from a deficiency in arylsulfatase A in the CNS. The methods include systemic administration of a bifunctional fusion antibody comprising an antibody to a human insulin receptor and an arylsulfatase A.06-06-2013
20100183612METHODS OF TREATMENT USING CTLA4 MUTANT MOLECULES - The present invention provides soluble CTLA4 mutant molecules which bind with greater avidity to the CD80 and/or CD86 antigen than wild type CTLA4 or non-mutated CTLA4Ig. The soluble CTLA4 molecules have a first amino acid sequence comprising the extracellular domain of CTLA4, where certain amino acid residues within the S25-R33 region and M97-G107 region are mutated. The mutant molecules of the invention may also include a second amino acid sequence which increases the solubility of the mutant molecule.07-22-2010
20110020342IGF-1 FUSION POLYPEPTIDES AND THERAPEUTIC USES THEREOF - A fusion protein comprising at least one IGF1 variant component and a fusion component (F), and, optionally, a signal sequence, exhibits improved stability relative to the native IGF1 or IGF2 polypeptide. The fusion component (F) may be a multimerizing component, such as an immunoglobulin domain, in particular, the Fc domain of IgG or a heavy chain of IgG. IGF1 variants were shown to have improved ability to increase muscle mass in a subject suffering from muscle atrophy caused by cachexia, immobilization, aging, chronic disease, cancer, hereditary condition, an atrophy-causing agent, and the like. IGF1 variants are also effective in decreasing blood glucose in a subject suffering from diabetes or hyperglycemia.01-27-2011
20110020345DRUG FUSIONS AND CONJUGATES - The present invention relates to drug fusions that have improved serum half lives. These fusions and conjugates comprise polypeptides, immunoglobulin (antibody) single variable domains and GLP and/or exendin molecules. The invention further relates to uses, formulations, compositions and devices comprising such drug fusions and conjugates.01-27-2011
20090155267MOLECULE AND CHIMERIC MOLECULES THEREOF - The present invention relates generally to the fields of proteins, diagnostics, therapeutics and nutrition. More particularly, the present invention provides an isolated protein molecule which comprises a C-type lectin or an EGF-like domain such as amphiregulin, CD209L, Langerin, L-selectin or chimeric molecules thereof comprising at least a portion of the protein molecule, such as amphiregulin-Fc, CD209L-Fc, Langerin S, Langerin L, Langerin L-FLAG, Langerin-Fc, L-selectin-Fc wherein the protein or chimeric molecule thereof has a profile of measurable physiochemical parameters, wherein the profile is indicative of, associated with or forms the basis of one or more pharmacological traits. The present invention further contemplates the use of the isolated protein or chimeric molecule thereof in a range of diagnostic, prophylactic, therapeutic, nutritional and/or research applications.06-18-2009
20110033464IMMUNOGLOBULIN FUSION PROTEIN FORMULATIONS - The present invention provides compositions of Ig fusion proteins, especially compositions including an Ig fusion protein, a bulking agent, a disaccharide, a surfactant, and a buffer. In one aspect, these compositions are stable under long-term storage or at least one freeze/thaw cycle. The invention also provides methods of preparation of the Ig fusion protein compositions. In one aspect, compositions of the invention are lyophilized. In a further aspect, the compositions are lyophilized by a process that includes an annealing step.02-10-2011
20110033463APHERESIS, ADMINISTRATION OF AGENT, OR COMBINATION THEREOF - A device is configured to remove a target molecule from a bodily fluid of a subject and to deliver a therapeutic agent to the subject. Such a device may be used for treatment of a disease associated with amyloid beta accumulation in the subject. Agents selected from the group consisting of an ApoE-modulating agent; a RAGE inhibitor; a β-secretase 1 (BACE1) inhibitor; a γ-secretase inhibitor; a muscarinic receptor subtype 1 (M1) agonists; a growth factor; an enzyme capable of degrading amyloid beta; a mitochondrial antioxidant; insulin; and an inhibitor of tumor necrosis factor (TNF) may be administered directly to the central nervous system of a subject for treatment of a disease associated with amyloid beta accumulation.02-10-2011
20110129470USE OF SPECIFICALLY ENGINEERED ENZYMES TO ENHANCE THE EFFICACY OF PRODRUGS - The invention provides methods for enhancing efficiency of prodrugs by specifically engineered enzymes with altered or enhanced activity and broader substrate specificity towards nucleoside analogs used in cancer chemotherapy, and delivering the enzymes to specific target cells in a patient. The invention also provides modified deoxycytidine kinase (dCK) mutants with such enhanced activities. Furthermore, the invention provides antibody-conjugated enzymes, pharmaceutical composition and kit containing the same, that can be specifically delivered to tumor cells.06-02-2011
20110110946SOLUBLE RECEPTOR BR43X2 AND METHODS OF USING - Soluble, secreted tumor necrosis factor receptor polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed. The polypeptides comprise one cysteine-rich repeat that is homologous to other tumor necrosis factor receptors, such as transmembrane activator and CAML-interactor (TACI). The polypeptides may be used for detecting ligands, agonists and antagonists. The polypeptides may also be used in methods that modulate B cell activation.05-12-2011
20110110945Immunoglobulin Fusion Proteins and Methods of Making - Disclosed are immunoglobulin fusion proteins and methods of making such proteins. In certain embodiments, the fusion protein may include a non-immunoglobulin polypeptide linked to an immunoglobulin polypeptide. In certain embodiments, the non-immunoglobulin polypeptide may comprise a region that replaces an immunoglobulin Fc hinge region, but that allows for correct assembly of the immunoglobulin chains.05-12-2011
20110117094Reactivation of Axon Growth and Recovery in Chronic Spinal Cord Injury - Disclosed are methods of treating chronic nervous system diseases or injuries, e.g., chronic spinal cord injury, using Nogo receptor antagonists, including Nogo receptor-1 (NgR1) polypeptides, Nogo receptor-1 antibodies and antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof, and polynucleotides. Also disclosed are methods of noninvasively monitoring axonal growth during and after treatment with an axonal growth promoting agent.05-19-2011
20120034223METHODS OF IMPROVING THE THERAPEUTIC EFFICACY AND UTILITY OF ANTIBODY FRAGMENTS - The present disclosure relates to methods and uses of improving the therapeutic efficacy and utility of antibody fragments by employing anti-epitope-tagging technologies.02-09-2012
20110243944Fusion Protein Inhibiting Osteoclast Formation, Preparation Method and Medicine Compositions Thereof - The present invention provides a coding gene having the nucleic acid sequence shown as SEQ ID NO:1 and the fusion protein RIG (SEQ ID NO:2) that inhibits osteoclast formation. The present invention also provides the preparation method for the fusion protein RIG as well as synthetic oligo-nucleotide primers, plasmids and host cells used in the method and a medicine having the above fusion protein RIG as active ingredient. The fusion protein RIG in present invention is derived from humanized immunoglobulin and RANKL with a flexible hinge region. RIG can cross link the cell surface receptor RANK and Fcγ 1 to induce a cytosolic inhibitory signal leading to the inhibition of osteoclast formation. The fusion protein RIG in present invention can play an essential role in treating osteoporosis and bone resorption diseases caused by tumor metastasis.10-06-2011
20110243942RELAXIN-FUSION PROTEINS WITH EXTENDED IN VIVO HALF-LIVES - Disclosed are human relaxin-Fc fusion proteins having an increased serum half-life, polynucleotides encoding the same, and intermediates formed during the fusion protein biosynthesis. The fusion proteins may include a linker portion or other sections as well. Suitable fusion proteins are also those predicted to have the same effect as human relaxin in vivo, based, for example, on structural modeling. The fusion protein is useful in the treatment of a number of diseases and conditions, including heart disease, vascular disease, wound healing, fibrosis, fibromyalgia, and promoting angiogenesis.10-06-2011
20100226920MEDICAL DELIVERY DEVICE FOR THERAPEUTIC PROTEINS BASED ON SINGLE DOMAIN ANTIBODIES - The present invention relates to a pen-style administration device for administering therapeutic or diagnostic therapeutic proteins that are based on single domain antibodies, and methods of using such a device in therapies or diagnoses.09-09-2010
20090092607FC-ERYTHROPOIETIN FUSION PROTEIN WITH IMPROVED PHARMACOKINETICS - The present invention provides Fc-erythropoietin (“Fc-EPO”) fusion proteins with improved pharmacokinetics. Nucleic acids, cells, and methods relating to the production and practice of the invention are also provided.04-09-2009
20100008918Methods for dosing an actriib antagonist and monitoring of treated patients - In certain aspects, the present invention provides methods for dosing a patient with an ActRIIb antagonist and methods for managing patients treated with an ActRIIb anatagonist. In certain aspects, the methods involve measuring one or more hematologic parameters in a patient.01-14-2010
20100196372FcgammaRIIB Fusion Proteins and Compositions Thereof - The present invention relates to molecules, preferably soluble (i.e., not membrane bound) polypeptides, most preferably soluble fusion polypeptides comprising the extracellular soluble regions of an FcγR, derivatives and analogs thereof, and nucleic acids encoding same. Molecules of the invention are particularly useful for the treatment, management, or prevention of, or amelioration of one or more symptoms of, an autoimmune disease, especially for ameliorating serum platelet deficiency associated with immune thrombocytopenic purpura. The invention provides methods and compositions for enhancing the therapeutic efficacy of standard, current or experimental therapies for an autoimmune disease by administering a molecule of the invention.08-05-2010
20110165160NEUTROKINE-ALPHA AND NEUTROKINE-ALPHA SPLICE VARIANT - The present invention relates to nucleic acid molecules encoding Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides, including soluble forms of the extracellular domain. Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to antibodies or portions thereof that specifically bind Neutrokine-alpha and/or Neutrokine-alphaSV and diagnostic and therapeutic methods using these antibodies. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders using the compositions of the invention.07-07-2011
20100008920Reagents and Methods for Engaging Unique Clonotypic Lymphocyte Receptors - Platforms comprising at least one lymphocyte affecting molecule and at least one molecular complex that, when bound to an antigen, engages a unique clonotypic lymphocyte receptor can be used to induce and expand therapeutically useful numbers of specific lymphocyte populations. Antigen presenting platforms comprising a T cell affecting molecule and an antigen presenting complex can induce and expand antigen-specific T cells in the presence of relevant peptides, providing reproducible and economical methods for generating therapeutic numbers of such cells. Antibody inducing platforms comprising a B cell affecting molecule and a molecular complex that engages MHC-antigen complexes on a B cell surface can be used to induce and expand B cells that produce antibodies with particular specificities.01-14-2010
20100034820BINDING DOMAIN-IMMUNOGLOBULIN FUSION PROTEINS - The invention relates to novel binding domain-immunoglobulin fusion proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, a wild-type IgG1, IGA or IgE hinge region polypeptide or a mutant IgG1 hinge region polypeptide having either zero, one or two cysteine residues, and immunoglobulin CH2 and CH3 domains, and that are capable of ADCC and/or CDC while occurring predominantly as polypeptides that are compromised in their ability to form disulfide-linked multimers. The fusion proteins can be recombinantly produced at high express levels. Also provided are related compositions and methods, including cell surface forms of the fusion proteins and immunotherapeutic applications of the fusion proteins and of polynucleotides encoding such fusion proteins.02-11-2010
20100055101CYTOKINE RECEPTOR ZCYTOR17 MULTIMERS - Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17-containing multimeric or heterodimer cytokine receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. The present invention also includes methods for producing the multimeric or heterodimeric cytokine receptor, uses therefor and antibodies thereto.03-04-2010
20110177071IMMUNOSUPPRESSIVE POLYPEPTIDES AND NUCLEIC ACIDS - The invention provides immunosuppressive polypeptides and nucleic acids encoding such polypeptides. In one aspect, the invention provides mutant CTLA-4 polypeptides and nucleic acids encoding mutant CTLA-4 polypeptides. Compositions and methods for utilizing such polypeptides and nucleic acids are also provided.07-21-2011
20110177070TGF-Beta Antagonist Multi-Target Binding Proteins - This disclosure provides a multi-target fusion protein composed of a TGF? antagonist domain and another binding domain antagonistic for a heterologous target (such as IL6, IL10, VEGF, TNF, HGF, TWEAK, IGF) or agonistic for a heterologous target (such as GITR). The multi-specific fusion protein may also include an intervening domain that separates the binding domains and allows for dimerization. This disclosure also provides polynucleotides encoding the multi-specific fusion proteins, compositions of the fusion proteins, and methods of using the multi-specific fusion proteins and compositions.07-21-2011
20110177069NOVEL INDUCER OF CHONDROCYTE PROLIFERATION AND DIFFERENTIATION - This invention provides a method for administration of an effective amount of RANKL-binding molecules that act on prechondrocytes and/or mesenchymal stem cells, accelerate cartilage differentiation, proliferation, and maturation of such cells, enhance chondrocyte differentiation, and induce chondrocyte proliferation to induce chondrocyte proliferation and differentiation or increase cartilage matrix production and a pharmaceutical composition used for inducing chondrocyte proliferation and differentiation or increasing cartilage matrix production. The pharmaceutical composition used for treatment or prevention of a chondropathies comprises, as an active ingredient, a compound that acts on prechondrocytes and/or mesenchymal stem cells and induces at least one of the following: (a) acceleration of prechondrocyte and/or mesenchymal stem cell differentiation; (b) acceleration of prechondrocyte and/or mesenchymal stem cell proliferation; (c) acceleration of prechondrocyte and/or mesenchymal stem cell maturation; (d) enhancement of chondrocyte differentiation; (e) chondrocyte proliferation; and (f) increased production of the cartilage matrix.07-21-2011
20110250200SOLUBLE LYMPHOTOXIN-BETA RECEPTOR FUSION PROTEIN AND METHODS FOR INHIBITING LYMPHOTOXIN BETA-RECEPTOR SIGNALING - This invention relates to compositions and methods comprising “lymphotoxin-β-receptor blocking agents”, which block lymphotoxin-β receptor signalling. Lymphotoxin-β receptor blocking agents are useful for treating lymphocyte-mediated immunological diseases, and more particularly, for inhibiting Th1 cell-mediated immune responses. This invention relates to soluble forms of the lymphotoxin-β receptor extracellular domain that act as lymphotoxin-β receptor blocking agents. This invention also relates to the use of antibodies directed against either the lymphotoxin-β receptor or its ligand, surface lymphotoxin, that act as lymphotoxin-β receptor blocking agents. A novel screening method for selecting soluble receptors, antibodies and other agents that block LT-β receptor signalling is provided.10-13-2011
20110250198ActRIIB FUSION POLYPEPTIDES AND USES THEREFOR - Methods and compositions for inhibiting growth and differentiation factor-8 (GDF-8) activity in vitro and in vivo are provided. The methods and composition can be used for diagnosing, preventing, or treating degenerative disorders of muscle, bone, or glucose homeostasis.10-13-2011
20110081344SOLUBLE ZCYTOR 11 CYTOKINE RECEPTORS - Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for soluble zcytor11 receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides and antibodies can also be used to block TIF activity in vitro and in vivo, and may be used in conjunction with TIF and other cytokines to selectively stimulate the immune system. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.04-07-2011
20110070233ACTRIIB ANTAGONISTS AND DOSING AND USES THEREOF - In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density, as well as for the treatment of multiple myeloma. Methods for dosing a patient with an ActRIIb antagonist are also provided.03-24-2011
20110150873ANTI-INFLAMMATORY COMPOSITIONS AND COMBINATIONS - The invention relates to the use of Broad-Spectrum Chemokine Inhibitors (BSCIs), and in particular members of the acylaminolactam class of pharmaceutical agents, for the prevention, prophylaxis, treatment or amelioration of symptoms of inflammatory diseases. In particular, improved compositions consisting of BSCI agents combined with one or more additional active pharmaceutical agents in order to achieve improved anti-inflammatory efficacy with a reduced side-effect profile are described and claimed.06-23-2011
20120148586GLUCAGON-LIKE PROTEIN-1 RECEPTOR (GLP-1R) AGONISTS FOR TREATING AUTOIMMUNE DISORDERS - Glucagon-like peptide-1 receptor (GLP-1R) agonists are provided for reducing leukocyte invasion of the central nervous system in autoimmune diseases such as multiple sclerosis. GLP-1R agonists include, e.g., naturally-occurring agonists, such as exendin-4, as well as GLP-1R agonist peptides linked to antibodies.06-14-2012
20120148585FUSION MOLECULES AND METHODS FOR TREATMENT OF IMMUNE DISEASES - The invention concerns bifunctional fusion molecules, and novel, safer and more efficacious methods for the treatment of immune disorders resulting from excessive or unwanted immune responses. The invention provides methods for the suppression of type I hypersensitive (i.e., IgE-mediated) allergic conditions, methods for the prevention of anaphylactic responses that occur as a result of traditional peptide immunotherapies for allergic and autoimmune disorders, and provides novel methods for the treatment of autoimmune conditions, where the methods have reduced risk of triggering an anaphylactic response. The invention provides novel therapeutic approaches for the treatment of allergic responses, including the prevention of anaphylactic response that can occur from environmental allergen exposure. The invention also provides methods for the treatment of autoimmune disorders such as multiple sclerosis, autoimmune type I diabetes mellitus, and rheumatoid arthritis. The invention also provides methods for preventing anaphylactic response during traditional antigen therapies.06-14-2012
20100272719Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains - Described herein are novel soluble chimeric fusion proteins comprising amino acid sequences derived from the vascular endothelial growth factor (VEGF) receptors flt-1 and KDR, including domain 4 of KDR. The claimed chimeric fusion proteins antagonize the endothelial cell proliferative and angiogenic activity of VEGF and are useful in the treatment of neovascularization-related disease.10-28-2010
20100297124INDUCED INTERNALIZATION OF SURFACE RECEPTORS - Disclosed is a hetero-bifunctional ligand for use in inducing internalization of a target receptor. The hetero-bifunctional ligand includes a target receptor-binding agent that specifically binds the target receptor linked to an internalizing receptor-binding agent that specifically binds to an internalizing receptor, where the two binding agents are non-identical. Also disclosed is a method of inducing the internalization of a target receptor on a cell. The method includes contacting a cell with a hetero-bifunctional ligand, where binding of the hetero-bifunctional ligand induces internalization of a target receptor of the cell. Also disclosed a method of treating a disease or condition associated with a target receptor using the disclosed hetero-bifunctional ligand and pharmaceutical compositions including a hetero-bifunctional ligand.11-25-2010
20100266592THERAPEUTIC ANTENNAPEDIA-ANTIBODY MOLECULES AND METHODS OF USE THEREOF - The present invention is based on the seminal discovery that an antibody or fragment thereof combined with Antennapedia or a fragment thereof, is an effective therapeutic agent. The invention describes the construction of antibody or antibody fragment fused or chemically conjugated with Antennapedia at its carboxyl or its amino terminus (a “cargo-carrier” construct).10-21-2010
20110150874FUSION PROTEINS, USES THEREOF AND PROCESSES FOR PRODUCING SAME - This invention provides fusion proteins comprising consecutive amino acids which beginning at the amino terminus of the protein correspond to consecutive amino acids present in (i) a cytomegalovirus human MHC-restricted peptide, (ii) a first peptide linker, (iii) a human β-2 microglobulin, (iv) a second peptide linker, (v) a HLA-A2 chain of a human MHC class I molecule, (vi) a third peptide linker, (vii) a variable region from a heavy chain of a scFv fragment of an antibody, and (viii) a variable region from a light chain of such scFv fragment, wherein the consecutive amino acids which correspond to (vii) and (viii) are bound together directly by a peptide bond or by consecutive amino acids which correspond to a fourth peptide linker, wherein the antibody from which the scFv fragment is derived specifically binds to mesothelin. This invention provides nucleic acid constructs encoding same, processes for producing same, compositions, and uses thereof.06-23-2011
20090022720Conjugate of an antibody against CD4 and antifusogenic peptides - The current invention is related to a conjugate comprising two or more antifusogenic peptides and an anti-CD4 antibody (mAb CD4) characterized in that one to eight antifusogenic peptides are each conjugated to one terminus of the heavy and/or light chains of said anti-CD4 antibody and to the pharmaceutical use of said conjugate.01-22-2009
20090324595CANCER PROGNOSTIC DIAGNOSTIC AND TREATMENT METHODS - The invention disclosed herein provides methods comprising detection of EphB2 polypeptide and/or polynucleotide in a biological sample from a subject, wherein the detection of EphB2 is predictive or indicative of cancer prognosis for the subject. The invention also provides methods for selecting cancer treatment, methods comprising detection of EphB2 polypeptide and/or polynucleotide expression in colon adenomas, and methods for treating a colon adenoma disorder. Kits, compositions, and articles of manufacture are also provided.12-31-2009
20090317389FUSION MOLECULES AND METHODS FOR TREATMENT OF IMMUNE DISEASES - The invention concerns bifunctional fusion molecules, and novel, safer and more efficacious methods for the treatment of immune disorders resulting from excessive or unwanted immune responses. The invention provides methods for the suppression of type I hypersensitive (i.e., IgE-mediated) allergic conditions, methods for the prevention of anaphylactic responses that occur as a result of traditional peptide immunotherapies for allergic and autoimmune disorders, and provides novel methods for the treatment of autoimmune conditions, where the methods have reduced risk of triggering an anaphylactic response. The invention provides novel therapeutic approaches for the treatment of allergic responses, including the prevention of anaphylactic response that can occur from environmental allergen exposure. The invention also provides methods for the treatment of autoimmune disorders such as multiple sclerosis, autoimmune type I diabetes mellitus, and rheumatoid arthritis. The invention also provides methods for preventing anaphylactic response during traditional antigen therapies.12-24-2009
20110150875EGF-A DOMAIN-MEDIATED MODULATION OF PCKS9 FOR TREATING LIPID DISORDERS - The present invention provides, in part, methods and compositions for treating lipid disorders comprising administering a polypeptide that inhibits PCSK9. A novel method for identifying polypeptides that interact with PCSK9 is also provided.06-23-2011
20120201819TREATMENT OF DRUG-RELATED SIDE EFFECT AND TISSUE DAMAGE BY TARGETING THE CD-24-HMGB1-SIGLEC10 AXIS - The present technology provides methods and compositions for the treatment of tissue-damage related immune dysregulation by administering a composition comprising one or more of CD24; CD24 fragments, variants and derivatives, CD24Fc fusion proteins; HMBG1-binding proteins, binding proteins to HMBG1 Box B; antagonists of HMGB1, polyclonal, monoclonal, recombinant, chimeric, humanized scFv antibodies and antibody fragments to HMGB1 or fragments of HMGB1 and antibodies that bind and suppress the activity of HMGB1 Box B; Siglec 10 agonists such as anti-Siglec 10 antibodies; and combinations thereof to a patient.08-09-2012
20110256133ANTI-POLYUBIQUITIN ANTIBODIES AND METHODS OF USE - The invention provides anti-polyubiquitin antibodies and methods of using the same.10-20-2011
20100285014IMMUNOGLOBULIN FUSION PROTEINS - The present invention relates to novel methods for making fusion proteins comprising a cytokine or growth factor fused to an immunoglobulin domain. The growth factor/cytokine can be fused directly to an immunoglobulin domain or through a peptide linker. The purified growth factor/cytokine-IgG fusion proteins produced by the novel methods are biologically active and can be used to treat diseases for which the non-fused growth factor/cytokine are useful.11-11-2010
20100278827CONCATAMERIC IMMUNOADHESION MOLECULE - Disclosed are concatameric proteins comprising two soluble domains, in which the C-terminus of a soluble domain of a biologically active protein is linked to the N-terminus of an identical soluble domain or a distinct soluble domain of a biologically active protein. Also, the present invention discloses dimeric proteins formed by formation of intermolecular disulfide bonds at the hinge region of two monomeric proteins formed by linkage of a concatamer of two identical soluble extracellular regions of proteins involving immune response to an Fc fragment pf an immunoglobulin molecule, their glycosylated proteins, DNA constructs encoding the monomeric proteins, recombinant expression plasmids containing the DNA construct, host cells transformed or transfected with the recombinant expression plasmids, and a method of preparing the dimeric proteins by culturing the host cells. Further, the present invention discloses pharmaceutical or diagnostic compositions comprising the dimeric protein or its glycosylated form.11-04-2010
20110020344HUMAN MONOCLONAL ANTIBODIES SPECIFIC FOR CD22 - Disclosed herein are isolated human monoclonal antibodies that specifically bind human CD22 with a dissociation constant (K01-27-2011
20110020341NOVEL MULTIDRUG RESISTANCE-ASSOCIATED POLYPEPTIDE - Compositions and methods are disclosed for improving the effectiveness of a chemotherapeutic regimen to eradicate multidrug-resistant transformed cells from the body of a mammal, preferably from the body of a human. The present disclosure capitalizes on the discovery of a novel multidrug-resistance associated protein (MRP), herein designated MRP-β. The disclosed compositions include MRP-β nucleic acids, including probes and antisense oligonucleotides, MRP-β polypeptides and antibodies, MRP-β expressing host cells, and non-human mammals transgenic or nullizygous for MRP-β. The disclosed methods include methods for attenuating aberrant MRP-β gene expression, protein production and/or protein function. In addition, methods are disclosed for identifying and using a modulator, such as an inhibitor, of MRP-β. Preferably, the modulator is a small molecule.01-27-2011
20110020340ANTIBODY-LIGHT FUSION PRODUCTS FOR CANCER THERAPEUTICS - Antibody-LIGHT fusion products or conjugates stimulate immunity against tumors and eradicate metastases. Tumor-specific antibodies coupled with LIGHT effectively target metastatic tumors and reduces cancer metastases.01-27-2011
20110020343AURISTATIN DRUG LINKER CONJUGATES - Drug Linker compounds and Drug Linker Ligand conjugates are provided that have auristatins linked via the C-terminus. The conjugates show efficacy without the need for a self-immolative group to release the drug.01-27-2011
20110027278REGULATORY T CELL MEDIATOR PROTEINS AND USES THEREOF - The present invention relates to novel regulatory T cell proteins. One protein, designated PD-L3, resembles members of the PD-L1 family, and co-stimulates αCD3 proliferation of T cells in vitro. A second, TNF-like, protein has also been identified as being upregulated upon αCD3/αGITR stimulation. This protein has been designated T02-03-2011
20100285015TARGETING RECOMBINANT THERAPEUTICS TO CIRCULATING RED BLOOD CELLS - Fusion proteins comprising a single chain antigen-binding domain (scFv) of a monoclonal antibody, linked to an anti-thrombotic agent, anti-inflammatory agent, or a pro-drug thereof are provided, where the polypeptide binds to a binding site (antigen) expressed on the surface of a red blood cell at a density greater than 5,000 copies per red blood cell. Pharmaceutical compositions comprising these fusion proteins, and methods of delivering an anti-thrombotic agent to the surface of a red blood cell via delivery of these fusion proteins, and methods of treating or preventing thrombosis, tissue ischemia, acute myocardial infarction (AMI), ischemic stroke, cerebrovascular disease, pulmonary embolism, or ischemic peripheral vascular disease via administration of the fusion proteins or compositions comprising same are also provided.11-11-2010
20110117093ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO B LYMPHOCYTE STIMULATOR PROTEIN - The present invention relates to antibodies and related molecules that immunospecifically bind to B Lymphocyte Stimulator. The present invention also relates to methods and compositions for detecting or diagnosing a disease or disorder associated with aberrant B Lymphocyte Stimulator expression or inappropriate function of B Lymphocyte Stimulator comprising antibodies or fragments or variants thereof or related molecules that immunospecifically bind to B Lymphocyte Stimulator. The present invention further relates to methods and compositions for preventing, treating or ameliorating a disease or disorder associated with aberrant B Lymphocyte Stimulator expression or inappropriate B Lymphocyte Stimulator function comprising administering to an animal an effective amount of one or more antibodies or fragments or variants thereof or related molecules that immunospecifically bind to B Lymphocyte Stimulator.05-19-2011
20110052585COMPOSITIONS AND METHODS FOR INHIBITING INTERLEUKIN PATHWAYS - Fusion proteins including an IL-17 receptor with a multimerization domain, or an IL-23 receptor and a multimerization domain, and recombinant viral vectors encoding such fusions, are described. The fusion proteins and vectors encoding such fusions, alone or in combination, can be used in methods for modulating the IL-17 and IL-23 signaling pathways and for treating or preventing diseases mediated by interleukin-17 and interleukin-23, such as immune-related and inflammatory diseases.03-03-2011
20100322929ANTIGEN PRESENTING CELL TARGETED CANCER VACCINES - The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.12-23-2010
20100330088STRATEGIES TO PREVENT AND/OR TREAT IMMUNIE RESPONSES TO SOLUBLE ALLOFACTORS - The present invention relates to the use of immunogenic peptides comprising a T-cell epitope derived from a soluble allofactor and a redox motif such as C-(X)2-[CST] or [CST]-(X)2-C in the prevention and/or suppression of immune responses to said soluble allofactor and in the manufacture of medicaments therefore.12-30-2010
20110097324COMPOSITIONS AND METHODS FOR MODULATING NICOTINIC/NMDA RECEPTOR FUNCTION - The present invention provides a method for modulating nicotinic/NMDA receptor function in a mammal in need of such treatment comprising administering a therapeutically effective amount of an agent that disrupts heterodimerization of α04-28-2011
20100158909Variant Target Binding Agents and Uses Thereof - The present invention provides variant target binding agents and methods relating to the use of such binding agents for the prophylaxis or treatment of cancers and immunological disorders. The variant target binding agent is conjugated to a therapeutic agent that exerts a cytotoxic, cytostatic, or immunomodulatory effect on target cells.06-24-2010
20100158910TREATMENT OF RENAL CELL CARCINOMA WITH ANTI-CD70 ANTIBODY-DRUG CONJUGATES - Disclosed are anti-CD70 antibodies and derivatives thereof conjugated to cytotoxic, therapeutic agents, as well as pharmaceutical compositions and kits comprising the antibody- and antibody derivative-drug conjugates. Also disclosed are methods, for the treatment of CD70-expressing a cancer, comprising administering to a subject the disclosed pharmaceutical compositions.06-24-2010
20100196373Intrathecal and Intratumoral Superantigens to Treat Malignant Disease - The presence of tumor nodules in organs often results in serious clinical manifestations and the permeation by cancer cells of sheaths surrounding organs often produces clinical manifestations of pleural effusion, ascites or cerebral edema. The present invention addresses this problem by providing a method for treating minors comprising (a) intratumoral administration of a superantigen and/or (b) intrathecal or intracavitary administration of a superantigen directly into the sheath. Intratumoral superantigen results in significant and sustained reduction of the tumor size. Intrathecal administration produces significant sustained reduction of the fluid accumulation associated with clinical improvement and prolonged survival. Useful superantigen compositions for intrathecal and intratumoral injection include tumoricidally effective homologues, fragments and fusion proteins of native superantigens. Also disclosed is combined therapy that includes intratumoral or intrathecal superantigen compositions in combination with (i) intratumoral low, non-toxic doses of one or more chemotherapeutic drugs or (ii) systemic chemotherapy at reduced and non-toxic doses of chemotherapeutic drugs.08-05-2010
20100196371METHOD OF MODULATING THE ACTIVITY OF FUNCTIONAL IMMUNE MOLECULES - The invention relates to a method for controlling the activity of an immunologically functional molecule, such as an antibody, a protein, a peptide or the like, an agent of promoting the activity of an immunologically functional molecule, and an immunologically functional molecule having the promoted activity.08-05-2010
20110189182PROTEOLYTICALLY CLEAVABLE FUSION PROTEINS WITH HIGH MOLAR SPECIFIC ACTIVITY - The invention relates to therapeutic fusion proteins in which a coagulation factor is fused to a half-life enhancing polypeptide, and in which both are connected by a linker peptide that is proteolytically cleavable. The cleavage of such linkers liberates the coagulation factor from activity-compromising steric hindrance caused by the half-life enhancing polypeptide and thereby allows the generation of fusion proteins may show relatively high molar specific activity when tested in coagulation-related assays. Furthermore, the fact that the linker is cleavable can enhance the rates of inactivation and/or elimination after proteolytic cleavage of the peptide linker compared to the rates measured for corresponding therapeutic fusion proteins linked by the non-cleavable linker having the amino acid sequence GGGGGGV.08-04-2011
20110189181Use of agents derived from CEACAM1 for the treatment of inflammatory diseases - The use of an agent that selectively modulates cross-linking of biliary glycoprotein polypeptides for the preparation of a pharmaceutical composition for preventing or treatment of a mammal subject afflicted with an inflammatory disease is provided. In particular, a method for preventing or treatment of a mammal subject afflicted with rheumatoid arthritis or multiple sclerosis, comprising the step of administering to a mammal in need thereof a therapeutic effective amount of a fusion protein of a fragment of biliary glycoprotein and a fragment of an immunoglobulin is described.08-04-2011
20110189180ANTIGENIC COMPOSITIONS AND USE OF SAME IN THE TARGETED DELIVERY OF NUCLEIC ACIDS - Methods and compositions are provided for delivery of therapeutic nucleic acids to a target cell. A chimeric antigen is provided to encapsulate, bind, or otherwise carry a nucleic acid molecule to a target cell where the chimeric antigen and nucleic acid are internalized by receptor-mediated endocytosis. The chimeric antigen has a nucleic acid interaction domain, a target binding domain, and an immune response domain that may include a target antigen. Targeting is generally provided by the specificity of the target binding domain for a particular target cell receptor, but may also be provided by inclusion of a targeting antigen within the immune response domain. The combined delivery of chimeric antigen and nucleic acid, which may be a siRNA, may be synergistic in certain applications, for example in breaking host tolerance to a virus or in providing immunostimulation.08-04-2011
20120308565CHEMOKINE-IMMUNOGLOBULIN FUSION POLYPEPTIDES, COMPOSITIONS, METHOD OF MAKING AND USE THEREOF - This application is directed to chemokine-immunoglobulin fusion polypeptides and chemokine-polymer conjugates. The fusion polypeptides and conjugates can be used for treating chemokine receptor-mediated disorders and modulating inflammation, inflammatory cell motility, cancer cell motility, or cancer cell survival.12-06-2012
20100021462GASP1: A FOLLISTATIN DOMAIN CONTAINING PROTEIN - The present invention relates to the use of a protein, GASP1, comprising at least one follistatin domain to modulate the level or activity of growth and differentiation factor-8 (GDF-8). More particularly, the invention relates to the use of GASP1 for treating disorders that are related to modulation of the level or activity of GDF-8. The invention is useful for treating muscular diseases and disorders, particularly those in which an increase in muscle tissue would be therapeutically beneficial. The invention is also useful for treating diseases and disorders related to metabolism, adipose tissue, and bone degeneration.01-28-2010
20100316643TARGETED ANTIMICROBIAL MOIETIES - This invention provides novel targeted antimicrobial compositions. In various embodiments chimeric moieties are provided comprising an antimicrobial peptide attached to a peptide targeting moiety that binds a bacterial strain or species.12-16-2010
20090297520Methods of using conjugated toxin peptide therapeutic agents - Disclosed is a composition of matter comprising an OSK1 peptide analog, and in some embodiments, a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises the composition and a pharmaceutically acceptable carrier. Also disclosed are DNAs encoding the inventive composition of matter, an expression vector comprising the DNA, and host cells comprising the expression vector. Methods of treating an autoimmune disorder and of preventing or mitigating a relapse of a symptom of multiple sclerosis are also disclosed.12-03-2009
20100303813BIOMARKERS FOR PREDICTING ANTI-TNF RESPONSIVENESS OR NON-RESPONSIVENESS - The present disclosure provides biomarkers that are predictive a subject's responsiveness or non-responsiveness to an anti-TNF therapy. The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities (e.g., an anti-TNF therapy or a non-anti-TNF therapy) for a subject suffering from a disease such as an immune disorder.12-02-2010
20090258017Lyophilized therapeutic peptibody Formulations - The present invention provides long-term stable formulations of a lyophilized therapeutic peptibody and methods for making a lyophilized composition comprising a therapeutic peptibody.10-15-2009
20100129366THIAZOLE INHIBITORS OF CYCLOOXYGENASE - The present invention relates to new thiazole inhibitors of cyclooxygenase, pharmaceutical compositions thereof, and methods of use thereof.05-27-2010
20130122004METHODS AND COMPOSITIONS USING FGF23 VARIANT POLYPEPTIDES - The present disclosure is directed to methods, kits and compositions for preventing or treating age-related conditions or metabolic disorders. The fusion polypeptides of the disclosure include FGF23 or an active fragment thereof. In one embodiment, the fusion polypeptide comprises (a) a polypeptide comprising fibroblast growth factor 23 (FGF23), or a functionally active variant or derivative thereof, wherein FGF23 has a mutation at one or more of the positions Q156, C206 and C244; and (b) either a modified Fc fragment having decreased affinity for Fc-gamma-receptor and/or increased serum half-life, or a polypeptide comprising at least one extracellular subdomain of a Klotho protein, or a functionally active variant or derivative thereof; and, optionally (c) a linker. The Klotho fusion proteins are useful in the treatment and prevention of a variety of age-related conditions and metabolic disorders. In another embodiment, the fusion polypeptide comprises a FGF (such as FGF23), or a functionally active variant or derivative thereof and a modified Fc fragment, or a functionally active variant or derivative thereof. In various embodiments of the fusion polypeptides, FGF23 has mutations which decrease aggregation and protease-mediated cleavage.05-16-2013
20100239578MODULATION OF SIRP-ALPHA - CD47 INTERACTION FOR INCREASING HUMAN HEMATOPOIETIC STEM CELL ENGRAFTMENT AND COMPOUNDS THEREFOR - The invention relates to modulating the SIRPα-CD47 interaction in order to increase hematopoietic stem cell engraftment and compounds therefor. In some embodiments, there is provided isolated SIRPα and CD47 polypeptides, fragments and fusion proteins for enhancing hematopoietic stem cell engraftment. Further there is provided methods for increasing hematopoietic stem cell engraftment through administration of the above polypeptides.09-23-2010
20110150872SOLUBLE HETERODIMERIC CYTOKINE RECEPTOR - A soluble receptor that binds to IL-20 having two polypeptide subunits, IL-22R and IL-20RB. The two subunits are preferably linked together. In one embodiment one subunit is fused to the constant region of the light chain of an immunoglobulin, and the other subunit is fused to the constant region of the heavy chain of the immunoglobulin. The light chain and the heavy chain are connected via a disulfide bond.06-23-2011
20090291080LEVELS OF APRIL IN SERUM AND USE IN DIAGNOSTIC METHODS - The present invention provides a method of measuring the levels of APRIL in a biological sample, in a preferred embodiment, in serum. The diagnostic assays are useful in predicting an individual's likelihood of developing or currently suffering from an autoimmune disease, such as RA, predicting the future severity of the disease, and for methods for treating an individual clinically diagnosed with an autoimmune disease. This diagnostic test serves to predict a patient's likelihood to respond to a specific drug treatment, in particular treatment with APRIL antagonists, either singly or in combination with other immune suppressive drugs.11-26-2009
20100136008TACI-Fc Fusion Proteins, Methods of Making and Uses Thereof - The subject invention relates generally to novel biologically active TACI-Fc fusion proteins that bind to BLyS and/or APRIL and uses thereof. The invention also relates to methods for recombinant production of homogeneous TACI-Fc fusion proteins on a large scale.06-03-2010
20110135643METHODS AND COMPOSITIONS FOR PROSTATE CANCER IMMUNOTHERAPY - The present invention features methods and compositions (e.g., immune response stimulating peptides (e.g., ERG or SIM2 peptides), activated immune cells, antigen-presenting cells, and antibodies or antigen-binding fragments thereof) for generating an immune response for the treatment of cancer (e.g., prostate cancer).06-09-2011
20100254983USES OF RAGE ANTAGONISTS FOR TREATING OBESITY AND RELATED DISEASES - This invention provides a method for treating obesity in which comprises administering to the subject an antagonist of a receptor for advanced glycation end products (RAGE) in an amount effective to inhibit binding of a ligand of RAGE to RAGE so as to thereby treat obesity in the subject. The present invention also provides a method for treating hyperglycemia and increased cholesterol, insulin, triglyceride and leptin levels comprising administering to the subject an antagonist of RAGE in an amount effective to inhibit binding of a ligand of RAGE to RAGE so as to thereby treat hyperglycemia and lower cholesterol, insulin, triglyceride and leptin levels on the subject.10-07-2010
20110305695Wnt Antagonists and Methods of Treatment and Screening - The present invention relates to compositions comprising Wnt antagonists and methods of treating Wnt-associated diseases and disorders, such as cancer, inducing differentiation, and reducing the frequency of cancer stem cells, as well as novel methods of screening for such Wnt antagonists. In particular, the invention discloses soluble FZD, SFRP and Ror receptors and their use.12-15-2011
20110305696 ANTI-SERUM ALBUMIN BINDING VARIANTS - The invention relates to improved variants of the anti-serum albumin immunoglobulin single variable domain DOM7h-11, as well as ligands and drug conjugates comprising such variants, compositions, nucleic acids, vectors and hosts.12-15-2011
20100297120APROTININ-LIKE POLYPEPTIDES FOR DELIVERING AGENTS CONJUGATED THERETO TO TISSUES - Based on our identification of a polypeptide (Angiopep-7) that is efficiently transported to cells such as liver, lung, kidney, spleen, and muscle, the invention provides polypeptides, conjugates including the polypeptides, and methods for treating diseases associated with these cell types. Unlike other aprotinin related polypeptides identified herein (including Angiopep-3, Angiopep-4a Angiopep-4b Angiopep-5, and Angiopep-6) which efficiently cross the blood-brain barrier (BBB), Angiopep-7 is not efficiently transported across the BBB.11-25-2010
20130195861SERUM AMYLOID P-ANTIBODY FUSION PROTEINS - Functionalized pentraxin-2 (PTX-2) protomers and functionalized PTX-2 pentamers, methods for preparing functionalized PTX-2 protomers and functionalized PTX-2 pentamers, pharmaceutical compositions including functionalized PTX-2 pentamers, and methods for using the same are described herein.08-01-2013
20100129365TREATMENT OF INFLAMMATION USING BST2 INHIBITOR - The application discloses a method of preventing immune cells from binding to other cells, which includes contacting the immune cells and the other cells with a composition comprising Bst2 antagonist.05-27-2010
20090074769GLP-1 ANALOG FUSION PROTEINS - The invention provides specific GLP-1 analogs fused to specific IgG4-Fc derivatives. These fusion proteins have an increased half-life, decreased immunogenicity, and reduce effector activity. The fusion proteins are useful in treating diabetes, obesity, irritable bowel syndrome and other conditions that would be benefited by lowering plasma glucose, inhibiting gastric and/or intestinal motility and inhibiting gastric and/or intestinal emptying, or inhibiting food intake.03-19-2009
20100233168Rationale for IL-1 Beta targeted therapy in sickle cell disease for ischemia-reperfusion induced complications - Sickle cell patients atypically experience exaggerated inflammatory responses to pathogens that normally cause mild respiratory infections in non-sickle cell humans. There appears to be heightened inflammatory responses to pathogens in combination with hypoxia in sickle cell disease. The novelty of this invention provides a new paradigm to explain the exaggerated inflammatory response of sickle cell disease to pathogens especially when accompanied by hypoxic stress. In particular, sickle cell chest injury and other complications associated with ischemia-reperfusion injury caused by vaso-occlusion can involve co-stimulation of the NALP-3 inflammasome by pathogen associated molecular patterns (PAMPs) and hypoxic-induced danger associated molecular patterns (DAMPs), leading to exaggerated pro-inflammatory responses marked by increased IL-1β secretion and subsequent induction of neutrophilic inflammation. This invention thereby provides the immunologic, biologic and biochemical rationale for IL-1β targeted therapies in sickle cell disease to block the pathological effects of IL-1β that leads to exaggerated inflammatory expressions, including neutrophilic inflammation.09-16-2010
20110110947VIRAL CHEMOKINE-ANTIGEN FUSION PROTEINS - The present invention relates to a vaccine for increasing the immunogenicity of a tumor antigen thus allowing treatment of cancer, as well as a vaccine that increases the immunogenicity of a viral antigen, thus allowing treatment of viral infection, including immunodeficiency virus (HIV) infection. In particular, the present invention provides a fusion protein comprising a viral chemokine fused to either a tumor antigen or viral antigen which is administered as either a protein or nucleic acid vaccine to elicit an immune response effective in treating cancer or effective in treating or preventing viral infection.05-12-2011
20120148587POLYPEPTIDE FORMULATION - The present invention relates to an aqueous pharmaceutical composition suitable for long-term storage of polypeptides containing an Fc domain of an immunoglobulin, methods of manufacture, methods of administration and kits containing same.06-14-2012
20100297121Methods for Treating Pressure Induced Optic Neuropathy, Preventing Neuronal Degeneration and Promoting Neuronal Cell Survival Via Administration of LINGO-1 Antagonists and TrkB Agonists - This invention relates to methods for promoting neuronal survival and regeneration using LINGO-1 antagonists and TrkB agonists. Additionally, the invention relates to methods for treating pressure induced optic neuropathies using LINGO-1 antagonists. The invention also relates generally to methods for increasing TrkB activity and inhibiting JNK pathway signaling using a LINGO-1 antagonist.11-25-2010
20110311533REGULATION OF PROTEIN LEVEL - The invention relates to regulating the level of a membrane-anchored target molecule using PrP or a fragment thereof and a polyanion. Direct or indirect methods for targeting protein downregulation, mediated through PrP or a fragment thereof and a polyanionare are described.12-22-2011
20110318346Alpha B-crystallin as a therapy for Ischemia or inflammation - The invention provides methods for treating inflammatory diseases by administering to the subject an effective amount of an agent that provides alpha B-crystallin activity, where the dose is effective to suppress or prevent initiation, progression, or relapses of disease, including the progression of established disease. In some embodiments, the methods of the invention comprise administering to a subject having a pre-existing inflammatory disease condition, an effective amount of alpha B-crystallin protein, to suppress or prevent relapses of the disease.12-29-2011
20110318345NASAL DELIVERY - substances and the nasal administration thereof, in particular as one of a liquid, as a suspension or solution, or a powder, to the nasal airway of a subject, in particular the posterior region of the nasal airway, and in particular the upper posterior region of the nasal airway, which includes the olfactory bulb, in particular in the treatment of neurological conditions and disorders.12-29-2011
20120301466CHEMICALLY PROGRAMMABLE IMMUNITY - Methods and compositions for immediately immunizing an individual against any molecule or compound. The present invention comprises an immunity linker with at least two sites; (1) at least one first binding site that binds to an immune response component in an individual that has been pre-immunized with a universal immunogen, and (2) at least one second binding site that binds specifically to a desired compound or molecule, the target.11-29-2012
20120301465COMPOSITIONS AND METHODS TO IMMUNIZE AGAINST HEPATITIS C VIRUS - Compositions comprising viral antigens and antigenic peptides corresponding to or derived from Hepatitis C virus (HCV) proteins or fragments thereof, fused to heavy and/or light chain of antibodies, or fragments thereof specific for dendritic cells (DCs) are described herein. Included herein are immunostimulatory compositions (HCV vaccines, HCV antigen presenting dendritic cells, etc.) and methods for increasing effectiveness of HCV antigen presentation by an antigen presenting cell, for a treatment, a prophylaxis or a combination thereof against hepatitis C in a human subject, and methods of providing immunostimulation by activation of one or more dendritic cells, methods to treat or prevent hepatitis C.11-29-2012
20090317388Tl1a in treatment of disease - Methods of modulating TL1A for the treatment of disease are disclosed.12-24-2009
20120207755CANCER - The invention provides methods of diagnosis, prognosis and treatment of cancer related to the OBCAM and NTM genes. The methods are particularly suited to ovarian and colorectal cancers.08-16-2012
20100178293USE OF ANTIBODIES AGAINST THE CD52 ANTIGEN FOR THE TREATMENT OF NEUROLOGICAL DISORDERS, PARTICULARLY TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY AND ALZHEIMER'S DISEASE - The present invention relates to the use of antibodies against the CD52 antigen, specifically monoclonal antibodies, for the production of medicaments for the treatment of diseases of the central nervous system, in particular transmissible spongiform encephalopathies, diseases that are also called prion diseases.07-15-2010
20120003223RECOMBINANT FUSION PROTEIN AND POLYNUCLEOTIDE CONSTRUCT FOR IMMUNOTOXIN PRODUCTION - The present invention relates to a polynucleotide construct encoding a fusion protein consisting of a domain which binds the immunoglobulin Fc region, genetically fused to a truncated form of 01-05-2012
20120003221HUMAN SERUM ALBUMIN LINKERS AND CONJUGATES THEREOF - Disclosed is a human serum albumin (HSA) linker and HSA linker with binding, diagnostic, and therapeutic agents conjugated thereto. Also disclosed is a conjugate in which the HSA linker is covalently bonded to amino and carboxy terminal binding moieties that are first and second single-chain Fv molecules (scFvs). Exemplified conjugates are useful, e.g., in reducing tumor cell proliferation, e.g., for therapeutic therapeutic applications. Also disclosed are methods and kits for the diagnostic and therapeutic application of an HSA linker conjugate.01-05-2012
20120003222FZD8 EXTRACELLULAR DOMAINS AND FZD8 EXTRACELLULAR DOMAIN FUSION MOLECULES AND TREATMENTS USING SAME - Methods of treatment using Fzd8 extracellular domains (ECDs), Fzd8 ECD fusion molecules, and/or antibodies that bind Fzd8 are provided. Such methods include, but are not limited to, methods of treating obesity and obesity-related conditions. Fzd8 ECDs and Fzd8 ECD fusion molecules are also provided. Polypeptide and polynucleotide sequences, vectors, host cells, and compositions comprising or encoding such molecules are provided. Methods of making and using Fzd8 ECDs, Fzd8 ECD fusion molecules, and antibodies that bind Fzd8 are also provided.01-05-2012
20100209424ANTIBODIES AND FC FUSION PROTEIN MODIFICATIONS WITH ENHANCED PERSISTENCE OR PHARMACOKINETIC STABILITY IN VIVO AND METHODS OF USE THEREOF - In certain embodiments, this present invention provides antibodies and Fc fusion proteins with enhanced pharmacokinetics, such as biotinylated antibodies or biotinylated Fc fusion polypeptides.08-19-2010
20120207756Modified Antibody Compositions, Methods of Making and Using Thereof - The present disclosure provides modified antibodies which contain an antibody or antibody fragment (AB) modified with a masking moiety (MM). Such modified antibodies can be further coupled to a cleavable moiety (CM), resulting in activatable antibodies (AAs), wherein the CM is capable of being cleaved, reduced, photolysed, or otherwise modified. AAs can exhibit an activatable conformation such that the AB is more accessible to a target after, for example, removal of the MM by cleavage, reduction, or photolysis of the CM in the presence of an agent capable of cleaving, reducing, or photolysing the CM. The disclosure further provides methods of making and using such modified antibodies and activatable antibodies.08-16-2012
20120207753METHODS OF USING CD44 FUSION PROTEINS TO TREAT CANCER - Pharmaceutical compositions and methods for treating cancer using CD44 antagonists are disclosed. In certain aspects, these pharmaceutical compositions and methods include treating a mammal having a cancer, such as glioma, colon cancer, breast cancer, prostate cancer, ovarian cancer, lung cancer, renal cell carcinoma, gastric cancer, esophageal cancer, head cancer, neck cancer, pancreatic cancer, or melanoma, with a CD44 fusion protein. These CD44 fusion proteins include CD44-Fc fusions and can be used to detect hyaluronan.08-16-2012
20100203051DIAGNOSTIC MARKERS FOR ANKYLOSING SPONDYLITIS AND USES THEREOF - Disclosed are methods and agents for detecting the presence or diagnosing the risk of ankylosing spondylitis (AS) in mammals. These methods are based on the detection of polymorphisms within any one or more of the ARTS-1 gene, the IL-23R gene, the TNFR1 gene locus, the TRADD gene locus and the chromosome loci 2P15 and 21Q22. The present invention also features methods for the treatment or prevention of AS based on the diagnosis.08-12-2010
20120009190IDENTIFICATION AND METHOD FOR USING THE PRE-LIGAND ASSEMBLY DOMAIN OF THE IL-17 RECEPTOR - The invention provides isolated Pre-Ligand Assembly Domain (PLAD) polypeptides comprising an amino acid sequence of a domain (e.g., a Fibronectin Ill-like domain) of an IL-17 Receptor (IL-17R) family member, wherein the PLAD polypeptide inhibits multimerization of a receptor complex comprising an IL-17R family member. Also provided are isolated PLAD-binding polypeptides, e.g., antibodies and avimers, which specifically bind to a PLAD polypeptide described herein. Related chimeric proteins, conjugates, nucleic acids, vectors, and host cells are provided herein. Further provided are methods of treating an inflammatory or autoimmune disease, methods of inhibiting IL-17-mediated signal transduction, methods of inhibiting IL-17 ligand binding, methods of inhibiting multimerization of IL-17R complexes, and methods of inhibiting the production of at least one cytokine, chemokine, matrix metalloproteinase, or other molecule associated with IL-17 signal transduction are provided.01-12-2012
20120058115 METHOD FOR PROMOTING BONE GROWTH USING ACTIVIN-ACTRIIA ANTAGONISTS - In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density.03-08-2012
20120058116FGFR1C ANTIBODY COMBINATIONS - The invention relates to combinations of FGFR1c antagonists with agonist peptides and provide dual targeting proteins which bind to FEFR1c comprising an antigen binding protein which is capable of binding to FGFR1c and which is linked to one or more agonist peptides, methods of making such constructs and uses thereof, particularly in treating obesity.03-08-2012
20120014953TREATING AND EVALUATING INFLAMMATORY DISORDERS - Methods of treating inflammatory disorders, such as rheumatoid arthritis, by modulating TWEAK and TNF-α are disclosed, as are other methods.01-19-2012
20120014952COMPLEMENT RECEPTOR 2 TARGETED COMPLEMENT MODULATORS - Modulation of the complement system represents a therapeutic modality for numerous pathologic conditions associated with complement activation. In a strategy to prepare complement inhibitors that are targeted to sites of complement activation and disease, compositions comprising a complement inhibitor linked to complement receptor (CR) 2 are disclosed. The disclosed are compositions can be used in methods of treating pathogenic diseases and inflammatory conditions by modulating the complement system.01-19-2012
20120058114ERBB2 antibodies comprising modular recognition domains - Antibodies containing one or more modular recognition domains (MRDs) that can be used to target the antibodies to specific sites are described. The use of antibodies containing one or more modular recognition domains to treat disease, and methods of making antibodies containing one or more modular recognition domains are also described.03-08-2012
20120207754THERAPEUTIC COMPOSITIONS AND METHODS FOR ANTIBODY AND FC-CONTAINING TARGETING MOLECULE-BASED TARGETED DELIVERY OF BIOACTIVE MOLECULES BY BACTERIAL MINICELLS - The present application relates to the use of bacterial minicells as targeted delivery agents in vivo and in vitro. Described herein are genetically engineered eubacterial minicells designed to preferentially target and deliver therapeutically relevant agents using a minicell surface coupling molecule capable of binding and displaying antibodies or other Fc-containing targeting moiety fusions and conjugates.08-16-2012
20090297522RECOMBINANT HUMAN EPO-FC FUSION PROTEINS WITH PROLONGED HALF-LIFE AND ENHANCED ERYTHROPOIETIC ACTIVITY IN VIVO - A recombinant fusion protein comprising a human erythropoietin peptide portion linked to an immunoglobulin peptide portion is described. The fusion protein has a prolonged half-life in vivo in comparison to naturally occurring or recombinant native human erythropoietin. In one embodiment of the invention the protein has a half-life in vivo at least three fold higher than native human erythropoietin. The fusion protein also exhibits enhanced erythropoietic bioactivity in comparison to native human erythropoietin. In one embodiment, the fusion protein comprises the complete peptide sequence of a human erythropoietin (EPO) molecule and the peptide sequence of an Fc fragment of human immunoglobulin IgG1. The Fc fragment in the fusion protein includes the hinge region, CH2 and CH3 domains of human immunoglobulin IgG1. The EPO molecule may be linked directly to the Fc fragment to avoid extraneous peptide linkers and lessen the risk of an immunogenic response when administered in vivo. In one embodiment the hinge region is a human Fc fragment variant having a non-cysteine residue at amino acid 6. The invention also relates to nucleic acid and amino acid sequences encoding the fusion protein and transfected cell lines and methods for producing the fusion protein. The invention further includes pharmaceutical compositions comprising the fusion protein and methods of using the fusion protein and/or the pharmaceutical compositions, for example to stimulate erythropoiesis in subjects in need of therapy.12-03-2009
20100183610GENETIC POLYMORPHISMS ASSOCIATED WITH ALZHEIMER'S DISEASE, METHODS OF DETECTION AND USES THEREOF - The present invention is based on the discovery of genetic polymorphisms that are associated with Alzheimer's Disease. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.07-22-2010
20120070435CHIMERIC ANTIGENS FOR ELICITING AN IMMUNE RESPONSE - Disclosed herein are compositions and methods for eliciting immune responses against antigens. In particular embodiments, the compounds and methods elicit immune responses against antigens that are otherwise recognized by the host as “self” antigens. The immune response is enhanced by presenting the host immune system with a chimeric antigen comprising an immune response domain and a target binding domain, wherein the target binding domain comprises a xenotypic antibody fragment. By virtue of the target binding domain, antigen presenting cells take up, process, and present the chimeric antigen, eliciting both a humoral and cellular immune response.03-22-2012
20120064075CHIMERIC FACTOR VII MOLECULES WITH ENHANCED HALF LIFE AND METHODS OF USE - The present invention relates to novel proteins and methods of using chimeric Factor VIIa polypeptides.03-15-2012
20120177647MDL-1 USES - The invention provides methods for treating bone resorption disorders with antagonists of MDL-1.07-12-2012
20120177645METHODS AND COMPOSITIONS FOR THE INHIBITION OF TRANSPLANT REJECTION - Methods for modulating immune responses in a subject are provided. A preferred embodiment provides methods and compositions for reducing or inhibiting transplant rejection in a subject, preferably a human subject. Transplant rejection can be inhibited or reduced in a subject by administering an effective amount of B7-H4 polypeptide, fragments or fusions thereof to inhibit or reduce the biological activity of an immune cell or to reduce the amounts of proinflammatory molecules at a site of transplant. Th1, Th17 and Th22 cells are exemplary T cells that can be targeted for inhibition by B7-H4 polypeptides, fusion proteins or fragments thereof to inhibit or reduce inflammation.07-12-2012
20120177644MESENCHYMAL STEM CELL DIFFERENTIATION - The present invention provides for methods and compositions for treating or preventing arthritis and joint injury.07-12-2012
20120156202AGE RELATED MACULAR DEGENERATION TREATMENT - A method for treating age related macular degeneration (AMD) using an insulin preparation applied topically to the conjunctival sac of the affected eye. Another aspect of this invention is using antiangiogenic adjuvant therapeutic agents such as bevacizumab, ranibizumab, pegaptanib, etanercept, instilled in to the afflicted eye conjunctival sac with insulin to prevent further formation of new blood vessels, and shrink the existing pathologically formed blood vessels and reduce the edema in wet AMD. This method incorporates putting the patients on low fat diet, aerobic exercise, ketamine-a NMDA blocker, reducing the blood cholesterol using adjuvant therapeutic agents selected from Statins, that are inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A, (i.e. HMG-Co A) reductase which in turn reduce drusen formation that leads to AMD, combined with insulin ophthalmic drops.06-21-2012
20100203052BINDING DOMAIN-IMMUNOGLOBULIN FUSION PROTEINS - The invention relates to novel binding domain-immunoglobulin fusion proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, a wild-type IgG1, IGA or IgE hinge region polypeptide or a mutant IgG1 hinge region polypeptide having either zero, one or two cysteine residues, and immunoglobulin CH2 and CH3 domains, and that are capable of ADCC and/or CDC while occurring predominantly as polypeptides that are compromised in their ability to form disulfide-linked multimers. The fusion proteins can be recombinantly produced at high express levels. Also provided are related compositions and methods, including cell surface forms of the fusion proteins and immunotherapeutic applications of the fusion proteins and of polynucleotides encoding such fusion proteins.08-12-2010
20110091460RECEPTOR-TARGETING REAGENTS - The present disclosure features, inter alia, receptor-targeting reagents (e.g., immunotoxic receptor-targeting reagents), which are useful in, e.g., methods of binding a receptor-targeting reagent to a cell and methods for treating a variety of disorders such as, but not limited to, cancers and inflammatory disorders. Also featured are methods, compositions, and kits useful for selecting an appropriate treatment modality for a subject (e.g., a subject with a cancer or inflammatory disorder) and/or treating a variety of disorders such as cell proliferative disorders.04-21-2011
20110091459IMIDAZOLE MODULATORS OF MUSCARINIC ACETYLCHOLINE RECEPTOR M3 - The present invention relates to new imidazole modulators of M3 muscarinic acetylcholine receptor activity, pharmaceutical compositions thereof, and methods of use thereof.04-21-2011
20110104163ANTI-HIV DOMAIN ANTIBODIES AND METHOD OF MAKING AND USING SAME - The invention provides single domain antibodies and derivatives thereof that bind antigens of interest, which are stable, soluble, and do not tend to aggregate. The invention also provides methods for constructing a dAb library and methods for screening dAb libraries to identify the dAb of the invention. The invention also provide methods of treating or preventing conditions by antigen neutralization by administering the dAbs of the invention.05-05-2011
20120251539Methods and Compositions for the Treatment of Immune Disorders - The present invention provides a method of treating an immune-related disorder in a subject, comprising administering to the subject an effective amount of an inhibitor of plexin-A4 activity, which results in reducing the plexin-A4 activity in the subject, and thereby treating the immune-related disorder Inhibitors of plexin-A4 activity include, for example, plexin-A4 antibodies and plexin-A4 fusion proteins. The present invention further provides a method of treating an immune-related disorder in a subject, comprising administering to the subject an effective amount of an inhibitor of semaphorin-3A (Sema3A) activity, which results in reducing the Sema3A activity in the subject, thereby treating the immune-related disorder. Inhibitors of Sema3A activity include, for example, Sema3A antibodies and Sema3A fusion proteins.10-04-2012
20120251538USE OF FGFR1 EXTRA CELLULAR DOMAIN PROTEINS TO TREAT CANCERS CHARACTERIZED BY LIGAND-DEPENDENT ACTIVATING MUTATIONS IN FGFR2 - The present invention relates to the use of Fibroblast Growth Factor Receptor I (FGFR1) extracellular domain (ECD) polypeptides for treatment of cancers characterized by ligand dependent activating mutations in Fibroblast Growth Factor Receptor 2 (FGFR2). For example, the present invention relates to the treatment of endometrial cancers and other cancers wherein tumor cells express FGFR2 mutants in the IgII-IgIII hinge region or IgIII domain of the protein, such as at amino acid positions 252 and/or 253.10-04-2012
20120251537COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFECTIONS AND TUMORS - PD-1 antagonists are disclosed that can be used to reduce the expression or activity of PD-1 in a subject. An immune response specific to an infectious agent or to tumor cells can be enhanced using these PD-1 antagonists in conjunction with an antigen from the infectious agent or tumor. Thus, subjects with infections, such as persistent infections can be treated using PD-1 antagonists. In addition, subjects with tumors can be treated using the PD-1 antagonists. In several examples, subjects can be treated by transplanting a therapeutically effective amount of activated T cells that recognize an antigen of interest and by administering a therapeutically effective amount of a PD-1 antagonist.10-04-2012
20120251536BIOPOLYMER HYBRID GEL-DEPOT DELIVERY SYSTEM - The invention relates to biopolymer-gel based depot systems for prolonged and/or controlled release delivery of biologically active agents, methods for the manufacture of the biopolymer based gel-depots which include a biologically active agent, and uses of such biopolymer gel-depots in therapy. The biopolymer-gel based depot systems comprise a biocompatible polyaminosaccharide and/or protein; a biocompatible phosphate and/or sulphonamide compound; a biologically active agent; an aqueous insoluble alkaline earth metal phosphate; and a biocompatible glycan and/or proteoglycan.10-04-2012
20130171138Immunoglobulin Chimeric Monomer-Dimer Hybrids - The invention relates to a chimeric monomer-dimer hybrid protein wherein said protein comprises a first and a second polypeptide chain, said first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and said second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.07-04-2013
20120121593METHOD FOR DETERMINING PREDISPOSITION TO PULMONARY INFECTION - Provided herein are methods and materials for diagnosing a subject's predisposition for pulmonary infection in a CF subject by detecting a pulmonary infection genetic marker. Pulmonary infection markers have been identified in the IL-1 gene cluster and may be useful in predicting CF disease progression and assessing a CF subject's response to therapy.05-17-2012
20120121594ANTI-IL-6 ANTIBODIES FOR THE TREATMENT OF ARTHRITIS - The present invention is directed to therapeutic methods using IL-6 antagonists such as anti-IL-6 antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat rheumatoid arthritis.05-17-2012
20120121590METHODS OF INHIBITING ADVERSE CARDIAC EVENTS AND TREATING ATHEROSCLEROSIS AND CORONARY ARTERY DISEASE USING GALECTIN-3 BINDING PROTEIN (GAL-3BP, BTBD17B, MAC-2 BINDING PROTEIN) - The invention provides Galectin-3 binding protein (Gal-3BP, BTBD17B) polypeptide sequences and compositions that include Gal-3BP polypeptide sequences, and methods of using Gal-3BP polypeptide sequences, including modified forms and wild type (native) forms of Gal-3BP polypeptide, such as in treatment, diagnostic, detection and prognostic methods.05-17-2012
20100008917TREATMENT OF APLASTIC ANEMIA - Methods of treating aplastic anemia in a patient and of increasing blood cell production in a patient having aplastic anemia are disclosed. The methods comprise administering to the patient a therapeutically effective amount of an IL-27 antagonist in combination with a pharmaceutically acceptable vehicle. IL-27 antagonists include soluble IL-27RA proteins and antagonists that comprise an antigen-binding site of an antibody.01-14-2010
20120164143HUMAN MONOCLONAL ANTIBODIES AGAINST INTERLEUKIN 8 (IL-8) - Isolated human monoclonal antibodies which bind to IL-8 (e.g., human IL-8) are disclosed. The human antibodies can be produced in a hybridoma, transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals, hybridomas, and transfectomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.06-28-2012
20120164142COMPOSITIONS COMPRISING NATRIURETIC PEPTIDES AND METHODS OF USE THEREOF - The present invention provides methods, compositions, and kits for the treatment of disorders associated with overactivation of FGFR3, such as achondroplasia; bone or cartilage disorders; or vascular smooth muscle disorders, or for the elongation of bone. In some embodiments, the present invention provides polypeptides having a natriuretic peptide fused to an Fc domain of an immunoglobulin. Such polypeptides can be administered to subjects, e.g., subcutaneously, to treat a disorder associated with overactivation of FGFR3, a bone or cartilage disorder, or a vascular smooth muscle disorder, or to elongate bone. The invention also features nucleic acid molecules encoding such polypeptides and the use of the nucleic acid molecules for treating disorders associated with overactivation of FGFR3, bone or cartilage disorders, or vascular smooth muscle disorders, or for elongating bone.06-28-2012
20120164141METHODS AND COMPOSITIONS FOR INDUCING APOPTOSIS - The C-terminal domain of focal adhesion kinase (FAK-CD) was isolated using a Baculoviral system. Using phage display techniques, a phage encoding a 12 amino-acid peptide (peptide 35) and AV3 that binds to FAK-CD were identified. The peptides were also conjugated to TAT-FITC to produce a fluorescently labeled chimeric molecule capable of penetrating cell membranes. Contacting various breast cancer cell lines with these molecule caused detachment, rounding, apoptosis and cell death. These effects were not observed in normal (non-cancerous) breast cells.06-28-2012
20120164140HEMOJUVELIN FUSION PROTEINS AND USES THEREOF - The present invention provides a hemojuvelin (HJV) fusion protein (e.g., a human HJV.Fc) protein, polynucleotides and vectors encoding such proteins, and methods for making such proteins. Also provided are methods for treating iron-related disorders which include administration of a HJV fusion protein to a patient in need thereof.06-28-2012
20100247536ONCOFETAL ANTIGEN/IMMATURE LAMININ RECEPTOR ANTIBODIES FOR DIAGNOSTIC AND CLINICAL APPLICATIONS - The present invention relates to antibodies against Oncofetal Antigen/immature Laminin receptor protein (OFA/iLRP) that can be used singly or in conjunction to detect or treat OFA/iLRP-related diseases. More specifically, the antibodies can be used for several purposes including: (i) detecting and measuring OFA/iLRP in different biofluids; and (ii) using OFA/iLRP with an antibody directed against the monomeric form and its associated diseases.09-30-2010
20100247535Chemically Programmable Immunity - Methods and compositions for immediately immunizing an individual against any molecule or compound. The present invention comprises an immunity linker with at least two sites; (1) at least one first binding site that binds to an immune response component in an individual that has been pre-immunized with a universal immunogen, and (2) at least one second binding site that binds specifically to a desired compound or molecule, the target.09-30-2010
20090130103PURIFICATION AND PROTECTIVE EFFICACY OF MONODISPERSE AND MODIFIED YERSINIA PESTIS CAPSULAR F1-V ANTIGEN FUSION PROTEINS FOR VACCINATION AGAINST PLAGUE - This disclosure concerns compositions and methods for the treatment and inhibition of infectious disease, particularly bubonic and pneumonic plague. In certain embodiments, the disclosure concerns immunogenic proteins, for instance substantially monodisperse F1-V fusion proteins, that are useful for inducing protective immunity against 05-21-2009
20090130104FUSION PROTEINS FOR INHIBITION AND DISSOLUTION OF COAGULATION - Fusion proteins containing a ligand which specifically binds to a selected vascular bed linked to an anti-thrombotic molecule are provided. Also provided are methods for use of these fusion proteins to prevent coagulation, to dissolve blood clots and to protect against the risk of iatrogenic side effects including those arising from cancer therapy and specific vascular occluding agents.05-21-2009
20120128673MODULATION OF PILR RECEPTORS TO TREAT MICROBIAL INFECTIONS - The present invention provides methods of using agonists and antagonists of PILRα and PILRβ, respectively, to treat 05-24-2012
20120128672TREATMENT OF CANCER WITH ELEVATED DOSAGES OF SOLUBLE FGFR1 FUSION PROTEINS - The present invention provides methods of treating a patient having a cancer comprising administering to the patient a soluble Fibroblast Growth Factor Receptor 1 (FGFR1) fusion protein such as an extracellular domain of an FGFR1 polypeptide linked to an Fc polypeptide or another fusion partner. The fusion protein may be administered at a dose of at least about 2 mg/kg body weight. In some embodiments, the patient has a fibroblast growth factor-2 (FGF-2) plasma concentration of at least 6 pg/ml. In some embodiments, the cancer is characterized by a Fibroblast Growth Factor Receptor 2 (FGFR05-24-2012
20110182898IMMUNOSUPPRESSIVE POLYPEPTIDES AND NUCLEIC ACIDS - The invention provides immunosuppressive polypeptides and nucleic acids encoding such polypeptides. In one aspect, the invention provides mutant CTLA-4 polypeptides and nucleic acids encoding mutant CTLA-4 polypeptides. Compositions and methods for utilizing such polypeptides and nucleic acids are also provided.07-28-2011
20110182897AMINO ACID SEQUENCES DIRECTED AGAINST ENVELOPE PROTEINS OF A VIRUS AND POLYPEPTIDES COMPRISING THE SAME FOR THE TREATMENT OF VIRAL DISEASES - The present invention relates in part to amino acid sequences that are directed against and/or that can specifically bind to an envelope protein of a virus, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.07-28-2011
20110182896CLOTTING FACTOR-Fc CHIMERIC PROTEINS TO TREAT HEMOPHILIA - The invention relates to a chimeric protein comprising at least one clotting factor and at least a portion of an immunoglobulin constant region. The invention relates to a method of treating a hemostatic disorder comprising administering a therapeutically effective amount of a chimeric protein wherein the chimeric protein comprises at least one clotting factor and at least a portion of an immunoglobulin constant region.07-28-2011
20120213783ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2 CHIMERIC ANTIGEN RECEPTORS AND USE OF SAME FOR THE TREATMENT OF CANCER - The invention provides chimeric antigen receptors (CARs) comprising an antigen binding domain of a KDR-1121 or DC101 antibody, an extracellular hinge domain, a T cell receptor transmembrane domain, and an intracellular domain T cell receptor signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of cancer in a host and methods of treating or preventing cancer in a host are also disclosed.08-23-2012
20120134993COMPOSITIONS AND METHODS FOR USING MULTISPECIFIC-BINDING PROTEINS COMPRISING AN ANTIBODY-RECEPTOR COMBINATION - Disclosed are bispecific binding proteins comprising a antibody/soluble receptor bispecific binding protein that reduces the biological activity of both VEGF-A and FGF. The FGF binding moieties are generally soluble FGFR3 or FGFR2. An Fc polypeptide is fused to the C-terminus of the FGF binding moiety and VEGF-A binding moiety are polypeptides fused using peptide or polypeptide linker sequences, and can be expressed as single bispecific binding protein. The bispecific antibody/soluble receptor binding proteins can be used to treat cancers characterized by solid tumor growth as well as other diseases.05-31-2012
20120134991COMPOSITIONS AND METHODS FOR MODULATING D1-D2 DOPAMINE RECEPTOR INTERACTION AND FUNCTION - The present invention provides for prevention and/or treatment of neurological or neuropsychiatric disorders involving abnormal D1-D2 dopamine receptor coupling and/or activation. Methods and agents are provided for modulating dopamine receptor function arising from D1-D2 coupling and/or activation. Agents of the present invention include fragments of D2 receptor or D1 receptor that can disrupt D1-D2 coupling.05-31-2012
20120230991METHODS AND COMPOUNDS FOR ENHANCING ANTI-CANCER THERAPY - The invention provides methods of treating neoplastic disorders in a mammal through the inhibition of Mer and/or AxI receptor tyrosine kinases as well as compounds and compositions useful for inhibiting these kinases in these methods. These treatment methods may be combined with the administration of one or more chemo therapeutic agent(s) to enhance the efficacy or minimize the toxicities of the chemotherapeutic agent(s).09-13-2012
20100172904MCP1 FUSIONS - The present invention provides polypeptides including MCP1 fused, optionally, by a linker, to an immunoglobulin. Methods for using the polypeptides to treat medical disorders are also covered.07-08-2010
20120171202Rage Fusion Proteins And Methods Of Use - Disclosed are RAGE fusion proteins comprising RAGE polypeptide sequences linked to a second, non-RAGE polypeptide. The RAGE fusion protein may utilize a RAGE polypeptide domain comprising a RAGE ligand binding site and an interdomain linker directly linked to an immunoglobulin C07-05-2012
20120171207DEPLETING IMMUNOSUPPRESSIVE MONOCYTES WITHIN A MAMMAL - This document provides methods and materials involved in depleting immunosuppressive monocytes (e.g., CD1407-05-2012
20120171206METHODS OF STIMULATING LIVER REGENERATION - Provided herein are methods and compositions, including pharmaceutical compositions, for stimulating liver regeneration after partial hepatectomy, massive liver resection and toxic injury, or following liver transplantation, including small-for-size liver transplantation, by inhibiting activation of complement.07-05-2012
20120171205Galectin-Immunoglobulin Chimeric Molecules - Described are Galectin-1/Ig fusion constructs and methods of use thereof, e.g., in diagnostic and biomedical assays, and as therapeutic agents for the treatment of conditions associated with immune dysfunction, e.g., autoimmune diseases, and cancers.07-05-2012
20120171204COMPOSITIONS AND METHODS FOR THE TREATMENT AND DIAGNOSIS OF IMMUNE DISORDERS - The present invention relates to methods and compositions for the treatment and diagnosis of immune disorders, especially T helper lymphocyte-related disorders, and also for the treatment of mast cell-related processes and disorders, ischemic disorders and injuries, including ischemic renal disorders and injuries. For example, genes which are differentially expressed within and among T helper (TH) cells and TH cell subpopulations, which include, but are not limited to TH0, TH1 and TH2 cell subpopulations are identified. Genes are also identified via the ability of their gene products to interact with gene products involved in the differentiation, maintenance and effector function of such TH cells and TH cell subpopulations. The genes identified can be used diagnostically or as targets for therapeutic intervention. In this regard, the present invention provides methods for the identification and therapeutic use of compounds as treatments of immune disorders, especially TH cell subpopulation-related disorders. Additionally, methods are provided for the diagnostic evaluation and prognosis of TH cell subpopulation-related disorders, for the identification of subjects exhibiting a predisposition to such conditions, for monitoring patients undergoing clinical evaluation for the treatment of such disorders, and for monitoring the efficacy of compounds used in clinical trials. Methods are also provided for the treatment of symptoms associated with mast cell-related processes or disorders and ischemic disorders and injuries using the genes, gene products and antibodies of the invention.07-05-2012
20120171203ACTIVIN RECEPTOR-LIKE KINASE-1 COMPOSITIONS AND METHODS OF USE - Disclosed herein are methods and compositions for treating disorders associated with angiogenesis or lymphangiogenesis using ALK-1 antagonists.07-05-2012
20120213780Efficient mucosal vaccination mediated by the neonatal Fc receptor - The present invention relates to methods and compositions for enhancing delivery of vaccine antigens to the mucosal epithelium, the composition comprising an antigen from an infectious agent fused with an Fc fragment of an immunoglobulin recognized by the neonatal receptors (FcRn). The composition is effective in eliciting a protective long-term memory T cell immune response against infection at a distant mucosal site.08-23-2012
20120213781Monovalent and Multivalent Multispecific Complexes and Uses Thereof - Monovalent and multivalent multispecific complexes including ELP-MRD fusion proteins containing one or more modular recognition domains (MRDs) that bind target antigens are described. The use of these monovalent and multivalent multispecific complexes (e.g., ELP-MRD fusion proteins) in diagnostic, prognostic, and therapeutic applications and methods of making these complexes are also described.08-23-2012
20120076785METHOD FOR INHIBITING NEURODEGENERATION - Methods for screening for compounds that inhibit neurodegeneration are presented. Shedding of APP can be a useful marker for neurodegeneration and compounds that inhibit shedding of APP are useful as inhibitors of neurodegeneration. Such compounds may be useful in treatment and/or prevention of various neurological diseases, disorders and neuronal damage and may enhance growth, regeneration or survival of mammalian neuronal cells or tissue.03-29-2012
20120213782BMP10 ANTIBODIES AND RELATED METHODS - In certain aspects, the present invention provides BMP10 propeptides for use in treating a variety of disorders including heart disorders and other disorders associated with unwanted activity of the mature BMP10 polypeptide. The present invention also provides methods of screening compounds that modulate activity of BMP10.08-23-2012
20100143358Use of Antibody Conjugates - Provided herein are methods for inducing growth arrest or apoptosis in cancer cells in a subject. Further provided are methods of inhibiting or treating metastasis of a cancer cell in a subject. The methods involve administering to the subject an antibody conjugate containing an antibody, variant thereof, or functional fragment thereof having binding specificity of the antibody as produced by the hybridoma having ATCC accession number PTA 2439 and a biologically active molecule. The antibody (e.g., mAb 3E10) variant or functional fragment thereof provides for the in vivo transduction of the conjugate to the nucleus of mammalian cells, where the conjugated biologically active molecule may exert its effect. In particular embodiments, the antibody conjugate comprises a single chain Fv fragment of an antibody having the binding specificity of mAb 3E10 produced by ATCC PTA 2439, conjugated to p53.06-10-2010
20120177646FGF21 MUTANTS AND USES THEREOF - The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.07-12-2012
20120315274Methods of Treating Glucose Metabolism Disorders - Methods of treating individuals with a glucose metabolism disorder such as diabetes, hyperglycemia, hyperinsulinemia or obesity by administering human FAM3D (family with sequence similarity 3, member D) are provided. Specifically a method of treating hyperglycemia resulting in a reduction of plasma glucose is provided. Additionally, a method of treating hyperinsulinemia resulting in a reduction of plasma glucose is provided. In addition, a method of treating glucose intolerance resulting in an increased glucose tolerance is provided. Pharmaceutical compositions are provided.12-13-2012
20100303811Recombinant multiple domain fusion protein mitogens and use thereof for inducing enhancement or repression of antigen-specific immunity. - The invention relates to cell stimulatory fusion proteins and DNA sequences, vectors comprising at least two agonists of TNF/TNFR super family, immunoglobulin super family, cytokine family proteins and optional antigen combination. Instructions for use of these proteins and DNA constructs as immune adjuvants and vaccines for treatment of various chronic diseases such as viral infection are also provided. Additionally, the use of these protein and DNA constructs as immune suppressant for treatment of various chronic diseases, such as autoimmunity and organ transplant rejection, is also illustrated.12-02-2010
20120258104Delivery System and Conjugates For Compound Delivery Via Naturally Occurring Intracellular Transport Routes - The present invention relates to a delivery system that comprises a conjugate that facilitates the delivery of a compound such as a biologically-active macromolecule, a nucleic acid or a peptide in particular, into a cell. The present invention also relates to said conjugate for delivery of a compound, such as a biologically-active macromolecule, a nucleic acid or a peptide, into a cell. The present invention further relates to a pharmaceutical composition comprising said conjugate and to its use. The present invention also relates to a method of delivering a compound to a cell or an organism, preferably a patient. The conjugates comprise: (a) at least one module that mediates cell targeting and facilitates cellular uptake, (b) at least one module that facilitates transport to the endoplasmic reticulum (ER), (c) at least one module that mediates translocation from the ER to the cytosol, and (d) at least one compound to be delivered wherein the modules (a) to (c) and the compound (d) are linked to each other in any arrangement.10-11-2012
20120258106MUTATED ANTI-CD22 ANTIBODIES WITH INCREASED AFFINITY TO CD22-EXPRESSING LEUKEMIA CELLS - Recombinant immunotoxins are fusion proteins composed of the Fv domains of antibodies fused to bacterial or plant toxins. RFB4 (Fv)-PE38 is an immunotoxin that targets CD22 expressed on B cells and B cell malignancies. The present invention provides antibodies and antibody fragments that have improved ability to bind the CD22 antigen of B cells and B cell malignancies compared to RFB4. Immunotoxins made with the antibodies and antibody fragments of the invention have improved cytotoxicity to CD22-expressing cancer cells. Compositions that incorporate these antibodies into chimeric immunotoxin molecules that can be used in medicaments and methods for inhibiting the growth and proliferation of leukemia and lymphoma cells.10-11-2012
20120258105METHODS AND COMPOSITIONS TO REGULATE IRON METABOLISM - The present invention provides new systems and strategies for the regulation of iron metabolism in mammals. In particular, methods of using agonists and antagonists of TGF-β superfamily members to modulate the expression or activity of hepcidin, a key regulator of iron metabolism, are described. The inventive methods find applications in the treatment of diseases associated with iron overload, such as juvenile hemochromatosis and adult hemochromatosis, and in the treatment of diseases associated with iron deficiency, such as anemia of chronic disease and EPO resistant anemia in end-stage of renal disease. The present invention also relates to screening tools and methods for the development of novel drugs and therapies for treating iron metabolism disorders.10-11-2012
20120082669HUMAN EPO MIMETIC HINGE CORE MIMETIBODIES, COMPOSITIONS, METHODS AND USES FOR PREVENTING OR TREATING GLUCOSE INTOLERANCE RELATED CONDITIONS OR RENAL DISEASE ASSOCIATED ANEMIA - The present invention relates to at least one novel human EPO mimetic hinge core mimetibody or specified portion or variant, including isolated nucleic acids that encode at least one EPO mimetic hinge core mimetibody or specified portion or variant, EPO mimetic hinge core mimetibody or specified portion or variants, vectors, host cells, and methods of making and using thereof, for preventing or treating glucose intolerance and/or renal disease associated anemia, including therapeutic compositions, methods and devices.04-05-2012
20120082668SOLUBLE IL-17RA/RC FUSION PROTEINS AND RELATED METHODS - Disclosed are antagonists of IL-17A and IL-17F. The antagonists are based on soluble IL-17RA and IL-17RC fusion proteins, including hybrid soluble receptors comprising portions of both IL-17RC and IL-17RA (“IL-17RC/IL-17RA”). Such antagonists serve to block, inhibit, reduce, antagonize or neutralize the activity of IL-17F, IL-17A, or both IL-17A and IL-17F. Also disclosed are methods of using such antagonists for treating disease, particularly inflammatory diseases mediated at least in part by IL-17A and/or IL-17F.04-05-2012
20120263718BLOCKADE OF TL1A-DR3 INTERACTIONS TO AMELIORATE T CELL MEDIATED DISEASE PATHOLOGY AND ANTIBODIES THEREOF - Provided are methods and compositions for treating inflammatory autoimmune diseases in a subject comprising blocking the interaction between DR3 and TL1A. The interaction between DR3 and TL1A can be blocked by reducing expression of TL1A. The interaction between DR3 and TL1A can be blocked by administration of anti-DR3 antibodies. The interaction between DR3 and TL1A can be blocked by administration of anti-TL1A antibodies. In the methods of treating inflammatory or autoimmune disease, the inflammatory or autoimmune disease can be an autoimmune disease with a T cell component. In the methods of treating inflammatory or autoimmune disease, the inflammatory or autoimmune disease can be asthma, multiple sclerosis, rheumatoid arthritis, type 1 diabetes, graft versus host disease or inflammatory bowel disease (IBD).10-18-2012
20120230994BLADDER CANCER SPECIFIC LIGAND PEPTIDES - The present invention is directed to bladder cancer specific ligand peptides, comprising the amino acid sequence X09-13-2012
20120230992VEGF-RELATED PROTEIN - A human VEGF-related protein (VRP) has been identified and isolated that binds to, and stimulates the phosphorylation of, the receptor tyrosine kinase Flt4. The VRP is postulated to be a third member of the VEGF protein family. Also provided are antibodies that bind to VRP and neutralize a biological activity of VRP, compositions containing the VRP or antibody, methods of use, chimeric polypeptides, and a signal polypeptide for VRP.09-13-2012
20120230993AXL TYROSINE KINASE INHIBITORS AND METHODS OF MAKING AND USING THE SAME - Disclosed are novel inhibitors of the Axl receptor tyrosine kinase (RTK) and methods of using such inhibitors in a variety of therapeutic approaches in the areas of cancer therapy and anti-thrombosis (anti-clotting) therapy.09-13-2012
20100322930FIBRONECTIN-BASED BINDING MOLECULES AND THEIR USE - The invention provides fibronectin-based binding molecules and methods for introducing donor CDRs into a fibronectin-based binding scaffold, in particular, Fn3. The fibronectin-based binding molecules of the invention may be further conjugated to another moiety, for example, Fc, anti-FcRn, HSA, anti-HSA, and PEG, for improved half life and stability, particularly in mammalian cells. The invention also provides methods for screening such molecules for binding to a target antigen as well as the manufacture and purification of a candidate binder.12-23-2010
20120237514VASCULAR ENDOTHELIAL CELL GROWTH FACTOR ANTAGONISTS AND USES THEREOF - The present invention provides vascular endothelial cell growth factor (VEGF) antagonists and methods of using VEGF antagonists. VEGF antagonists contemplated by the invention include VEGF antibodies and VEGF receptor fusion proteins. Methods of treating edema and stroke using VEGF antagonists are also provided.09-20-2012
20110002924TWEAK RECEPTOR AGONISTS AS ANTI-ANGIOGENIC AGENTS - The present invention relates to methods of modulating angiogenesis and inhibiting tumor progression by using TWEAK receptor (Fn14) agonists. In particular, methods for inhibiting angiogenesis are disclosed.01-06-2011
20110038866IMPROVED FIBRONECTIN-BASED BINDING MOLECULES AND USES THEREOF - The invention provides fibronectin type III (Fn3)-based binding molecules that bind to a specific target antigen. The invention further provides bispecific Fn3-based binding molecules that bind to two or more targets simultaneously. The Fn3-based binding molecules of the invention can also be linked together to form multispecific Fn3-based binding molecules, and/or can be conjugated to a non-Fn3 moiety, such as, Human Serum Albumin (HSA), for improved half life and stability. The invention also provides methods for generating, screening and using Fn3-based binding molecules in a variety of therapeutic and diagnostic applications.02-17-2011
20110038865ANTIBODY- ENDOSTATIN FUSION PROTEIN AND ITS VARIANTS - Chimeric molecules comprising endostatin and all or a portion of a tumor antigen specific binding molecule for use in treating tumors. The chimeric molecule, includes endostatin, endostatin mutants and variants and an antibody or aptamer specific for a desired tumor antigen. Methods of treating cancer comprise administering the chimeric fusion molecules.02-17-2011
20120269806METHODS OF INDUCING TOLERANCE - Methods of inducing tolerance, and promoting graft acceptance, are described herein. The methods include administering to a recipient hematopoietic stem cells and an agonist of Programmed Death 1 (PD-1).10-25-2012
20120269807COMPOSITIONS AND METHODS FOR BLOOD-BRAIN BARRIER DELIVERY OF lgG-DECOY RECEPTOR FUSION PROTEINS - Provided herein are compositions and related methods for delivering an IgG-decoy receptor to the CNS. The methods include systemic administration of a bifunctional decoy receptor-BBB receptor antibody fusion antibody comprising a receptor extracellular domain (ECD) covalently linked to an antibody to a receptor expressed on the surface of the blood-brain barrier (BBB receptor). In some embodiments, the compositions described herein are administered to treat a subject suffering from a CNS condition.10-25-2012
20120269808METHODS AND COMPOSITIONS FOR MODULATING TWEAK AND FN14 ACTIVITY - Agonists and antagonists which modulate the activity of TWEAK and TWEAK receptor are provided. The methods, compositions and kits of the invention may be employed in the treatment of disorders such as cancer and immune-related diseases.10-25-2012
20120128671NEUTRALIZING MOLECULES TO INFLUENZA VIRUSES - The present invention concerns methods and means for identifying, producing, and engineering neutralizing antibodies against influenza A viruses, and to the neutralizing antibodies produced. In particular, the invention concerns neutralizing antibodies against various influenza A virus subtypes, and methods and means for making such antibodies.05-24-2012
20110236384DIRECT DRUG DELIVERY SYSTEM BASED ON THERMALLY RESPONSIVE BIOPOLYMERS - A method for delivering a drug depot of a compound of interest to a selected region in a subject. The method comprises administering a composition directly to said region of interest, the composition comprising the compound of interest to be delivered (such as an antiinflammatory agent or a chemotherapeutic agent) and a polymer (such as an elastin-like peptide or ELP) that undergoes an inverse temperature phase transition, so that a sustained release of the compound of interest at the selected region is provided. Compositions useful for carrying out the invention are also described.09-29-2011
20100233169Methods for treating obesity using fibroblast growth factor-Like polypeptides - The present invention provides novel Fibroblast Growth Factor-like (FGF-like) polypeptides and nucleic acid molecules encoding the same. The invention also provides vectors, host cells, antibodies and methods for producing FGF-like polypeptides. Also provided for are methods for the diagnosis and treatment of diseases associated with FGF-like polypeptides.09-16-2010
20100233167CHAIN REACTION CREATING OLIGOMERS FROM REPEAT UNITS OF BINDING MOLECULES - The present invention concerns a chain reaction of cross-linking antibodies or other binding molecules prior or subsequent to binding to a target, such as a target antigen. The invention further concerns oligomers comprising repeat units of binding molecules, such as antibodies, optionally bound to a target, such as a target antigen. The invention also relates to antibodies and other binding molecules with multiple specificities useful in the methods of the invention, as well as various uses of the oligomers and individual binding molecules present in the oligomers.09-16-2010
20090068184Engineered Antibody-Stress Protein Fusions - Provided are fusion polypeptides comprising an engineered antibody and a stress protein that bind to antigens with high affinity, are highly immunogenic, exhibit MHC class I priming and are able to be produced in non-mammalian cells, such as 03-12-2009
20090092608Human Tumor Necrosis Factor Receptor-Like 2 - The present invention relates to novel members of the Tumor Necrosis Factor family of receptors. The invention provides isolated nucleic acid molecules encoding a human TR2 receptor and two splice variants thereof. TR2 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TR2 receptor activity. Also provided are diagnostic methods for detecting disease states related to the aberrant expression of TR2 receptors. Further provided are therapeutic methods for treating disease states related to aberrant proliferation and differentiation of cells which express the TR2 receptors.04-09-2009
20120321623ILT3 Polypeptides and Uses Thereof - This invention provides a first polypeptide comprising all or a portion of the extracellular domain of ILT3, wherein the polypeptide is water-soluble and does not comprise the Fc portion of an immunoglobulin. This invention also provides a second polypeptide comprising (i) all or a portion of the extracellular domain of ILT3 operable affixed to (ii) the Fc portion of an immunoglobulin, wherein the Fc portion of the immunoglobulin comprises a function-enhancing mutation, and wherein the polypeptide is water-soluble. This invention further provides a third polypeptide comprising (i) all or a portion of the extracellular domain of ILT3 operable affixed to (ii) a transmembrane domain. This invention further provides related nucleic acids, expression vectors, host vector systems, compositions, and articles of manufacture and therapeutic and prophylactic methods using the polypeptides of the invention.12-20-2012
20130183309Fragments, Mutants and Chimeric Fusion Proteins of Leptin For Treating Alzheimer's Disease - The described invention relates to methods for treating, preventing, or diagnosing the pathology of progressive cognitive disorders resulting from accumulation of an amyloid peptide, in particular, Alzheimer's disease, Down's syndrome and cerebral amyloid angiopathy, in mammalian subjects using a composition comprising therapeutically effective amount of a leptin, leptin mimic, leptin derivative, leptin agonist, or AMP-dependent protein kinase activator, alone, or in combination with, one or more lipolytic/antilipogenic compounds. It further relates to methods for improving cognitive function using a composition comprising a therapeutically effective amount of leptin, a leptin mimic, a leptin derivative, an AMP-dependent protein kinase activator, a leptin agonist, a leptin blocker, a mimic of a leptin blocker, a leptin antagonist, an AMP-dependent protein kinase inhibitor; or a pharmaceutically acceptable salt thereof.07-18-2013
20100215657Methods and Compositions Using Klotho-FGF Fusion Polypeptides - The present invention is directed to methods, kits and compositions for preventing or treating age-related conditions or metabolic disorders. The Klotho fusion polypeptides of the invention include at least a Klotho protein or an active fragment thereof. In one embodiment, the fusion polypeptide comprises a Klotho polypeptide, a FGF (such as FGF23) and (optionally) a modified Fc fragment. The Fc fragment can, for example, have decreased binding to Fc-gamma-receptor and increased serum half-life. The Klotho fusion proteins are useful in the treatment and prevention of a variety of age-related conditions and metabolic disorders. In another embodiment, the fusion polypeptide comprises a FGF (such as FGF23) and a modified Fc fragment.08-26-2010
20120100141DRUG FUSIONS AND CONJUGATES - The present invention relates to drug fusions that have improved serum half lives. These fusions and conjugates comprise polypeptides, immunoglobulin (antibody) single variable domains and GLP and/or exendin molecules. The invention further relates to uses, formulations, compositions and devices comprising such drug fusions and conjugates.04-26-2012
20120100140STABILIZED FC POLYPEPTIDES WITH REDUCED EFFECTOR FUNCTION AND METHODS OF USE - A method of producing Fc-containing polypeptides, such as antibodies, having stabilized Fc regions is provided, together with stabilized Fc polypeptides produced according to these methods as well as methods of using such antibodies as therapeutics.04-26-2012
20120100139CD86 Antagonist Multi-Target Binding Proteins - This disclosure provides a multi-specific fusion protein composed of a CD86 antagonist binding domain and another binding domain that is an IL-10 agonist, an HLA-G agonist, an HGF agonist, an IL-35 agonist, a PD-1 agonist, a BTLA agonist, a LIGHT antagonist, a GITRL antagonist or a CD40 antagonist. The multi-specific fusion protein may also include an intervening domain that separates the other domains. This disclosure also provides polynucleotides encoding the multi-specific fusion proteins, compositions of the fusion proteins, and methods of using the multi-specific fusion proteins and compositions.04-26-2012
20120288503POLYNUCLEOTIDES AND POLYPEPTIDE SEQUENCES INVOLVED IN THE PROCESS OF BONE REMODELING - This invention relates, in part, to unique and newly identified genetic polynucleotides involved in the process of bone remodeling; variants and derivatives of the polynucleotides and corresponding polypeptides; uses of the polynucleotides, polypeptides, variants and derivatives; and methods and compositions for the amelioration of symptoms caused by bone remodeling disorders. Disclosed in particular are, the isolation and identification of polynucleotides, polypeptides, variants and derivatives involved in osteoclast activity, validation of the identified polynucleotides for their potential as therapeutic targets and use of the polynucleotides, polypeptides, variants and derivatives for the amelioration of disease states and research purposes.11-15-2012
20100203050ERYTHROPOIETIN FUSION PROTEIN - The present invention relates to recombinant fusion proteins wherein erythropoietin (EPO) is linked via its C-terminus to an Fc fragment, and wherein said recombinant fusion proteins are further carbamoylated at the primary amines of the fusion protein. More specifically the invention relates to carbamoylated EPO-Fc fusion proteins, wherein at least one, preferably two or more, lysine amine residues and/or the N-terminal amino acid of said fusion protein are carbamoylated. The carbamoylated EPO-Fc fusion proteins of the present invention having a reduced hematopoietic activity whereas the tissue regenerative activity, i.e. the nerval cell regenerative activity remains unaltered or is even enhanced as compared to unmodified EPO-Fc fusion proteins. The invention further relates to a process for the manufacture of such fusion proteins and to pharmaceutical compositions containing them, as well as to the use of such fusion proteins and pharmaceutical compositions for medical therapy.08-12-2010
20120134992MESOTHELIN ANTIBODY PROTEIN FUSIONS AND METHODS OF USE - The invention relates to fusion proteins comprising a stress protein fused with an engineered antibody or fragment that binds to mesothelin, or a stress protein fused with a biotin-binding protein in combination with a biotinylated engineered antibody or fragment that binds to mesothelin. The invention also relates to fusion proteins comprising a stress protein fused with an antibody binding protein in combination with an engineered antibody or fragment that binds to mesothelin. The invention also relates to fusion proteins comprising an engineered antibody or fragment that binds specifically to mesothelin fused in frame with a biotin binding protein. The invention also provides fusion proteins comprising an engineered antibody or fragment, that binds to mesothelin, fused with an antibody binding protein. The invention also relates to methods of using fusion proteins of the invention to induce an immune response to mesothelin and to treat disease.05-31-2012
20100166756METHOD FOR TREATING AN AUTOIMMUNE DISEASE USING A SOLUBLE CTLA4 MOLECULE AND A DMARD OR NSAID - The present invention relates to compositions and methods for treating immune system diseases such as rheumatic disease, by administering to a subject soluble CTLA4 molecules that block endogenous B7 molecules from binding their ligands, alone, or in conjunction with other agents including Disease Modifying Anti-Rheumatic Drugs (DMARDs).07-01-2010
20130011398Serpin Fusion Polypeptides and Methods of Use Thereof - This invention relates to molecules, particularly polypeptides, more particularly fusion proteins that include a serpin polypeptide or an amino acid sequence that is derived from a serpin and second polypeptide comprising of at least one the following: an Fc polypeptide or an amino acid sequence that is derived from an Fc polypeptide; a cytokine targeting polypeptide or a sequence derived from a cytokine targeting polypeptide; a WAP domain containing polypeptide or a sequence derived from a WAP containing polypeptide; and an albumin polypeptide or an amino acid sequence that is derived from a serum albumin polypeptide. This invention also relates to methods of using such molecules in a variety of therapeutic and diagnostic indications, as well as methods of producing such molecules.01-10-2013
20130011397Transforming growth factor-beta (TGF-beta) antagonists for use in treating pain - Provided herein are methods for treating pain and for reducing the excitability of nociceptors, comprising administering a TGF-β antagonist. In some embodiments, a TGF-β antagonist is a monoclonal TGF-β neutralizing antibody or a fusion product comprising a monoclonal TGF-β neutralizing antibody, a soluble receptor, an antisense oligodeoxynucleotides (ODNs), a ribozymes, a small inhibitory RNA (siRNA), Smad 6, Smad7, or a small molecule that blocks TGF-β signaling.01-10-2013
20130011399WAP Domain Fusion Polypeptides and Methods of Use Thereof - This invention relates to fusion proteins that include a whey acidic protein (WAP) domain-containing polypeptide and a second polypeptide. Additionally, the invention relates to fusion proteins that include a WAP domain-containing polypeptide, a second polypeptide, and a third polypeptide. The second and/or third polypeptides of the fusion proteins of the invention are an Fc polypeptide; an albumin polypeptide; a cytokine targeting polypeptide; or a serpin polypeptide. This invention also relates to methods of using such molecules in a variety of therapeutic and diagnostic indications, as well as methods of producing such molecules.01-10-2013
20130017199SIMULTANEOUS INHIBITION OF PD-L1/PD-L2 - Methods and compositions for treating an infection or disease that results from (1) failure to elicit rapid T cell mediated responses, (2) induction of T cell exhaustion, T cell anergy or both, or (3) failure to activate monocytes, macrophages, dendritic cells and/or other APCs, for example, as required to kill intracellular pathogens. The method and compositions solve the problem of undesired T cell inhibition by simultaneously inhibiting the PD-1 ligands, PD-L1 and PD-L2. The immune response can be modulated by providing antagonists which bind with different affinity, by varying the dosage of agent which is administered, by intermittent dosing over a regime, and combinations thereof, that provides for dissociation of agent from the molecule to which it is bound prior to being administered again. In some cases it may be particularly desirable to stimulate the immune system, then remove the stimulation.01-17-2013
20110158995Multi-Specific Binding Proteins Targeting B Cell Disorders - This disclosure provides a multi-specific fusion protein composed of a CD72-ligand binding domain and another binding domain specific for a heterologous target, such as a B-cell specific protein. The multi-specific fusion protein may also include an intervening domain that separates the other domains. This disclosure also provides polynucleotides encoding the multi-specific fusion proteins, compositions of the fusion proteins, and methods of using the multi-specific fusion proteins and compositions.06-30-2011
20110158994POLYPEPTIDES SPECIFICALLY BINDING TO VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2 AND METHODS THEREFOR - A polypeptide inhibiting binding between vascular endothelial growth factor receptor-2 and a vascular endothelial growth factor, a fusion protein including the same, and a method of preparing the fusion protein are disclosed.06-30-2011
20110158993Train-R: A Cysteine Rich Member of the TNF-Receptor Family - Novel receptor in the TNF family: TRAIN-receptor.06-30-2011
20100086548Use of Anti-IL-20 Antibody for Treating Rheumatoid Arthritis and Osteoporosis - Treatment of rheumatoid arthritis and osteoporosis using an anti-IL-20 antibody 7E, and optionally, in combination with an etanercept polypeptide.04-08-2010
20130177560METHODS OF TREATMENT USING RAGE FUSION PROTEINS - The present invention provides novel therapeutics and methods of treatment for diseases associated with activation of the advanced glycatioπ endproducts receptor (RAGE).07-11-2013
20110274689COMPOUNDS AND METHODS TO MEASURE METABOLIC FUNCTION AND RESTORE NORMAL METABOLIC FUNCTION - The invention relates to treatment to restore normal metabolic function, including but not limited to normal glucose levels. The invention in one embodiment contemplates methods of reducing elevated glucose levels in subjects with elevated glucose levels by administering a composition comprising at least a portion of human Sfrp5. The invention in one embodiment contemplates methods of reducing elevated glucose levels in subjects with elevated glucose levels by administering a composition comprising an inhibitor of Wnt5a, including but not limited to an antibody inhibitor.11-10-2011
20130171140HOMODIMERIC PROTEIN CONSTRUCTS - The present disclosure relates to recombinant fusion proteins, such as human antibody-based molecules called Vaccibodies, which are able to trigger both a T cell- and B cell immune response. The present disclosure also relates to a method of treating a cancer or an infectious disease by means of these specific fusion proteins.07-04-2013
20130171141COMBINATION OF HDAC INHIBITORS WITH THROMBOCYTOPENIA DRUGS - The invention relates to a combination which comprises: 07-04-2013
20130171139NCAM-VASE AND NEURODEGENERATION - Inhibitors of NCAM-VASE, compositions comprising said inhibitors, and methods of using said inhibitors for stimulation of neuroplasticity and/or neuroregeneration in the central nervous system, and for increasing neuronal cell response to agents that stimulate neuroplasticity and/or neuroregeneration in the central nervous system, are provided. The inhibitor or composition may be used, for example, for treating brain or spinal cord injury; schizophrenia, motor neurone disease; a neurodegenerative disorder such as Alzheimer's disease, multiple sclerosis or Parkinson's disease; ischaemia caused by stroke; or for improving learning and/or memory.07-04-2013
20130142796TREATMENT FOR ANGIOGENIC DISORDERS - Disclosed are pharmaceutical compositions comprising a therapeutically effective amount of a first compound, wherein the first compound binds the heparin-binding domain of the vascular endothelial growth factor (VEGF); and a therapeutically effective amount of a second compound, wherein the second compound binds to VEGF, thereby inhibiting the binding of VEGF to its cognate receptor. Also disclosed are methods of treating a VEGF-related disorder in a subject, the method comprising identifying a subject in need thereof, and administering to the subject a therapeutically effective amount of a first compound, wherein the first compound binds the heparin-binding domain of the vascular endothelial growth factor (VEGF); and a therapeutically effective amount of a second compound, wherein the second compound binds to VEGF, thereby inhibiting the binding of VEGF to its cognate receptor.06-06-2013
20130142797METHOD OF TREATING VIRUS-INDUCED CANCER - The present invention relates to methods of treating virus-induced cancer with the polypeptides that are capable of killing cells. The polypeptide comprises a targeting agent covalently attached to a channel-forming moiety. In a preferred embodiment, the channel-forming moiety comprises a colicin and the targeting agent is a reconstructed antibody mimetic derived from monoclonal antibody variants against Epstein-Barr virus gp350/22006-06-2013
20130177559Truncated ActRIIb-Fc Fusion Protein - In certain aspects, the present invention provides compositions and methods for modulating (promoting or inhibiting) growth of a tissue, such as bone, cartilage, muscle, fat, brown fat and/or neuronal tissue and for treating metabolic disorders such as diabetes and obesity, as well as disorders associated with any of the foregoing tissue.07-11-2013
20130177561THERAPEUTIC NUCLEASE COMPOSITIONS AND METHODS - Hybrid nuclease molecules and methods for treating an immune-related disease or disorder in a mammal, and a pharmaceutical composition for treating an immune-related disease in a mammal.07-11-2013
20130177557VISTA REGULATORY T CELL MEDIATOR PROTEIN, VISTA BINDING AGENTS AND USE THEREOF - The present invention relates to a novel regulatory T cell protein. This protein, designated PD-L3 OR VISTA resembles members of the PD-L1 family, identified a novel and structurally-distinct, Ig-superfamily inhibitory ligand, whose extracellular domain bears homology to the B7 family ligand PD-L1. This molecule is designated as PD-L3 OR VISTA or V-domain Immunoglobulin Suppressor of T cell Activation (VISTA). Expression of VISTA is primarily within the hematopoietic compartment and is highly regulated on myeloid APCs and T cells. Therapeutic intervention of the VISTA inhibitory pathway represents a novel approach to modulate T cell-mediated immunity for the treatment of a wide variety of cancers, e.g., ovarian, bladder cancer and melanomas. Also, VISTA proteins, especially multimeric VISTA proteins and antibodies may be used to suppress T cell immunity in autoimmune disease, allergy, infection and inflammatory conditions, e.g. multiple sclerosis and arthritic conditions such as RA.07-11-2013
20130177558Method of Treating Immunological Disorders by Administering Truncated BAFF Receptors - The disclosure provides a non-naturally occurring BAFF-R glycoprotein having a deletion in the extracellular domain which results in an altered O-linked glycosylation pattern. The disclosure also provides methods and pharmaceutical compositions for treating B-cell- and T-cell-mediated disorders.07-11-2013
20130202597ANTI-SERUM ALBUMIN BINDING VARIANTS - The invention relates to improved variants of the anti-serum albumin immunoglobulin single variable domains, as well as ligands and drug conjugates comprising such variants, compositions, nucleic acids, vectors and hosts.08-08-2013
20130202598ACTIVATABLE TOXIN COMPLEXES COMPRISING A CLEAVABLE INHIBITORY PEPTIDE - The present invention relates to activatable toxin complexes which include a cleavable inhibitory peptide. More specifically, the complexes comprise a cell targeting domain, a toxin catalytic domain, a specific protease cleavage site and an inhibitory peptide domain. The inhibitory peptide prevents the catalytic domain from exerting toxic effects until its release from the complex by the action of a protease, such a viral protease, at the protease cleavage site. Further provided are pharmaceutical compositions comprising the complexes and use thereof for treating infections and malignant disease.08-08-2013
20130202599NOVEL IMMUNOGLOBULINS INSERTIONS, DELETIONS, AND SUBSTITUTIONS - An Fc variant of a parent Fc polypeptide, wherein said Fc variant exhibits altered binding to one or more FcγRs, wherein said Fc variant comprises at least one amino acid insertion in the Fc region of said parent Fc polypeptide.08-08-2013
20080219978Soluble FcgammaRIA and related methods - Disclosed are soluble FcγRIA polypeptide compositions and related methods of using such polypeptides to treat IgG-mediated and immune complex-mediated inflammation. Also disclosed are related compositions and methods for producing the soluble FcγRIA polypeptides.09-11-2008
20110268735MULTIMERIC CONSTRUCTS - Multimeric fusion proteins of an Ig-like domain of Flt-1 are rendered functional by inclusion of a linker moiety. Vectors encoding the fusion proteins and host cells expressing the fusion proteins can be used therapeutically to block neovascularization in individuals with pathological conditions related to neovascularization. Such conditions include age-related macular degeneration, cancer, psoriasis, proliferative diabetic retinopathy, asthma, uveitis, osteoarthritis, and rheumatoid arthritis. The same means of multimerization used for an Iglike domain of Flt-1, i.e., a linker and a multimerization domain, can be used for other polypeptides, including extracellular receptors, antibody variable regions, cytokines, chemokines, and growth factors.11-03-2011
20130115211CYTOKINE ANTAGONISTS FOR NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS - A method, comprising: introducing a therapeutically effective amount of a specific TNF blocker to cerebrospinal fluid of a human in need of treatment for symptoms associated with neronal compression.05-09-2013
20130101585METHOD OF INHIBITING OSTEOCLAST ACTIVITY - Methods for inhibiting osteoclastogenesis by administering a soluble RANK polypeptide are disclosed. Such methods can be used to treat a variety of different cancers, including bone cancer, multiple myeloma, melanoma, breast cancer, squamous cell carcinoma, lung cancer, prostate cancer, hematologic cancers, head and neck cancer and renal cancer.04-25-2013
20130101583Etanercept Formulations Stabilized with Sodium Chloride - The invention provides stabilized aqueous pharmaceutical etanercept compositions suitable for long-term storage of etanercept, methods of manufacture of these compositions, methods of administration, and kits containing same.04-25-2013
20130129725HUMAN FGF RECEPTOR AND BETA-KLOTHO BINDING PROTEINS - The present invention provides compositions and methods relating to or derived from antigen binding proteins and antigen binding protein-FGF21 fusions that specifically bind to β-Klotho, or β-Klotho and one or more of FGFR1c, FGFR2c, FGFR3c, and FGFR4. In some embodiments the antigen binding proteins and antigen binding protein-FGF21 fusions induce FGF21-like signaling. In some embodiments, an antigen binding protein or antigen binding protein-FGF21 fusion antigen binding component is a fully human, humanized, or chimeric antibody, binding fragments and derivatives of such antibodies, and polypeptides that specifically bind to β-Klotho, or β-Klotho and one or more of FGFR1c, FGFR2c, FGFR3c, and FGFR4. Other embodiments provide nucleic acids encoding such antigen binding proteins and antigen binding protein-FGF21 fusions, and fragments and derivatives thereof, and polypeptides, cells comprising such polynucleotides, methods of making such antigen binding proteins and antigen binding protein-FGF21 fusions, and fragments and derivatives thereof, and polypeptides, and methods of using such antigen binding proteins and antigen binding protein-FGF21 fusions, fragments and derivatives thereof, and polypeptides, including methods of treating or diagnosing subjects suffering from type 2 diabetes, obesity, NASH, metabolic syndrome and related disorders or conditions.05-23-2013
20130129726PEPTIDE HAVING CELL MEMBRANE PENETRATING ACTIVITY - Provided are transmembrane complexes that contain a protein transduction domain (PTD) from the N-terminus of IgE-dependent histamine-releasing factor (HRF) and a target substance that is to be delivered into a cell. Also provided are nucleic acid molecules encoding the transmembrane complex, and methods of delivering the target substance into a cell interior by contacting the transmembrane complex with a cell. Also provided are transfection kits containing the PTD and the target substance.05-23-2013
20130129728ANTIBODIES TO THE C3D FRAGMENT OF COMPLEMENT COMPONENT 3 - The present invention relates to methods and materials for modulating the complement alternative pathway (CAP), the complement classical pathway (CCP), the complement lectin/mannose pathway (CMP), or combinations thereof, as well as methods and materials for targeting diagnostic, prophylactic and therapeutic agents to localized areas of tissue within the body where they may more directly exert their effects upon the intended target cells or tissue, with reduced, associated systemic effects compared with administration of the same or similar agents in an untargeted, systemic manner. The methods and materials of the present invention may therefore allow for increased efficacy, lower threshold effective dosages and/or lower effective maintenance doses, and/or reduced associated undesired or adverse effects in terms of frequency or severity of occurrence, or both. The present invention also relates to methods and materials for modulating a host humoral immune response, especially reducing, inhibiting, or preventing a host humoral immune response.05-23-2013
20130142795FUSION PROTEIN OF EXENDIN-4 AND ITS ANALOG, PREPARATION METHOD AND USE THEREOF - Provided are a fusion protein of Exendin-4 and its analog, the preparation method and use thereof. The fusion protein is obtained by fusing of Exendin-4 or its analog to Fc region of human IgG2 via a linking peptide, which has the better stability and prolonged serum half-life, and can be used for treating diabetes and obesity.06-06-2013
20130142792RAGE Fusion Protein Compositions And Methods Of Use - Disclosed are fusion proteins comprising a RAGE polypeptide, wherein the RAGE polypeptide comprises a fragment of a mammalian wild type RAGE peptide and at least one point mutation in the RAGE polypeptide portion of the fusion protein relative to the wild type RAGE peptide. The point mutation may remove and/or alter a glycosylation site or an enzyme cleavage site. Also disclosed are nucleic acids encoding such proteins as well as methods of using such proteins for treating RAGE-mediated pathologies.06-06-2013
20130142793BINDING DOMAIN-IMMUNOGLOBULIN FUSION PROTEINS - The invention relates to novel binding domain immunoglobulin fusion proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, a hinge region polypeptide having either zero or one cysteine residue, and immunoglobulin CH2 and CH3 domains, and that are capable of ADCC and/or CDC while occurring predominantly as monomeric polypeptides. The fusion proteins can be recombinantly produced at high expression levels. Also provided are related compositions and methods, including immunotherapeutic applications.06-06-2013
20130101584Etanercept Formulations Stabilized with Xylitol - The invention provides stabilized aqueous pharmaceutical etanercept compositions suitable for long-term storage of etanercept, methods of manufacture of these compositions, methods of administration, and kits containing same.04-25-2013
20080206245COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF BREAST CANCER - Compositions and methods for the therapy and diagnosis of cancer, particularly breast cancer, are disclosed. Illustrative compositions comprise one or more breast tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly breast cancer.08-28-2008
20080199467Immunoglobulin fusion proteins and methods of making - Disclosed are immunoglobulin fusion proteins and methods of making such proteins. In certain embodiments, the fusion protein may include a non-immunoglobulin polypeptide linked to an immunoglobulin polypeptide. In certain embodiments, the non-immunoglobulin polypeptide may comprise a region that replaces an immunoglobulin Fc hinge region, but that allows for correct assembly of the immunoglobulin chains.08-21-2008
20080199466HUMAN MONOCLONAL ANTIBODY AGAINST A COSTIMULATORY SIGNAL TRANSDUCTION MOLECULE AILIM AND PHARMACEUTICAL USE THEREOF - Immunization of human antibody-producing transgenic mice, which have been created using genetic engineering techniques, with AILIM molecule as an antigen resulted in various human monoclonal antibodies capable of binding to AILIM and capable of controlling a variety of biological reactions (for example, cell proliferation, cytokine production, immune cytolysis, cell death, induction of ADCC, etc.) associated with AILIM-mediated costimulatory signal (secondary signal) transduction. Furthermore, it has been revealed that the human monoclonal antibody is effective to treat and prevent various diseases associated with AILIM-mediated costimulatory signal transduction, being capable of inhibiting the onset and/or advancement of the diseases.08-21-2008
20110243943TREATMENT USING RELAXIN-FUSION PROTEINS WITH EXTENDED IN VIVO HALF-LIVES - Disclosed are human relaxin-Fc fusion proteins having an increased serum half-life, polynucleotides encoding the same, and intermediates formed during the fusion protein biosynthesis. The fusion proteins may include a linker portion or other sections as well. Suitable fusion proteins are also those predicted to have the same effect as human relaxin in vivo, based, for example, on structural modeling. The fusion protein is useful in the treatment of a number of diseases and conditions, including heart disease, vascular disease, wound healing, fibrosis, fibromyalgia, and promoting angiogenesis.10-06-2011
20110250199IMMUNOTOXINS AND USES THEREOF - The invention provides novel recombinant immunotoxins comprising domain III of cholix toxin and exotoxin from 10-13-2011
20120276101VIRAL CHEMOKINE-ANTIGEN FUSION PROTEINS - The present invention relates to a vaccine for increasing the immunogenicity of a tumor antigen thus allowing treatment of cancer, as well as a vaccine that increases the immunogenicity of a viral antigen, thus allowing treatment of viral infection, including immunodeficiency virus (HIV) infection. In particular, the present invention provides a fusion protein comprising a viral chemokine fused to either a tumor antigen or viral antigen which is administered as either a protein or nucleic acid vaccine to elicit an immune response effective in treating cancer or effective in treating or preventing viral infection.11-01-2012
20120276100Compositions and Methods of Use of Immunotoxins Comprising Ranpirnase (Rap) Show Potent Cytotoxic Activity - The present invention concerns methods and compositions for forming immunotoxin complexes having a high efficacy and low systemic toxicity. In preferred embodiments, the toxin moiety is a ranpirnase (Rap), such as Rap(Q). In more preferred embodiments, the immunotoxin is made using dock-and-lock (DNL) technology. The immunotoxin exhibits improved pharmacokinetics, with a longer serum half-life and significantly greater efficacy compared to toxin alone, antibody alone, unconjugated toxin plus antibody or even other types of toxin-antibody constructs. In a most preferred embodiment the construct comprises an anti-Trop-2 or anti-CD22 antibody conjugated to Rap, although other combinations of antibodies, antibody fragments and toxins may be used to form the subject immunotoxins. The immunotoxins are of use to treat a variety of diseases, such as cancer, autoimmune disease or immune dysfunction.11-01-2012
20120276099MONOSPECIFIC POLYPEPTIDE REAGENTS - The present invention relates to a novel antigen-binding protein construct or “modubody”, which contains at least three functional single domain modules of an antibody. The modubodies contain a domain from the heavy chain variable region of an antibody (VH), a domain from the light chain variable region of an antibody (VL) and bind monospecifically to an antigen. The modubodies further contain a domain from the constant region of antibodies. The modubodies can be used for diagnostic or therapeutic purposes.11-01-2012
20120276098DRUG FUSIONS AND CONJUGATES WITH EXTENDED HALF LIFE - The present invention relates to drug fusions and conjugates that have improved serum half lives. These fusions and conjugates comprise immunoglobulin (antibody) single variable domains and insulinotropic and/or incretin and/or gut peptide molecules. The invention further relates to uses, formulations, compositions and devices comprising such drug fusions and conjugates. The invention also relates to compositions which comprise more than one insulinotropic and/or incretin and/or gut peptide molecules present as part of a fusion or conjugate and to uses and formulations thereof.11-01-2012
20120276097IMMUNOGLOBULIN FUSION PROTEINS - Disclosed are fusion proteins comprising a biologically active molecule and an immunoglobulin (Ig) Fc domain which is linked to the biologically active molecule. The Fc domain is a hybrid human Fc domain of (i) IgG1, IgG2 or IgG4 or (ii) IgG4 and IgD. The hybrid Fc is useful as a carrier of biologically active molecules.11-01-2012
20120276096IMMUNOGLOBULIN FUSION PROTEINS - Disclosed are fusion proteins comprising a biologically active molecule and an immunoglobulin (Ig) Fc domain which is linked to the biologically active molecule. The Fc domain is a hybrid human Fc domain of (i) IgG1, IgG2 or IgG4 or (ii) IgG4 and IgD. The hybrid Fc is useful as a carrier of biologically active molecules.11-01-2012
20120276095B7-H4 FUSION PROTEINS AND METHODS OF USE THEREOF - Fusion proteins containing B7-H4 polypeptides are disclosed. The B7-H4 fusion proteins can include full-length B7-H4 polypeptides, or can contain a fragment of a full-length B7-H4 polypeptide, including some or all of the extracellular domain of the B7-H4 polypeptide. Methods for using the fusion proteins to downregulate T cell activation and for the treatment of inflammatory and autoimmune diseases and disorders are also disclosed. The B7-H4 fusion proteins are useful for treating inflammation by inhibiting or reducing differentiation, proliferation, activity, and/or cytokine production and/or secretion by ThI, ThI 7, Th22, and/or other cells that secrete, or cause other cells to secrete, inflammatory molecules, including, but not limited to, IL-1β, TNF-α, TGF-beta, IFN-γ, IL-17, IL-6, IL-23, IL-22, IL-21, and MMPs; or enhancing IL-IO secretion by Tregs, increasing the differentiation of Tregs, increasing the number of Tregs, or combinations thereof.11-01-2012
20130149306Antagonists of Sema3E/PlexinD1 interaction as anti-cancer agents - The present invention is related to the treatment of certain cancers using antagonists of the binding between a Plexin and a Sema3E. The invention may be helpful in treating primary cancer cell development and metastasis development wherein Sema3E is expressed, in particular overexpressed by the tumoral cells or the stroma. Breast cancer, in particular with distant metastases is concerned. Prostate cancer, melanoma and glioblastoma are also concerned. The antagonist may be any molecule that specifically binds to PlexinD1 or Sema3E and blocks the Sema3E/PlexinD1 binding. In an embodiment, the antagonist is a polypeptide or an antibody.06-13-2013
20130149305SOLUBLE CD80 AS A THERAPEUTIC TO REVERSE IMMUNE SUPRESSION IN CANCER PATIENTS - The present invention provides for a therapeutic cancer treatment using a soluble CD80 fusion protein that binds to PDLL and inhibits PDLL-PD1 interactions thereby overcoming PDLL-induced immune suppression and restoring T cell activation.06-13-2013
20130149304USE OF MODULATORS OF COMPOUNDS OF TGF-BETA SUPERFAMILY TO REGULATE HEPCIDIN-MEDIATED IRON METABOLISM - The present invention provides new systems and strategies for the regulation of iron metabolism in mammals. In particular, methods of using agonists and antagonists of TGF-β superfamily members to modulate the expression or activity of hepcidin, a key regulator of iron metabolism, are described. The inventive methods find applications in the treatment of diseases associated with iron overload, such as juvenile hemochromatosis and adult hemochromatosis, and in the treatment of diseases associated with iron deficiency, such as anemia of chronic disease and EPO resistant anemia in end-stage of renal disease. The present invention also relates to screening tools and methods for the development of novel drugs and therapies for treating iron metabolism disorders.06-13-2013
20100291081RAGE FUSION PROTEINS - The present invention provides novel therapeutics and methods of treatment for diseases associated with activation of the advanced glycation endproducts receptor (RAGE).11-18-2010
20100291079Heterodimeric Follicle Stimulating Hormone-Fc (FSH-Fc) Fusion Proteins for the Treatment of Infertility - The invention provides novel heterodimeric fusion proteins comprising a first polypeptide including an alpha subunit of FSH (αFSH) linked directly or indirectly to a binding partner of neonatal Fc receptor (FcRn) and a second polypeptide including a beta subunit of FSH (βFSH) linked directly or indirectly to an FcRn binding partner. In one embodiment the FcRn binding partner includes an Fc fragment of an immunoglobulin, e.g., an Fc fragment of IgG. Also provided are methods making and using the fusion proteins of the invention. The invention provides a method for increasing fertility in a subject and a method for treating a subject having a disease state responsive to treatment by FSH.11-18-2010
20100310561NATRIURETIC FUSION PROTEINS - Natriuretic peptide fusion proteins comprising natriuretic peptides linked to antibody Fc domains, nucleic acid molecules encoding the fusion proteins disclosed herein, expression vectors expressing said fusion proteins, pharmaceutical compositions comprising said fusion proteins, and methods for their therapeutic use are disclosed.12-09-2010
20100316644TRUNCATED ACTRIIB-FC FUSION PROTEINS - In certain aspects, the present invention provides compositions and methods for modulating (promoting or inhibiting) growth of a tissue, such as bone, cartilage, muscle, fat, brown fat and/or neuronal tissue and for treating metabolic disorders such as diabetes and obesity, as well as disorders associated with any of the foregoing tissue.12-16-2010
20100316642COMPLEXES OF GRP94 WITH HUMAN IMMUNOGLOBULIN G - Complexes are described that form in vitro following incubation of “Heat Shock Protein” (HSP) “Glucose-regulated Protein” 94 (Grp94) with human non-immune immunoglobulin G. Results show that complexes of Grp94-IgG are resistant to denaturing agents. Moreover, complexes display an important cytokine-like property that can be exploited to induce positive effects of immuno-modulation in pathologies characterized by either a reduced or exacerbated immune response. In addition, stability of Grp94-IgG complexes make them useful as diagnostic tools to detect antibodies directed against Grp94 in various pathological conditions.12-16-2010
20130156763ILT3 Polypeptides and Uses Thereof - This invention provides a method for inhibiting the rejection of transplanted islet cells, comprising administering to the subject a polypeptide comprising all or a portion of the extracellular domain of ILT3, wherein the polypeptide is water soluble. This invention further provides a method of treating diabetes, by inhibiting the rejection of transplanted islet cells through the administration of the polypeptide to the subject.06-20-2013
20120282256CHIMERIC RECEPTORS WITH 4-1BB STIMULATORY SIGNALING DOMAIN - The present invention relates to a chimeric receptor capable of signaling both a primary and a co-stimulatory pathway, thus allowing activation of the co-stimulatory pathway without binding to the natural ligand. The cytoplasmic domain of the receptor contains a portion of the 11-08-2012
20120282255METHODS AND COMPOSITIONS FOR THE TREATMENT OF ALCOHOLISM AND ALCOHOL DEPENDENCE - The present invention provides for compositions and methods for treating or preventing addictive and compulsive diseases and disorders, particular alcohol-related diseases and disorders, disclosed herein. The GLP activators of the present invention are effective against various alcohol and drug dependency diseases. In accordance with the invention, the present compositions and methods can be used to intercede upstream or downstream in the signal transduction cascade involved in GLP action to treat various alcohol and drug dependency diseases. In one embodiment, the synthesis or release of endogenous GLP can be stimulated. In another embodiment, the endogenous synthesis or release of another molecule active in the cascade downstream from GLP, (e.g., a molecule produced in response to GLP binding to a receptor), can be stimulated. Accordingly, the methods and compositions of the invention are useful for preventing, treating, diagnosing, or monitoring the progression various alcohol and drug dependency diseases disclosed herein.11-08-2012
20130156764NEUTRALIZATION OF FLT3 LIGAND AS A LEUKEMIA THERAPY - Disclosed herein are methods and compositions for treating leukemia and preventing leukemia relapse related to the administration of agents that inhibit the binding of FLT3 ligand to FLT3.06-20-2013
20130156765FUSION PROTEINS OF NATURAL HUMAN PROTEIN FRAGMENTS TO CREATE ORDERLY MULTIMERIZED IMMUNOGLOBULIN Fc COMPOSITIONS - The current invention involves a series of fully recombinant multimerized forms of immunoglobulin Fc which thereby present polyvalent immunoglobulin Fc to immune cell receptors. The fusion proteins exist as both homodimeric and highly ordered multimeric fractions, termed stradomers. In comparison to the homodimeric fraction, purified multimeric stradomers have higher affinity and avidity for Fc Rs with slower dissociation and are useful in the treatment and prevention of disease. The current invention demonstrates that directly linking IgG1 Fc regions to multimerization domains leads to enhanced multimerization and biological activity.06-20-2013
20110305697FC FUSION PROTEINS - The invention relates to fusion proteins comprising at least a first domain and a second domain selected from a constant Fc immunoglobulin domain; wherein there is at least one amino acid overlap between the first domain and the second domain in the fusion region. In a preferred embodiment of the invention, the first domain is a ligand-binding receptor domain comprising the extra-cellular domain of a membrane-anchored receptor or a ligand-binding fragment thereof.12-15-2011
20110311537METHODS OF USING IL-1 ANTAGONISTS TO TREAT FAMILIAL MEDITERRANEAN FEVER (FMF) - Methods of treating, inhibiting, or ameliorating Familial Mediterranean Fever (FMF) by administering to a subject in need thereof a therapeutically effective amount of an interleukin 1 (IL-1) antagonist, are provided. The IL-1 antagonist can be an antibody or derivative thereof, which is capable of blocking or inhibiting the biological action of IL-1, thereby treating, inhibiting or ameliorating FMF. Also provided are methods of treating, inhibiting, or ameliorating FMF by administering a therapeutically effective amount of an IL-1 antagonist in combination with additional therapeutic agents, including IL-1-specific fusion proteins, TNF inhibitors, NSAIDs, steroids, and the like.12-22-2011
20110311536PREVENTION OF TYPE 1 DIABETES BY TREG VACCINATION WITH AN INSULIN MIMETOPE - The invention involves methods and products for inducing Treg cells for immune suppression in connection with autoimmune disease and transplant rejection.12-22-2011
20110311535NKG2D-FC FOR IMMUNOTHERAPY - Methods for cancer immunotherapy are provided. The methods involve the use of a chimeric molecule (e.g., fusion protein) comprising an NKG2D portion and an Fc portion, which binds one or more NKG2D ligands. The methods disclosed herein are useful for the treatment of cancer that is associated with abnormal expression of one or more NKG2D ligands.12-22-2011
20110311534WNT ANTAGONISTS AND THEIR USE IN THE DIAGNOSIS AND TREATMENT OF WNT-MEDIATED DISORDERS - The present invention provides for chimeric Wnt antagonists comprising a Frz domain component derived from a Frizzled protein, a secreted Frizzled related protein or Ror protein and an Fc immunoglobulin component, and their use in the treatment and diagnostic detection of cellular Wnt signaling and Wnt-mediated disorders, including cancer.12-22-2011
20110311532INHIBITION OF COMPLEMENT AND CELLULAR ACTIVATION - A method of inhibiting Fc mediated platelet activation in a subject induced by administration of a therapeutic antibody or fragment thereof includes administering to the subject an amount of anti-platelet agent effective to inhibit Fc induced platelet activation in the subject.12-22-2011
20130189257USE OF PKC-IOTA INHIBITORS FOR THE TREATMENT OF BREAST CANCER - The subject invention pertains to uses of PKC-iota inhibitors for treatment of breast cancer. In one embodiment, the subject invention provides novel uses of 1H-imidazole-4-carboxamide, 5-amino-1-[2,3 -dihydroxy-4-[(phosphonooxy) methyl]cyclopentyl]-,[1R-(1α, 2β, 3β, 4α)] (ICA-1) and related compounds for treatment of breast cancer. The compounds of the subject invention have potent anti-proliferative effects against human breast cancer cells. The compounds of the subject invention also inhibit the phosphorylation of IKK-α/IKK-β, induce chromatin condensation, and/or induce DNA fragmentation in cancer cells.07-25-2013
20130189253MODULATION OF SIRP-ALPHA - CD47 INTERACTION FOR INCREASING HUMAN HEMATOPOIETIC STEM CELL ENGRAFTMENT AND COMPOUNDS THEREFOR - The invention relates to modulating the SIRPα-CD47 interaction in order to increase hematopoietic stem cell engraftment and compounds therefor. In some embodiments, there is provided isolated SIRPα and CD47 polypeptides, fragments and fusion proteins for enhancing hematopoietic stem cell engraftment. Further there is provided methods for increasing hematopoietic stem cell engraftment through administration of the above polypeptides.07-25-2013
20130189254Inhibition of AXL/GAS6 Signaling in the Treatment of Disease - Compositions and methods are provided for alleviating endometriosis, kidney disease, inflammatory disease and/or transplant rejection in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits AXL, MER or Tyro3 protein activity, for example by competitive or non-competitive inhibition of the binding interaction between AXL, MER or Tyro3 and its ligand GAS6.07-25-2013
20130189255FUSIONS AND CONJUGATES OF INSULINOTROPIC AGENTS - The present invention relates to drug fusions of insulinotropic agents and incretin drugs that have improved serum half lives. These fusions and conjugates comprise polypeptides, immunoglobulin (antibody) single variable domains and GLP and/or exendin molecules. The invention further relates to uses, formulations, compositions and devices comprising such drug fusions and conjugates.07-25-2013
20130189256ANTIPROLIFERATIVE COMPOUNDS, CONJUGATES THEREOF, METHODS THEREFOR, AND USES THEREOF - Antiproliferative compounds having a structure represented by formula (II), where n, R07-25-2013
20090148448METHODS AND COMPOSITIONS FOR MODULATING AND DETECTING WISP ACTIVITY - Methods and compositions for use in modulating the activity(s) of WISP-1 polypeptide are provided. WISP-1 antagonists include anti-WISP-1 antibodies, WISP-1 immunoadhesins and WISP-1 variants (and fusion proteins thereof) which inhibit or neutralize induction or secretion of HAS2, HA, CD44 or RHAMM by native human WISP-1 polypeptide in at least one type of mammalian cell. The invention also provides methods for in vitro, in situ, and/or in vivo diagnosis and/or treatment of mammalian cells or pathological conditions associated with native WISP-1 polypeptides.06-11-2009
20120020969Compositions And Methods For Inhibiting Viral Adhesion - The present invention provides compositions and methods for treating or preventing viral infections.01-26-2012
20120020968Chimeric DRG11-Responsive (DRAGON) Polypeptides - This invention features methods and compositions useful for treating and diseases caused by a dysregulation of the BMP/GDF branch of the TGF-β signaling pathway. Also disclosed are methods for identifying compounds useful for such therapy.01-26-2012
20120020967VEGF antibodies comprising modular recognition domains - Antibodies containing one or more modular recognition domains (MRDs) that can be used to target the antibodies to specific sites are described. The use of antibodies containing one or more modular recognition domains to treat disease, and methods of making antibodies containing one or more modular recognition domains are also described.01-26-2012
20120020966Multispecific antibody targeting and multivalency through modular recognition domains - Antibodies containing one or more modular recognition domains (MRDs) that can be used to target the antibodies to specific sites are described. The use of antibodies containing one or more modular recognition domains to treat disease, and methods of making antibodies containing one or more modular recognition domains are also described.01-26-2012
20120020965Molecules that bind CD180, compositions and methods of use - The present invention provides novel CD180 binding molecules, methods for their identification, and methods for their use.01-26-2012
20120027759METHODS OF ENHANCING T CELL RESPONSIVENESS - The invention features methods of enhancing the responsiveness of a T cell. Such methods involve interfering with the interaction between a T cell and a B7-H1 molecule.02-02-2012
20130195865METHOD OF PREVENTING THE DEVELOPMENT OF RHEUMATOID ARTHRITIS IN SUBJECTS WITH UNDIFFERENTIATED ARTHRITIS - The invention relates to methods and compositions for treating undifferentiated arthritis (UA) and/or preventing the development of rheumatoid arthritis (RA) in subjects with UA by administering to a subject in need thereof an effective amount of soluble CTLA4 molecule.08-01-2013
20130195864FGFR-FC FUSION PROTEIN AND USE THEREOF - The present invention belongs to the field of biotechnology and relates to the treatment of diseases, especially the treatment of FGF overexpression-related diseases. Particularly, the present invention relates to FGFR-Fc fusion proteins and the use thereof in the treatment of angiogenesis regulation-related diseases. More particularly, the present invention relates to isolated soluble FGFR-Fc fusion proteins and their applications in manufacture of the medicament for the treatment of angiogenesis regulation-related diseases.08-01-2013
20130195859Compositions and methods for modulating cardiac conditions - Embodiments herein report methods and compositions for treating cardiac conditions. In certain embodiments, compositions and methods relate to reducing, inhibiting or treating a subject having or suspected of undergoing cardiac remodeling after a cardiac event. Other embodiments herein relate to compounds including naturally occurring and synthetic compositions of alpha-1 antitrypsin and fragments thereof.08-01-2013
20130195860Antibody targeting through a modular recognition domain - The present invention provides antibodies containing one or more modular recognition domains (MRDs) for targeting the antibodies to specific sites. The use of the antibodies containing one or more modular recognition domains to treat disease, and methods of making antibodies containing one or more modular recognition domains are also provided in the invention.08-01-2013
20130195862ACTIVIN-ACTRIIA ANTAGONISTS FOR INHIBITING GERM CELL MATURATION - In certain aspects, the present invention provides compositions and methods for decreasing FSH levels in a patient. The patient may, for example, be diagnosed with an FSH-related disorder or desire to delay or inhibit germ cell maturation.08-01-2013
20130195863Methods and Pharmaceutical Compositions for the Treatment of Bone Density Related Diseases - The invention relates to methods and pharmaceutical compositions for the treatment of bone density related diseases. More particularly, the present invention relates to a ROBO1 modulator for use in a method for the treatment of a bone mineral density related disease in a subject. In a particular embodiment the ROBO1 modulator is selected from the group consisting of small organic molecules, antibodies, aptamers or polypeptides. In another particular embodiment said bone mineral density related disease is selected from the group consisting of ghosal hematodiaphyseal dysplasia syndrome (GHDD), osteoporosis, osteoporosis associated to pseudoglioma, osteoporosis and oculocutaneous hypopigmentation syndrome, osteoporosis due to endocrinological dysfunction, osteogenesis imperfecta osteopenia, Paget's disease, osteomyelitis, hypercalcemia, osteonecrosis, hyperparathyroidism, lytic bone metastases, periodontitis, bone loss due to immobilization and osteoporosis associated with a disease selected from the group consisting of cachexia, anorexia, alopecia, rheumatoid arthritis, psoriatic arthritis, psoriasis, and inflammatory bowel disease.08-01-2013
20090136500Humanized PAI-1 Antibodies - The present application relates to compositions of humanized anti-PAI-1 antibodies and antigen-binding fragments thereof which convert PAI-1 to its latent form. One aspect relates to antibodies having one or more modifications in at least one amino acid residue of at least one of the framework regions of the variable heavy chain, the variable light chain or both. Another aspect relates to antibodies which bind and neutralize PAI-1 by converting PAI-1 to its latent form or increasing proteolytic cleavage. Another aspect relates to the use of humanized antibodies which inhibit or neutralize PAI-1 for the detection, diagnosis or treatment of a disease or condition associated with PAI-05-28-2009
20120039884COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE - Provided are methods for treating cardiovascular diseases and related conditions and symptoms (e.g., cardiac arrhythmia, vascular disease, myocardial infarction, congestive heart failure, myocarditis, atherosclerosis, and restenosis), comprising administering to a subject in need thereof a therapeutically effective amount of an electrokinetically altered aqueous fluid as described herein. In particular aspects, the electrokinetically altered aqueous fluids comprise an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures predominantly having an average diameter of less than about 100 nanometers and sufficient to provide modulation of at least one of cellular membrane potential and cellular membrane conductivity. Provided are routes of administration or formulations for the electrokinetically-altered fluids (e.g., electrokinetically-altered gas-enriched fluids and solutions) and therapeutic compositions, along with use of the electrokinetically altered aqueous fluids in surgical contexts, including but not limited to cardiovascular related surgeries. Additionally provided are methods for measuring biological activity of electrokinetically altered fluids.02-16-2012
20120039883DETECTION AND DIAGNOSIS OF INFLAMMATORY DISORDERS - Soluble H4 (sH4) levels have been discovered to correlate with the stage or severity of inflammatory disorders including autoimmune disorders. In particular, circulating levels of sH4 can be used as a diagnostic for determining the severity of an inflammatory disorder or the propensity for developing an inflammatory disorder. The severity of an inflammatory disorder can be determined by assaying the levels of sH4 in a subject and comparing the levels of sH4 to reference sH4 concentrations that correlate to specific stages of an inflammatory disorder. The therapeutic efficacy of treatments for inflammatory disorders can also be determined by comparing levels of sH4 before and during treatment. Methods and devices for measuring sH4 are also provided.02-16-2012
20130202593INTRACELLULAR IMMUNITY - A compound which may comprise a ligand which binds, directly or indirectly, specifically to an antigen of a pathogen, provided that said ligand is not the PRYSPRY domain of TRIM21; and a RING domain and/or an inducer of TRIM21 expression.08-08-2013
20130202600Polypeptides And Methods For Modulating D1-D2 Dopamine Receptor Interaction And Function - The present invention provides for prevention and/or treatment of neurological or neuropsychiatric disorders involving abnormal D1-D2 dopamine receptor coupling and/or activation. Methods and agents are provided for modulating dopamine receptor function arising from D1-D2 coupling and/or activation. Agents of the present invention include fragments of D2 receptor or D1 receptor that can disrupt D1-D2 coupling.08-08-2013
20130202601ASSAYS, METHODS AND KITS FOR PREDICTING RENAL DISEASE AND PERSONALIZED TREATMENT STRATEGIES - Assays, methods and kits for predicting a subject's (e.g., human) risk of primary glomerulopathy, secondary glomerulopathy or recurrence (e.g., post-transplant recurrence) of any glomerular disease include examining cells for the presence or absence of cytoskeletal disruptions or rearrangements and examining cells for modulation of expression and/or activity of markers such as SMPDL-3b. Assays for predicting if a diabetic subject will develop kidney disease or a patient with FSGS will develop recurrent disease after transplant also include examining cells for the presence or absence of cytoskeletal disruptions or rearrangements and examining cells for modulation of expression and/or activity of markers such as SMPDL-3b. Also described herein are compositions and methods for treating and preventing the afore-mentioned disorders.08-08-2013
20130202592Composition for the Anti-Cancer Metastasis Containing DLK1-Fc Fusion Protein as an Effective Ingredient - A recombinant expression vector, comprising extracellular soluble domain genes of DLK1 and IgG antibody Fc domain genes, is constructed, and DLK1-Fc fusion protein is expressed and purified at 293E cell. The invention confirmed the efficacy as a drug for inhibiting cancer metastasis by confirming markedly reduced migration of cancer cells by DLK1-Fc fusion protein and also computing pharmacokinetic parameters. DLK1-Fc fusion protein has relatively higher stability than non-fusion protein, significantly reduces migration of various cancer cell lines, and provides superior cancer metastasis inhibition effect even at small concentration. Accordingly, DLK1-Fc fusion protein can be used efficaciously as an effective ingredient of a composition for inhibiting cancer metastasis.08-08-2013
20130202596Processable Single Chain Molecules and Polypeptides Made Using Same - The present invention features inter alia nucleic acid molecules which encode polypeptides comprising a single chain Fc region and the polypeptides they encode. The Fc moieties of these constructs are linked by a cleavable scFc linker which is adjacent to at least one enzymatic cleavage site, e.g., an intracellular processing site. The resulting processed molecules comprise two polypeptide chains and substantially lack the extraneous amino acid sequence found in single chain Fc linker molecule. Methods of making and using these dimeric molecules are also described.08-08-2013
20130202595Factor IX Polypeptides and Methods of Use Thereof - The present invention provides methods of administering Factor IX; methods of administering chimeric and hybrid polypeptides comprising Factor IX; chimeric and hybrid polypeptides comprising Factor IX; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.08-08-2013
20130202594ALK1 Antagonists and Their Uses in Treating Renal Cell Carcinoma - In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit tumor growth of renal cell carcinoma (RCC) in vivo. In additional aspects the disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of ALK1 dramatically increases the ability of a standard of care receptor tyrosine kinase inhibitor to inhibit RCC tumor growth in vivo.08-08-2013
20120064076METHODS AND COMPOSITION TO REGULATE IRON METABOLISM - The present invention provides new systems and strategies for the regulation of iron metabolism in mammals. In particular methods of using agonists and antagonists of TGF-β superfamily members to modulate the expression or activity of hepcidin, a key regulator of iron metabolism, are described. The inventive methods find applications in the treatment of diseases associated with iron overload, such as juvenile hemochromatosis and adult hemochromatosis, and in the treatment of diseases associated with iron deficiency, such as anemia of chronic disease and EPO resistant anemia in end-stage of renal disease. The present invention also relates to screening tools and methods for the development of novel drugs and therapies for treating iron metabolism disorders.03-15-2012
20120301467FAS BINDING ANTIBODIES - The disclosed invention relates to monoclonal antibodies (MAbs) which recognize human fatty acid synthase (hFAS) and are distinct from previously known anti-hFAS antibodies. Compositions, devices and kits comprising the MAbs are provided along with methods of using the MAbs in a variety of applications.11-29-2012
20130095102DIMERIC FUSION PROTEINS AND RELATED COMPOSITIONS AND METHODS - Compositions and methods relating to soluble dimeric proteins are disclosed. The dimeric proteins comprise first and second polypeptide fusions linked via a dimerizing domain, each polypeptide fusion comprising first and second monomer domains corresponding to a cytokine or an extracellular domain of a cell-surface receptor. The monomer domains may be positioned amino terminal and carboxyl terminal to the dimerizing domain. Alternatively, the monomer domains may be positioned in tandem, either carboxyl terminal or amino terminal to the dimerizing domain. The dimeric proteins are useful in methods for therapy, diagnosis, and research.04-18-2013
20120087921NOVEL CHEMOKINE BINDING POLYPEPTIDES CAPABLE OF INHIBITING THE COURSE OF AUTOIMMUNITY, INFLAMMATION AND CANCER - Novel polypeptides comprising a chemokine-binding peptide and an Fc fragment are disclosed. The polypeptides are capable of binding to certain chemokines so as to modulate their activity. These polypeptides can be used to modulate in vivo chemokine-dependent processes such as inflammation and autoimmunity, and to treat associated conditions.04-12-2012
20120087920FGF21 MUTANTS AND USES THEREOF - The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.04-12-2012
20120087919METHOD FOR TREATING DIABETES - Fusion proteins binding specifically to cell types of the islets of Langerhans and delivering therapeutic or prophylactic agents are provided herein, as well as compositions thereof. Methods for treating or preventing diseases related to the pancreas such as diabetes are also disclosed. The therapeutic or prophylactic agents include Nemo-binding domain peptides and other inhibitors of NF-kB activation.04-12-2012
20120093815FGF21 MUTANTS AND USES THEREOF - The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.04-19-2012
20120093814Fusion Proteins Comprising Canine FC Portions - The present invention relates to therapeutic peptides and proteins fused to a canine antibody Fc domain. Methods and compositions of using the same are described.04-19-2012
20130209463POLYPEPTIDES AND USES THEREOF AS A DRUG FOR TREATMENT OF MULTIPLE SCLEROSIS, RHEUMATOID ARTHRITIS AND OTHER AUTOIMMUNE DISORDERS - This invention relates to a protein C1ORF32 and its variants and fragments and fusion proteins thereof, and methods of use thereof for immunotherapy, and drug development, including but not limited to as immune modulators and for immune therapy, including for autoimmune disorders.08-15-2013
20130209464POLYPEPTIDES HAVING ANTIVIRAL ACTIVITY AND METHODS FOR USE THEREOF - A polypeptide is provided that comprises an actinohivin variant polypeptide having an amino acid sequence selected from SEQ ID NOS: 4-12. The polypeptide can be provided as part of a fusion protein that includes the actinohivin variant polypeptide and either a fragment crystallizable domain of an antibody (Fc), a fragment antigen-binding domain of an antibody (Fab), or a single chain variable fragment of an antibody (scFv). Isolated nucleic acid molecules encoding the polypeptides are also provided along with vectors and plant cells capable of expressing the polypeptides. Methods of treating an infection of a subject by an enveloped virus are further provided and include administering an effective amount of the polypeptides to a subject.08-15-2013
20130209465Stabilized Aqueous Antibody Compositions - The present invention provides an aqueous solution comprising an antibody protein at a concentration of at least about 10 mg/m L and a stabilizing amount of polyethyleneimine.08-15-2013
20130209466COMPOSITIONS AND METHODS FOR PRODUCING BIOACTIVE FUSION PROTEINS - Disclosed is a composition of matter involving a recombinant fusion protein comprising a a pharmacologically active protein partner, and a small pharmacologically inactive protein domain partner of human origin, such as but not limited to, a 1008-15-2013
20130209462CERBERUS/COCO DERIVATIVES AND USES THEREOF - The invention relates to Cerberus/Dan/Gremlin polypeptides or variants thereof for use in treating a variety of disorders associated with myostatin, nodal and GDF-11. Preferred polypeptides are Coco or Cerberus derivatives.08-15-2013

Patent applications in class Antibody, immunoglobulin, or fragment thereof fused via peptide linkage to nonimmunoglobulin protein, polypeptide, or fragment thereof (i.e., antibody or immunoglobulin fusion protein or polypeptide)